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ABSTRACT 
BACKGROUND 
Chronic respiratory inflammation is a major cause of recurrent airway 
obstruction (RAO) in mature horses. RAO has aetiological and clinical 
similarities to human asthma. Remodelling of airway tissue after bronchial 
inflammation is evident in RAO and human asthma. Severe asthma in 
humans is associated with defective lipoxin A4 (LXA4) synthesis and 
abnormal expression of specific lipoxin receptor (ALX). 
Arachidonic acid metabolite LXA4 modulates acute inflammation in a 
number of species and models of acute inflammation. Dysfunctional LXA4 
synthesis and/or expression of the ALX receptor may contribute to the 
chronic inflammatory response seen in asthma. Abnormal LXA4 and/or 
ALX expression may also be present in horses with RAO thereby 
promoting airway remodelling. 
HYPOTHESIS 
Equine inflammation and its resolution can be modelled in vitro using 
respiratory epithelial and smooth muscle models. 
AIMS 
To develop an in vitro equine respiratory model of respiratory epithelium 
and airway smooth muscle. 
Characterise the response of this model to exogenous lipolysaccharide 
(LPS) and lipoxin A4 on selected molecules associated with inflammation 
and inflammatory resolution. 
2 
METHODS 
Primary equine tracheal epithelial (ETE) cells were obtained from trypsin-
dissociation of tracheal epithelial tissue derived from healthy horses with 
no sign of inflammation at post-mortem. Primary airway smooth muscle 
(ASM) cells were cultured from explants of equine trachealis muscle. 
Near confluent (70-75%) ETE and ASM cells were stimulated with 0.1, 10 
and 100llg/ml LPS at 4 and 24 hrs (ETE cells) or 12, 24 and 72hrs (ASM 
cells). Expression of COX-2 mANA in these cells was used to determine a 
suitable time point and LPS concentration to induce inflammation. 
Inflammatory resolution was then examined by comparing the selected 
time pOints and LPS concentrations with the response of ETE and ASM 
cells to 15 minutes incubation with 100ilM LXA4 and LXA4/LPS treatment. 
Finally, the inflammatory relationship between the epithelium and smooth 
muscle layer was examined by a co-culture model of ETE and ASM cells. 
Conditioned media from ETE cells treated with 0.11lg/ml LPS, 100llM 
LXA4 and LXA4/LPS treatment for 24hrs was used to culture ASM cells for 
a further 24hrs. 
To examine inflammation and its resolution, selected genes, namely ALX, 
toll-like receptor 4 (TLA-4), tumour-necrosis factor alpha (TNF-a), 
interleukin-1 beta (IL-1 ~ ) , , inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) were amplified and quantified by real time 
PCR. ALX and COX-2 proteins were monitored by Western blot and nitric 
oxide (NO) levels measured by fluorometric analysis. Values for statistical 
analysis of ETE and ASM cells were obtained with a two and one-way 
ANOVA and Tukey's multiple comparisons test. 
3 
RESULTS 
Primary ETE and ASM cells were identified by positive 
immunocytochemical staining with pan cytokeratin-26 and alpha-smooth 
muscle actin respectively. 
Treatment of ETE cells with 0.1I1g/ml LPS for 24hrs increased iNOS and 
COX-2 mRNA levels, and significantly increased mRNA expression for 
ALX, TLR-4 TNF-a and IL-1 j3 mRNA (p values <0.05). ASM cells 
incubated over 72hrs incubation with 0.1119/ml LPS showed increased 
expression of selected genes but only significant increases in COX-2 
mRNA were observed (p values <0.05). 
Incubation of ETE and ASM cells with LXA4 did not significantly increase 
or inhibit inflammation as measured by real time PCR, Western blot and 
fluorometric anlaysis. Western blotting showed some inhibition of COX-2 
protein in ASM cells but not ETE cells at 72hrs after LXA4 treatment. 
Fluorometric analysis of NO levels in ETE and ASM cells showed no 
significant difference after treatment in either cell type. No noticeable 
evidence of inflammation or inhibition of inflammation was observed in the 
co-culture model of ETE and ASM cells. 
CONCLUSION 
It was concluded that an in vitro equine model of respiratory epithelium 
and smooth muscle was successfully established. It was possible to 
induce partial inflammation in ETE and ASM cells but inflammatory 
resolution could not be definitively shown in either cell type. 
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Chapter 1: Immunity and the airways 
1.1 Initiation of inflammation 
Acute inflammation is an essential part of the immune defence in both the 
innate and adaptive systems. It is a necessary response to trauma, tissue 
injury and pathogen infection (Lawrence et a/2002). A prompt return to 
homeostatic equilibrium following acute inflammation ensures minimal 
damage to surrounding tissue and cells (Han and Ulevitch 2005). 
Acute inflammation comprises three key phases: 
i) Pathogen recognition and the initiation of inflammation. 
ii) Cellular recruitment with synthesis of pro-inflammatory mediators. 
iii) Resolution of inflammation. 
Disruption of these principal phases can result in progression into chronic 
inflammation with the development of disease (Henson 2005). During 
chronic inflammation, both tissue destruction and repair run in parallel in a 
vicious cycle of host injury. 
Chronic inflammation is fundamental to the development of multiple 
diseases and harmful conditions in humans and in horses. Persistent 
allergy-induced respiratory inflammation is a feature of both recurrent 
airway obstruction (RAO) in horses and human asthma. 
1.2 Toll-like receptors and the initiation of acute 
inflammation 
Inflammation is triggered after recognition of a wide range of pattern 
associated molecular pattern (PAMPs), by a group of receptors called 
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pattern recognition receptors (PRRs). Toll-like receptors (TLRs) are the 
most influential group of PRRs. 
TLRs are transmembrane receptors expressed during innate immune 
responses and subsequently activate T -lymphocytes in adaptive immunity 
(Akira and Hemmi 2003). Recognition of invading pathogens by TLRs 
activates signalling pathways that enable the expression of inflammatory 
cytokines (Kawai & Akiro 2007). TLRs (Fig.1) are stimulated by viruses, 
bacteria, fungi and helminths, reactive oxygen species (RDS) and by-
products from damaged cells (Chaudhuri et a/2005). 
_ Principal ligand for 
., TLR activation 
* TLR al 0 identified 
inhor e 
TLR-ll 
Oo,bl.- trn",,",RNA _> TLR-3' 
Imidazoquinoline e'- TLR-7* 
Loxoribine rr-
Imh"_'"U", _> TLR-S 
CpG-containing e'- TLR-9* 
DNA rr-
Figure 1: TLRs expressed in human and horse with their principal ligands 
(Figure adapted from Akira and Hemmi 2000, and Werners et 812006) . 
Cell types closely associated with innate defence such as dendritic cells, 
macrophages, mast cells and respiratory epithelial cells predominantly 
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express TLRs. Human airway smooth muscle is also known to express 
functional TLRs (Sukkar et aI2006). 
The expression of TLR-2, 3, 4, 6, and 9 have been identified in the horse 
(Gornik et al2011, Quintana et aI2011). Evidence of TLR-2 and TLR-4 
activity has been found in the lungs of healthy horses (Singh Suri et al 
2006). 
1.3 TLR expression in asthma and pathogen 
recognition 
Excessive binding of TLR-2 and 4 to ligands such as LPS are implicated in 
the aetiology of asthma (Chaudhuri et al 2005). TLR-2 and TLR-4 
recognise bacterial cell wall components, found in Gram positive and 
Gram negative bacteria respectively (Hirshfeld et al 2000, Knapp et at 
2008). 
TLR-2 recognises a wide variety of ligands including Aspergillus fumigatus, 
abundant in poor quality hay (Chaudhuri et aI2005). TLR-4 responds to 
the endogenous ligands neutrophil elastase, heat-shock proteins, 
surfactant protein A and fibronectin peptides. Additionally, LPS binding to 
TLR4 utilises the LPS-binding protein, CD14, and glycoprotein MD-2 and 
is further aided by the cell-surface integrins CD11 b/CD18 (Perera et al 
2001). 
CD14 is found on cells associated with early inflammatory responses like 
monocytes, macrophages and neutrophils. CD14 initiates TLR-4 pathogen 
recognition and triggers TLR-4 to form a homodimer complex with MD-2 
(Chow et al 1999). Formation of such a complex triggers signalling 
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pathways (Fig.2) leading to the formation of inflammatory products (Barata 
et a12011) 
TLR-4 
Membrane 
TIRdomain 
/ ~ ~ ~ ~MyD88 ~ ~
MKK TRAF6 TRAF6 Cytosol 
1 
~ ~ 1 IKB kinase (IKK) complex ~ ~
Jnk • NF-KB • NF-KB 
• Early NF-KB 
• Late NF-KB 
translocation __ + ~ ~ Synthesis of inflammatory 
AP-l 
----------... ~ ~ cytokines 
Nucleus 
Figure 2: Principal components of TLR-4 signalling pathways 
(Figure adapted from Chadhuri et aI2005). 
1.4 TLR expression in RAO 
Exposure to stable dust results in increased TLR-4 mRNA expression in 
bronchial epithelium with a concomitant increase in IL-8 in horses with 
RAO (Berndt et aI2007). Unusually, TLR-2 mRNA was not increased in 
bronchial epithelial cells collected from RAO-affected horses after stabling 
(Berndt et al 2009). An 'altered-self response by TLR-4 may promote 
inflammation by increased recognition of inflammatory mediators (Greene 
& McElvaney 2005). 
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1.5 Defective TLR expression and the onset of 
allergies 
TLR dysfunction can initiate an extreme immune response and cause 
disease (Atkinson 2008). TLRs actively regulate inflammatory mediator 
formation and cytokine signalling in airway epithelial cells (Kato and 
Schleimer 2007, Laberge and Bassam 2004). A point mutation in the 
human TLR-4 gene (Asp299Gly) may occur in affected individuals (Child 
et a/2003). The Asp299Gly mutation is thought to cause changes to the 
extra-cellular domain structure (Arbour et a/2000). The potential for TLR 
mutations to cause disease in horses has been investigated. A whole 
blood assay using 10 healthy horses was used to determine TNF-a 
expression induced by LPS. A significant alteration of TNF-a production 
was found in 3 horses with a mutation in their TLR4 cDNA sequence. 
Despite this, it was not possible to relate this TLR-4 mutation to the altered 
TNF-a response. The lack of correlation was attributed to differences in 
TLR-4 expression and the effect of circulating LPS binding protein (LBP) 
(Werners et a/2006). 
1.6 TLR activity in early life and allergic disease 
The onset of asthma or allergen-related signs of asthma depends on the 
timing and specific type of allergen exposure. School-aged children who 
have TLR-4 (Asp299Gly) polymorphisms show an increased prevalence of 
asthma. These TLR-4 polymorph isms potentially affect the normal early 
life immune response to environmental pathogens (Fageras-Bottcher et a/ 
2003). Dust mites in domestic environments increase the prevalence of 
childhood asthma (Liu 2002). In contrast, agricultural environments are 
associated with a decrease in childhood asthma or airway hyper-
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responsiveness (Liu 2002). This decrease is attributed to frequent animal 
exposure and early life exposure to stables or barns (von Ehrenstein 2000, 
Riedler et a/2001). 
The effect of exposure in early life to environmental dust and allergens in 
horses is unknown. Hotchkiss et a/ (2007) performed a questionnaire using 
a sample of horse owners in Great Britain. The questions related to 
management and exposure to known RAO risk factors. The study showed 
that before five years of age, 67.5% of 380 horses had been exposed to 
straw, and 14.5% of those had experienced respiratory infection of more 
than a few days. However, the report relies on largely anecdotal evidence, 
with no description of length of time for exposure, the degree of stabling 
experienced by the horses or the proportion that went on to develop RAO 
in later life. 
1.7 Cytology of the airways during acute 
pulmonary inflammation 
Excessive TLR expression is shown to be important in both the 
development of allergic respiratory disease and the promotion of acute 
inflammation. Once acute inflammation is initiated, cellular recruitment and 
the synthesis of pro-inflammatory products occurs. 
Airway inflammation in RAO and asthma is a complex interaction between 
different cell types. In addition to mast cell and T-Iymphocyte activity, 
sentinel cells (dendritic cells, macrophages, and neutrophils) actively 
promote or initiate inflammation. (Pietra et a/ 2007). Macrophages, 
resident dendritic cells and epithelial cells are particularly primed to 
activate inflammation. Increased eosinophils in circulation are found in mild 
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to moderate asthma, whereas a high neutrophil count (>25%) is more 
prevalent in RAO. Severe human asthma is now increasingly associated 
with neutrophilic inflammation (Sur et a/1993, Kamath et a/2005, Turato 
et a/2007). 
In contrast, samples of SAL fluid (200-500ml of saline) from RAO-free 
animals contain predominantly alveolar macrophages (60%) and 
lymphocytes (35%), with the remainder a mixture of neutrophils, mast cells 
and epithelial cells (Lavoie 2007). Respiratory epithelial and airway smooth 
muscle cells are now recognised as forming part of the inflammatory 
response and for the role they play in airway remodelling. 
Dendritic cells 
Dendritic cells (DCs) are key sentinel cells for pathogen recognition and 
initiating inflammation. Dendritic cells present antigen for processing by T-
cells which can trigger Th 1 or Th2-type responses (Hammad & Lambrecht 
2008). DCs may initiate excessive Th2 immune responses to allergens 
(Lambrecht & Hammad 2011). Equine dendritic cells have been 
successfully isolated and identified using morphology and immuno-staining 
for MHC class II (Siedek et al 1997), as activated dendritic cells show 
MHC II upregulation. 
Innate immune responses and DCs' antigen presentation is directly 
influenced by their activation state (Cavatorta et a/2009). DC involvement 
is seen in both a compromised immune system as well as respiratory and 
allergic disease. Work investigating equine Des has predominantly 
focused on their role in bacterial diseases, particularly Rhodococcus equi 
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infection in foals (Flaminio et a/2009). Other investigations (Dietze et a/ 
2008) indicate that LPS and IL-4 can affect Des' maturation in horses. 
However, neither LPS nor the synthetic immunostimulant polyinosinic: 
polycytidylic acid poly (I: e) alone are considered sufficient for full Des 
maturation (Mauel et a/2006). Additionally, human airway epithelial cells 
are shown to directly influence Des' activity (Lambrecht & Hammad 2011). 
Despite this, no substantial evidence of a role for Des' in the development 
of RAO exists. 
Macrophages 
Macrophages playa prominent role in antigen presentation during immune 
responses. Alveolar macrophage (AM) activity may contribute to sensitivity 
to LPS-induced endotoxemia in horses (Parbhakar et a/2004, Hammond 
et a/1999). 
Alveolar macrophages from RAO-affected horses show increased 
expression of TNF-a, IL-1 ~ ~ and IL-6 after exposure to an LPS and hay 
dust suspension (Laan et a/ 2006). Equine alveolar macrophages have 
been shown to release IL-8 and macrophage inflammatory protein (MIP-2), 
both potent chemokines for neutrophil activity and recruitment (Laan et a/ 
2006). 
Evaluation of alveolar macrophages' influence on neutrophil recruitment 
and influx during respiratory disease was investigated over a period of 2 
years (Joubert et a/ 2011). Macrophages were not thought to be the 
principal cell type causing neutrophil influx despite expression of neutrophil 
chemoattractants IL-8 and MIP-2. 
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AM activity is attributed to the airway remodelling observed in human 
chronic obstructive pulmonary disease (COPO) rather than asthma 
(Aoshiba & Nagai 2004). Pulmonary responses in horses induced by LPS 
were compared with and without pulmonary macrophages. Reduction of 
pulmonary macrophages was achieved by the use of intravenous 
gadolinium chloride, a macrophage inhibitor. Depletion of pulmonary 
macrophages reduced but did not eliminate LPS-related inflammation 
(Parbhakar et a/2005). This suggests that their role is contributory, but not 
a dominating factor in airway inflammation and airway remodelling. 
Neutrophils 
Early influx of neutrophils and their activation is a distinguishing feature of 
chronic inflammation in RAO. Airway neutrophil numbers are greater in 
RAO-affected horses when compared with normal horses (Brazil et al 
2005, Franchini et aI2000). Following an investigation of the potential 
variation in BAL fluid samples from horses with RAO, it was estimated that 
the proportion of neutrophils was over 25% in all samples (Jean et al 
2011 ). 
Neutrophil migration to the airways is recorded in horses with clinical signs 
of RAO after 5 hours of mouldy hay/straw challenge. Neutrophils persist in 
the airways if exposure to organic dust and mould continues, with 
apoptosis delayed by LPS exposure (Brazil et al 2005). Continued 
neutrophil activity, inhibition of apoptosis, or ineffective neutrophil removal 
perpetuates chronic inflammatory conditions (EI Kebir et aI2008). 
Neutrophils release a combination of damaging substances in RAO; 
proteases, nucleases, peroxides, nitric oxide and reactive oxygen species 
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(Franchini et a/ 1998). Reactive oxygen species are linked to airway 
disorders, including asthma by promoting respiratory inflammation 
(Henricks & Nijkamp 2001). 
The role of neutrophils in allergic airway inflammation is controversial. 
Morphological changes were induced by IL-4 in neutrophils with Th2 type 
lung inflammation related to neutrophil activity (Lavoie-Lamoureux et a/ 
2010). In contrast, no difference was found in the expression of mRNA for 
TNF-a and IL-1 ~ ~ in peripheral blood neutrophils from RAO-affected horses 
and control groups (Joubert et a/ 2008). The authors considered these 
results indicated that such neutrophils were unlikely to contribute to the 
development of RAO. 
Neutrophils are also recruited by other cell types, typically those prominent 
in pathogen recognition. TLR-4 mRNA is increased in bronchial epithelial 
cells from horses with RAO, with the subsequent production of IL-8, a 
potent chemokine for neutrophils (Berndt et a/ 2007). The European 
Network for Understanding Mechanisms of Severe Asthma (2003) 
considers severe asthma to have a phenotype characterised by a 
neutrophilic infiltrate. Additionally, other work suggests predominance of 
neutrophil chemokine IL-8 in severe asthma (Planaguma et a/ 2008, 
Wenzel et a/2006, and Holgate et a/2006). 
Neutrophils are undoubtedly a significant contributory element during 
acute airway inflammation. A continued neutrophil presence, either 
through prolonged antigen exposure or a failure of neutrophil apoptosis 
and removal is noted as part of chronic inflammation (Hughes et a/2011). 
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However, neutrophil recruitment is secondary to inflammation rather than 
acting as the prime mediator of it. 
Therefore, other cell types in the airways must be capable of initial 
pathogen detection, initiation of acute inflammation, and promotion of 
chronic inflammation should dysfunction or irregularities occur. Human 
bronchial epithelial cells are known to be active in all these respects. Such 
cells are also able to direct the migration and actions of monocytes, and T-
lymphocytes (Mayer et aI2007). Human bronchial cells are described as 
having the capacity to create a "microenvironment" and actively direct 
immunity (Altraja et aI2009). 
Airway epithelial cells 
Airway epithelial cells directly interact and influence other immune cells 
and so orchestrate both the innate and acquired immune response 
(Hamilton et al 2001, Holgate et al 2009). Stimulated human airway 
epithelial cells can release high concentrations of biological mediators that 
perpetuate inflammation and bronchial hyperesponsiveness (Takizawa 
1998, Schleimer 2004). 
The equine respiratory epithelium is also suggested to be a source of such 
mediators during early inflammatory reactions (Ainsworth et aI2003). The 
biological mediators generated by the epithelium are broadly divided into 
cytokines, chemokines, enzymes and eicosanoids and include: TNF-a, IL-
1 ~ , , IL-8, IL-6, COX-2, lipid mediators and nitric oxide (Knight & Holgate 
2003, Polito & Proud 1998). 
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Airway smooth muscle cells 
Airway smooth muscle (ASM) is an additional cell type in the airways that 
plays an active part in immune and inflammatory regulation (Ozier et al 
2011). ASM is the primary determinant of airway resistance (Robinson 
2007). Bronchospasm of ASM is exacerbated by elevated nitric oxide (NO) 
concentrations (Matera et aI2002). 
The role of airway smooth muscle in the pathophysiology of RAO and 
asthma is associated with increasing airway hype responsiveness and 
narrowing of the airways. ASM is also a source of inflammatory mediators, 
particularly once the disease has entered a chronic phase (Hirst 1992). 
This is typically once remodelling of the airways has been instigated. 
1.8 Pro-inflammatory mediators generated during 
acute airway inflammation 
Cytokines 
Tumour necrosis factor alpha (TNF-a) 
TNF-a has roles in the instigation of acute and chronic inflammation and 
acts as a mediator responsible for airway remodelling (Cho 2011). As 
such, the expression of TNF-a is frequently used as marker of 
inflammation. Suppression of TNF-a in people is considered to be a target 
for disease treatment (Tracey & Cerami 1994). The influence of TNF-a is 
widely studied in equine conditions such as osteoarthritis, gastro-intestinal 
(GI) disturbances, and insulin resistance. 
In contrast, the role of TNF-a in equine airway inflammation or RAO in 
horses has received relatively little consideration in comparison to human 
asthma. TNF-a expression in circulating blood is readily induced in horses 
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performing severe or high intensity exercise (Liburt et a/ 2010). Equine 
peripheralleucocytes show increased expression of mRNA for TNF-a in 
response to inhaled LPS (Sykes et a/2005). An increase in TNF-a mRNA 
expression has been demonstrated in equine vascular smooth muscle, 
and considered to be an indicator of early endotoxemia (Rodgerson et a/ 
2001). Unusually, TNF-a incubation of equine monocytes did not induce 
TLR-2 or TLR-4 activation suggesting that although TNF-a is vital in the 
initiation of signalling pathways, it does not influence TLR activation (Kwon 
et a/2010). 
RAO-affected horses during exacerbation show increased TNF-a levels 
despite clinical resolution following treatment with anti-inflammatory 
glucocorticoid fluticasone (Giguere et al 2002). Similarly, RAO-affected 
horses still have detectable levels of TNF-a in serum despite the absence 
of clinical signs. This suggests that current anti-inflammatory treatment 
fails to fully resolve TNF-a induced inflammation (Lavoie-Lamoureux et a/ 
2012). 
Interleukin-1 beta (IL-1 Il) 
In a similar manner to TNF-a, the expression of IL-1 P is frequently used as 
a biomarker of early or acute inflammation. Expression of IL-1 p mRNA in 
horses is rapid with a considerable fold concentration change following 
LPS exposure or incubation (Ainsworth & Ryner 2012). Horses treated 
with intravenous doses of LPS (total dose, 80 I-/g), developed systemic 
inflammation, with IL-1 p expression strongly associated with expression of 
cytokines IL-6 and IL-8. 
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IL-1 P in people has been correlated with inducing COX-2 and iNOS 
expression, both strongly associated with human airway disease (Redinton 
et a/2001). COX-2 mRNA expression was correlated to IL-1P levels in 
equine smooth muscle cells after LPS incubation (Rodgerson et aI2001). 
Horses with inflammatory airway disease (lAD) also show significantly 
increased levels of IL-1 P mRNA in cell pellets obtained from BAL samples 
(Hughes et aI2011). 
In contrast, bronchial alveolar lavage (BAL) samples from RAO-affected 
horses after 24 hours of dusty hay had neutrophils removed. Cell samples 
were treated with LPS solutions, but this treatment did not significantly 
increase IL-1 J3 levels (Reyner et al 2009). The complexities of IL-1 J3 
expression, and its interaction with TNF-a, during respiratory inflammation 
are not fully understood in the horse. 
Chemokines 
Interleukin 8 (ll-8) 
IL-8 has been subject to more recent investigation as it is produced by 
several cell types including neutrophils, endothelial cells, epithelial cells 
and smooth muscle cells. Neutrophil number and lung dysfunction in 
asthma has been associated with a corresponding increase in IL-8levels 
(Pease and Sabroe 2002). Previous studies have demonstrated evidence 
of increased expression of IL-8 mRNA from BAL fluid and epithelium of 
RAO-affected horses (Franchini et a12000, Ainsworth et a/2003, 2006, 
Laan et al2006 Berndt et a/2007, and Riihimaki et a/2008b). 
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Interleukin G (Il-G) 
During acute inflammation, epithelial cells synthesise IL-6, a cytokine with 
pleiotropic qualities. IL-6 can increase neutrophil activation, recruitment 
and adhesion during migration, as well as stimulating Th2 cells (Horohov 
et a/2005). SAL fluid from RAO-affected horses has elevated IL-6 mRNA 
concentrations (Pietra et a/2007, Riihimaki et a/2008). 
Enzymes 
Cyclooxygenase (COX)-2 
The enzyme cyclooxygenase has two distinct isoforms. COX-1 is 
expressed constitutively and COX-2 is synthesized during inflammation 
(Blikslager 2006). COX-2 is an important mediator of prostaglandins, noted 
for their role in asthma pathogenesis. 
Prostaglandins, thromboxanes and leukotrienes are pro-inflammatory 
eicosanoids generated from arachidonic acid metabolism (Serhan et a/ 
2008). COX-2 expression enables production of prostaglandin E2 (PGE2). 
Elevated PGE2 concentrations induce bronchoconstriction and Th2 subset 
differentiation (Kalinski et a/ 1997). Epithelial expression of COX-2 is 
significantly increased in human patients with asthma (Sousa et a/1997). 
Acute inflammatory models using equine leukocytes show LPS-induced 
expression of COX-2 mRNA and COX-2 proteins (Stewart et a/ 2009, 
Eckert et al 2007). In vitro, equine vascular smooth muscle cells also 
synthesise COX-2, in response to endotoxin exposure (Janicke et a/2003, 
Rodgerson et a/2001). 
The importance of COX-2 expression in the pathogenesis of RAO is 
largely unresolved; however, COX-2 may have a beneficial role in the 
subsequent generation of anti-inflammatory mediators. COX-2 is taken up 
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by monocytes, endothelial cells or airway epithelial cells for the synthesis 
of lipoxins (Brezinski & Serhan 1990). COX-2 uptake by these cells may 
be significant in preventing the development of chronic inflammation. 
Nitric oxide (NO) 
NO is a complex and diverse molecule with both beneficial and harmful 
actions (Bogdan 2001). NO regulates vascular tone and aspects of 
immunity and inflammation (Hayward et a/1999). 
NO production is reported to vary within species, and according to the 
inciting stimulus (Aktan 2004). NO production relies on the oxidation of L-
arginine, mediated by a group of enzymes, the nitric oxide synthases 
(NOS), either membrane-bound (eNOS), or soluble (nNOS, iNOS) (Aktan 
2004). 
Increased synthesis of NO and its metabolites is considered to promote 
airflow limitation and the pathogenesis of respiratory disease. This 
includes asthma, COPO, and cystic fibrosis (Hayward et a/1999, Knight & 
Holgate 2003, Ricciardolo et a/2006). Numerous cell types synthesize NO 
but increased iNOS production is prevalent in airway epithelial and airway 
smooth muscle cells (Karpuzoglu & Ahmed 2006). The synthesis of NO by 
human airway epithelial cells is considered to suppress Th1 cytokine 
production. This enhances Th2 subset activity and contributes to allergic 
inflammation (Barnes & Liew 1995). Expression of the NO metabolite 
peroxynitrite (ONOO-) may promote the continued recruitment of 
neutrophils (Jozsef et a/2002). 
35 
1.9 Lipoxins as pro-resolution and anti-
inflammatory mediators 
Moderation of the inflammatory process 
Acute inflammation is a necessarily self-limiting process to prevent 
excessive tissue damage. Several mechanisms signal the change from 
pro-inflammation to active resolution of this process (Haworth & Buckley 
2007, Serhan 2007). The end of inflammation is indicated by synthesis of 
pro-inflammatory leukotrienes and prostaglandins switching (Fig.3) to the 
formation of pro-resolution mediators, namely resolvins, protectins and 
lipoxins. Resolvins and protectins are associated with promoting tissue 
repair, and lipoxins represent the pivotal point in ending inflammation 
(Medzhitov 2008). 
Arachidonic acid 
;/ n ~ ~
S-LO! SolO COX-2 
II COX-2 ~ ~U 
Prostaglandins Llpoxlns 
Thromboxanes 
Figure 3: Arachidonic acid metabolites and pathways for synthesis 
(Figure adapted from Serhan 2007) 
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Leukotrlenes 
Lipoxins as pro-resolution agents 
Lipoxin production is obseNed in several species, including rat, mouse, 
fish and humans (Serhan 2005). Synthesis occurs in vivo, mainly through 
cell-cell interaction and predominantly uses three specific pathways acting 
separately or jointly (Rowley et 8/1994). Single cell production of lipoxins 
can occur, as demonstrated in activated leukocytes from asthmatics after 
exposure to inflammatory cytokines (Chavis et 8/1995). 
The cells involved in lipoxin synthesis include neutrophils, airway epithelial 
cells, platelets, monocytes, macrophages, eosinophils and vascular 
endothelial cells. Synthesis occurs when arachidonic acid is taken up by 
these cells (Fig.4) and converted to either LXA4 or LXB4 through the 
enzymatic action of lipoxygenases (LO) 5-LO, 12-LO, and 15-LO 
(Brezinski and Serhan 1990). 
Epithelial cells 
Endothelial 
cells 
Monocytes 
5-LO uptake: 
Leukocytes 
15-LO uptake: 
Epithelial cells 
5-LO uptake: 
Leukocytes 
Figure 4: Pathways and cells Involved for synthesis of IIpoxlns 
(Figure adapted from Brink et a12003) 
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Lipoxin receptors 
Lipoxins bind with high affinity to the receptors designated ALX and Ahr. 
ALX is a G-protein-coupled receptor (GPCR) originally designated formyl 
peptide receptor-like 1 (FPRL-1). Current nomenclature favours the term 
ALX, or ALXlFPRL-1 based on the high affinity binding and selectivity 
displayed by this receptor for LXA4 (Brink et a/2003). Lipoxins also signal 
through the ligand-activated aryl hydrocarbon receptor (Ahr), a nuclear 
receptor from the superfamily of DNA-binding proteins (Schaldach et al 
1999). 
Cell types that exhibit ALX receptors are mainly leukocytes, but lipoxins 
regulate macrophages, dendritic cells and affect Th1 and Th2 expression 
(Parkinson 2006). The main organs of expression are the spleen and lung 
but also include heart, placenta and liver. 
LXA4 is the most potent naturally occurring ligand for ALX but other lipid 
ligands are able to activate this receptor, namely 15-epi-LXA, ATLa 1 and 
ATLa2. There is also partial competition from L TC4, L TD4, fMLF and 15-
deoxy-LXA4 indicating that ALX is capable of binding to several ligands 
(Brink et a/2003). 
Lipoxin modulation of inflammation 
Lipoxins may be capable of anti-inflammatory roles by modulating activity, 
signalling pathway intermediates and inhibiting inflammatory cytokine 
production (Machado et a/2008). Inhibition of TLR activity occurs when 
Ahr signalling causes degradation of TLR signalling intermediates, TNF 
Receptor Associated Factor (TRAF) 2 and 6 (Machado et a/2008). 
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LXA4 analogues also inhibit cellular signalling by preventing nuclear 
accumulation of AP-1 and NF-KB in polymorphonuclear and mononuclear 
leukocytes (Jozsef et a/ 2002). Inhibition of NF-KB and AP-1 activity 
subsequently decreases expression of the neutrophil chemo-attractant 
ONOO (Filep et a/2005). The principal effect of LXA4 binding to ALX in 
relationship to the pathways generating inflammatory molecules is shown 
in Fig 5. 
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Figure 5: Diagram of principal effects of LXA4 on Inflammation 
(Figure adapted from Serhan 2008) 
Dysfunctional lipoxin synthesis and chronic disease 
Inadequate or dysfunctional lipoxin synthesis is implicated in chronic 
inflammation and disease. Asthma severity is associated with decreased 
or defective capacity for LXA4 production (Celik et a/2007). Whole blood 
analyzed from severely asthmatic patients revealed low concentrations of 
LXA4 (Planaguma et a/2008). A similar lack of LXA4 in sputum collected 
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from equally asthmatic subjects was accompanied by increased 
concentrations of LTB4 and IL-8. 
In contrast, patients with mild asthma had increased concentrations of 
LXA4 in their sputum (Vachier et a/2005). Interestingly, dexamethasone 
treatment inhibited LXA4 expression in severe asthmatics compared with 
non-severe asthmatics (Bhavsar et a/201 0). This suggests that the anti-
inflammatory effects of dexamethasone may prevent full resolution of 
acute inflammation and thus promote chronic inflammation. Additionally, 
LXA4 production appears to be defective in cystic fibrosis (CF), a 
pulmonary disease characterised by neutrophil-mediated inflammation, 
persistent infection and tissue damage. (Karp et a12004). Dysfunctional 
expression of ALX may also increase the effect of acute serum amyloid A 
(SAA). SAA is a protein that signals through ALX and has the capacity to 
modulate or promote inflammation (EI Kebir et a/2008). 
Exercise-induced asthma elicits airway hyper-responsiveness and 
bronchoconstriction. Asthmatic children have decreased levels of plasma 
LXA4 after exercise with LXA4 levels related to the severity of asthma 
(Tahan et a/ 2008). Similarly, horses with RAO frequently exhibit such 
exercise intolerance (Davis et a/2005, Lykkesfeldt & Svendsen 2007), 
which may be related to low LXA4 levels. 
The cause of defective synthesiS of LXA4 and loss of ALX expression in 
severe asthma is currently poorly understood (Celik et a/2007). However, 
if lipoxin synthesis is restricted in severe neutrophil-dominated asthma, 
then lipoxin synthesis in horses with RAO may be similarly diminished. 
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1.10 Recurrent airway obstruction 
Recurrent airway obstruction (RAO) in horses is classified as chronic lower 
airway inflammation, caused by the environment in which stabled horses 
are kept (Robinson et aI1996). RAO has previously been thought to be 
similar to human chronic obstructive pulmonary disease (COPO), and was 
previously described as equine COPO. Human COPO differs from RAO in 
its aetiology and pathogenesis and so this term is now considered 
inaccurate. 
The phrase 'Recurrent airway obstruction' has been proposed to define 
mature horses with reversible airway obstruction arising from 
environmental challenge. RAO is thought to be caused by an allergic 
reaction to irritants entering the respiratory tract such as allergens, dust or 
pollen (Robinson 2001). 
Clinical signs and epidemiology of RAO 
Clinical signs of RAO become apparent in horses frequently described in 
the literature as 'middle-aged'. The mean age of onset has been calculated 
as 12.4 years (s.d.± 6.8 years) (Hotchkiss et a/2007). Horses with RAO 
commonly present with airway hyper-responsiveness (AHR), 
bronchospasm, mucus accumulation, and airway inflammation. 
RAO has been estimated to affect half of all horses worldwide (Bowles et 
al 2002). Susceptible individuals may have a genetic predispOSition to 
acquiring the condition (Gerber et a/2008, Jost et a/2007). The risk of 
developing the condition is increased in the offspring of RAO-affected 
parents (Marti et a11991, Ramseyer et a/2007). Neither breed nor gender 
influences the risk of the development of RAO. 
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Clinical differentiation of RAO from other equine 
respiratory diseases 
Certain respiratory disorders in the horse may initially present with generic 
signs of airway disease (Table 1). 
Airway disorders Reduced Airflow Increased 
Inflammation 
Upper airway disorders ~ ~
Dorsal displacement of ~ ~
soft palate 
Laryngeal hemiplegia ~ ~
Pharyngeal collapse ~ ~
Sinusitis ~ ~
Epiglotitis ~ ~
Lower Airway 
disorders 
Inflammatory airway ~ ~
disease 
RAO ~ ~ ~ ~
Table 1: Common airway disorders in the horse where reduced airflow and Increased 
Inflammation are present 
(Adapted from Lavoie 2007) 
Confirmation of inflammatory airway disease (lAD) in poorly performing 
sports horses that show increased levels of mucus and inflammatory cells 
in the LRT (Hughes et a12011) requires careful evaluation to distinguish it 
from RAO (Table 2). 
42 
Category RAO lAD 
Age of onset 12.4 years Any age 
Respiratory changes Respiratory distress Respiration relatively 
including at rest unaffected 
Bronchial alveolar Neutrophil count >25% Neutrophil count < 20% 
lavage cytology 
Table 2: Clinical differentiation between lAD and RAO in horses 
(Adapted from Couetii et al2007 and International Workshop on Equine Chronic Airway 
Disease 2001) 
Differential diagnosis of RAO is based on the clinical history of the affected 
animal, a clinical examination, and interpretation of diagnostic tests (Table 
3) (Couetil et a/2007). 
Diagnostic test Method of evaluation 
Respiratory function Clinical scoring of cough, nasal discharge and abdominal 
effort 
Degree of airway Respiratory mechanics for evaluation of lung function: 
obstruction Measurement of flow rates, forced oscillation techniques, 
forced expiration respiratory inductance plethysmography 
Gas exchange Arterial blood gas analysis of arterial hypoxemia 
Pulmonary inflammation Exhaled breath condensate, SAL samples, bronchial 
brushings and lung biopsy 
Imaging methods Endoscopy and radiography for signs of mucopus and 
lung changes 
Table 3: Diagnostic tests for RAO 
(information from Equine Respiratory Medicine and Surgery (Lavoie 2007) 
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Sronchoalveolar lavage (SAL) cytology is considered representative of 
lung histopathology (Hoffman 2008) with its results frequently used to 
confirm a diagnosis of RAO. Total cell counts recovered from SAL fluid 
containing >25% neutrophils indicate an RAO-associated airway 
obstruction (Robinson 2001). In contrast, neutrophil numbers in SAL fluid 
of unaffected horses represent <10% of total cell count (Couetil et a/ 
2001). 
Welfare implications for horses with RAO 
Clinical manifestation of RAO in horses becomes increasingly apparent as 
the disease progresses. Mild to moderate RAO-affected animals can be 
free from clinical signs and remain bright with good appetite. Signs of mild 
RAO may include slight or modest exercise intolerance. 
In severe cases, the health and welfare of the animal may be 
compromised. Such animals display visible respiratory distress, often at 
rest (Robinson 2001). Horses with RAO can deteriorate rapidly and 
experience severe inhibition of their athletic capabilities. 
The prognosis for a return to normal health in horses with RAO is poor. 
Episodes of exacerbation in RAO include bouts of severe non-productive 
coughing and periods of dyspnoea. During such periods a double 
expiratory effort may be required to maintain adequate ventilation. 
Advanced cases of RAO develop hypertrophy of the external abdominal 
oblique muscle from the respiratory exertion. This appears as a visible 
external line and has led to the colloquial description of RAO as 'heaves' 
(Robinson 2001). 
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Available management and treatment of the disease 
Current management of RAO requires stringent control of environmental 
irritants accompanied by anti-inflammatory medication (Table 4). 
Treatment is limited to symptomatic relief (Cunningham & Dunkel 2008). 
Principal effect and drug 
Medication 
mechanism 
Anti-inflammatory group of 
glucocorticoid steroids. The 
principal action is to bind to the 
Corticosteroids e.g. 
glucocorticoid receptor which 
Dexamethasone/Beclommethasone/Fluticasone 
prevents translocation of 
transcription factors into the 
cytosol to inhibit the production 
of inflammatory proteins 
Improve breathing by reducing 
airway obstruction and mucus 
Bronchodilators e.g. 
accumulation. Bronchodilators 
Clenbuterol/Salmeterol/Pirbuterol act on ~ 2 - a d r e n e r g i c c receptors to 
relax smooth muscle and enable 
dilation of bronchial airways 
Table 4: Principal treatments available for symptomatic control of RAO 
(Adapted from Lavoie 2007) 
Despite careful management and medication, clinical signs of RAO can 
take several weeks to subside (Dixon et al 1995). RAO remains a poorly 
understood disease with high welfare and financial implications. For these 
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reasons, further investigation of RAO and its underlying mechanisms is 
warranted. 
Similarities between human asthma and RAO 
Aspects of the aetiology, pathogenesis and clinical signs of RAO are 
comparable with human asthma. Asthma is described as a narrowing of 
the airways following contact with an irritant. Symptoms of asthma include 
shortness of breath, bouts of coughing, and a tight feeling in the chest 
(Wenzel 2006). 
Clinical similarities of RAO to asthma 
Equine RAO and asthma in humans both show varying degrees of 
pulmonary dysfunction affecting airflow and respiration. Either condition 
can present with airway hyper-responsiveness (AHR), bronchospasm, 
mucus accumulation, and airway inflammation (Robinson 2001, Chipps et 
a/2012). 
Airway hyperesponsiveness 
AHR is triggered by multiple factors and may subsequently provoke 
bronchospasm. Bronchospasm induces bronchoconstriction, with coughing 
and dyspnoea (Robinson 2001, Suguikawa et a/2009). Variable airflow 
obstruction in RAO and asthma is reversible either spontaneously or with 
intervention and altered clinical management. Clinical management 
frequently requires severely limiting exposure or removal of the principal 
allergen (Suguikawa et a/2009). 
Mucus accumulation 
Persistent mucus accumulation perpetuates the bronchoconstriction 
present in asthma and RAO. Excessive mucus production is correlated 
with lung dysfunction and damage (Murdoch & Lloyd 2010). 
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The exact cause of asthma is unclear but several factors increase the 
likelihood of its development. This includes genetic predisposition such as 
a family history of allergy and environmental influences including smoking 
and pollution. Asthma may develop at any age with several key triggers 
(Fig.6) capable of initiating an exacerbation (Chipps et a/2012). 
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Figure 6: Common asthma triggers 
(Adapted from Chipps et a/2012) 
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The pathogenesis of asthma is associated with the multi-cellular action of 
mast cells, eosinophils, neutrophils and CD4 + T -lymphocytes (Holgate 
2008). Severe asthma sufferers are therapy resistant and experience 
increasingly worsening symptoms (Haselkorn 2009). Human asthma has 
well documented origins in allergy as a Type 1 hypersensitivity reaction 
(Holgate 2011). Evidence for the role of type 1 hypersensitivity in the 
pathogenesis of RAO is equivocal. 
1.11 Evidence for RAO as an allergic disease 
Type I hypersensitivity 
Evidence outlining a Type 1 hypersensitivity reaction as the pathogeniC 
basis for RAO is divisive (Wagner 2009). Type I hypersensitivity immune 
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reactions occur in people and are frequently initiated by environmental 
factors such as pathogens or diet. Immunoglobulin E (lgE) concentrations 
are frequently elevated in individuals with type I hypersensitivity. 
Antigen exposure can cause IgE-bound high-affinity Fc£RI receptors 
expressed on mast cells to cross-link. Cross-linking initiates degranulation 
of mast cells and the release of molecules such as histamine, heparin, and 
eicosanoids which initiate clinical signs of allergy and inflammation 
(Tizzard 2004). 
Clinical signs of Type 1 hypersensitivity in atopic or sensitized humans 
present with an early and late phase response. Early phase reactions 
occur within minutes of allergen exposure with late phase responses 
peaking at 6-12 hours before subsiding (Tizzard 2004). 
Allergen testing in horses 
IgE-mediated allergies in horses such as insect bite hypersensitivity are 
well documented (Wagner 2009). Intra-dermal skin tests to measure 
immune reactivity to IgE indicative of Type 1 hypersensitivity yield 
inconclusive results in RAO-affected horses. Results showed considerable 
variability, with positive results recorded in control groups, and 
repeatability of tests proving questionable (Lebis et a/2002, Tahon et al 
2009). Data from dermal allergy testing has not indicated significant early 
phase IgE mediated development of RAO. Evidence for both early and late 
phase hypersensitivity in horses with RAO is unclear 
Early phase hypersensitivity in RAO 
Early studies suggested inhalation of allergens Faenia rectivirgula sp. and 
Aspergillus fumigatus sp. induced type I hypersensitivity responses 
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(McGorum ef a/1993, Robinson 1996). More recent works demonstrate 
that serum from RAO horses has increased IgE levels, specifically in 
response to recombinant mould A. fumigafus 8 (rAspf8) (Kunzle ef al 
2007). 
Data confirming mast cell activity in RAO as an indicator of early stage 
hypersensitivity is limited. Allergen challenges using suspensions of 
hay/straw dust increased SAL fluid histamine concentrations in control 
horses, but not in RAO-susceptible horses. Similar studies found SAL fluid 
from RAG-affected horses had increased histamine concentrations only 
after several hours of inhalation challenge (McGorum ef a/1993, Deaton ef 
aI2007,). Despite the development of antibodies to detect IgE and assays 
to quantify total serum IgE levels, early stage assessment of RAG remains 
controversial (Wagner 2009). 
Late phase hypersensitivity in RAO 
Clinical signs of RAO can be induced 6-12 hours after allergen challenges 
such as dry/mouldy hay or stabling on straw bedding. This is associated 
with a Th2-type response indicating late phase hypersensitivity (Lavoie ef 
a12001, Cordeau ef aI2004). 
Divergence of undifferentiated CD4+ T helper cells (ThO) into Th1 (cell 
mediated immunity) or Th2 (humoral immunity) subsets is determined by 
the cellular environment (Opal and DePalo 2000). Following activation, by 
antigen recognition and co-stimulation, Th1 or Th2 cells undergo clonal 
expansion and express cytokines specific to that cell subset (Tizzard 
2004). Th1 cells are characterised by production of IFN-y, while Th2 cells 
produce IL-4, -5 and -13 (Fig.7) 
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Figure 7: Th1 and Th2 differentiation subsets 
(Adapted from Opal & Depalo 2000) 
Evidence for a Th2-type profile in RAO includes elevated concentrations of 
mRNA for IL-4, IL-5 and IL-13 from BAL fluid RAO-affected horses, with 
decreased expression of IFN-y (Lavoie et a/2001, Beadle et a/2002, and 
Cordeau et a/2004). Additionally, a 'modified Type 2 cytokine response', 
has been described where mRNA for IL-4, IL-13 but not IL-5 was 
expressed in RAO-affected horses (Horohov et a12005). Some studies 
have not established Th 1 or Th2 type cytokine responses in RAO-affected 
horses (Kleiber et al 2005, Pietra et al 2007); others found increased 
concentrations of IFN-y indicating a Th1 influence for RAO pathogenesis 
(Ainsworth et aI2003). The lack of conclusive evidence for a Th2 based 
response suggests that RAO may not be an exclusively allergen-driven 
condition. 
Non-allergic or refractory asthma 
Conflicting results in establishing a definite Th2 phenotype in RAO could 
be attributed to 
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• differences in sampling methods and measurements 
• varying states of disease progression! antigen exposure times 
• The timing of sample collection. 
Other variations include the age and type of horses used in studies, and 
type of allergen challenge (older studies frequently only cite 'dusty' 
bedding or hay). Furthermore, although cytokine profiles may be skewed 
towards Th2 or Th1 subsets, both types continue to produce their 
respective subset cytokines to some degree (Horohov ef a/2005). 
Investigations into the differing forms of asthma in humans suggest a late-
onset or 'intrinsic' phenotype in adult life unrelated to atopic sensitization. 
Production of Th2 cytokines and IgE has been demonstrated in non-
allergic asthma (Wenzel 2001). Contributory factors to intrinsic asthma 
include: sensitization to environmental factors unconnected to IgE 
influence, and airway reactivity to prolonged tissue damage (Holgate 
2008). If a similar intrinsic phenotype occurs in horses with RAO, it has not 
yet been established. 
1.12 Respiratory inflammation and airway 
remodelling in RAO and asthma 
Histology and cell types of the trachea 
Gas exchange quality and respiration rate are reliant on healthy, 
structurally intact airway tissue. Air delivery to the lungs in asthma and 
RAO is restricted by smooth muscle contraction of the bronchi and 
bronchioles, inflammation of the bronchial mucosa and excess mucus in 
the airways. The mucosal layer lining the lumen of the trachea (Fig.S) and 
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primary bronchi is composed of ciliated pseudostratified columnar 
epithelium and the lamina propria (Beachey 1998). 
Tracheal is 
muscle 
Lumen . . . . . . . . I ~ . . ; ; - - ...... 
Figure 8: Cross section of the main tissue types found in the trachea 
(Figure adapted from Beachey 1998). 
The predominant cell types in the respiratory epithelium are ciliated 
pseudostratified columnar cells, goblet (mucus) cells and basal cells 
(8eachey 1998). Mucosal dendritic cells (DCs) and Clara cells are also 
present in the epithelial layer (Iwasaki 2007). 
The ciliated pseudostratified columnar cells form a single layer in contact 
with the basement membrane. Visually, they appear to be in many layers 
or 'pseudostratified'. These cells are secured at their apical , lateral and 
basal surfaces to effectively form an epithelial barrier. 
Goblet cells are cup-shaped cells in the lower respiratory tract (LRT) 
whose numbers decrease towards the bronchioles. They are simple 
columnar cells with membrane-bound mucin granules which are secreted 
and used in the formation of mucus. 
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Basal cells are small, roughly triangular shaped cells. They aid attachment 
of epithelial cells to the basal layer and are a reserve pool for epithelial 
cells. They are important in repair following injury to the epithelial layer, as 
they have a modest ability to migrate and then regenerate into different cell 
types. Regeneration of the epithelium is additionally aided by Clara cells, 
non-ciliated cells found in the bronchioles (Beachey 1998). 
Respiratory irritants and airway inflammation 
Environmental irritants and allergens entering the respiratory tract are 
strongly associated with the clinical onset of asthma (Heinrich 2011). The 
aetiopathogenesis of RAO indicates that inhalation of environmental stable 
dust is the main instigator of RAO (Gerber et a/2008). 
Horses in the UK are frequently stabled for extended periods, particularly 
in winter (Hotchkiss et a/2007). There is a connection between poorly 
ventilated stable environments and airway inflammation in susceptible 
horses (Clements & Pirie 2007, Marinkovic et a/2007). Subclinical airway 
inflammation and mucus accumulation may occur in horses in the absence 
of clinical signs. These findings are correlated with being housed in a 
conventional stable environment (Gerber et a/2003), which offers limited 
ventilation. 
Stabling increases exposure to organic dust, abundant in poor quality feed 
or bedding. Organic dust which enters the peripheral airways exacerbates 
RAO (Robinson et a/ 1996, Clements & Pirie 2007). RAO has been 
described as being similar to occupational or organic-dust induced asthma 
in humans (Deluca et a/2008). Grain dust exposure is shown to increase 
prO-inflammatory cytokine Il-6 expression in the human airways (Deetz et 
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a/1997, Von Essen at a/1998). This theory is further supported as clinical 
remission of RAO can be achieved if the animal is placed in a low dust, 
well ventilated environment (Dacre et aI2007). 
Other inhaled agents capable of inducing airway inflammation include 
noxious gases, moulds, and bacterial cell wall toxins (endotoxin) from 
Gram-negative bacteria or their lipopolysaccharide (LPS) derivatives. 
Moulds contributing to RAO pathogenesis include ( 1 - - + 3 ) - ~ - D - g l u c a n n from 
thermophilic types Aspergillus fumigatus, Thermoactinomyces vulgaris, 
and Faenia rectivirgu/a (Pirie et a/2003). 
Exposure to extracts from these moulds causes pulmonary inflammation in 
RAO-affected horses (McGorum et a/ 1993). However, the extent of 
mould-induced respiratory inflammation is less when compared to that 
initiated by hay or straw exposure. The potency of moulds considered to 
initiate RAO exacerbations is thought to be enhanced by airborne LPS 
fractions (Pirie et a/2003). 
Effects of airborne and systemic endotoxin in horses and 
humans 
The concentration of airborne endotoxin is increased 8-fold in the 
environment of stabled horses, compared to those at pasture. Endotoxin, 
in very small concentrations, is noted for provoking a rapid innate immune 
response, by activating Toll-like receptors and initiating inflammation. The 
effects of endotoxin are credited to its highly potent lipid-A moiety (Liu et a/ 
2002). 
Endotoxin exposure also recruits neutrophils to the airways, a typical 
feature of RAO (Pirie et a/2001). Inhalation of 1.6 and 5 mg A. fumigatu5 
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extract increased neutrophil numbers and lung dysfunction in RAO-
affected horses. Removal of LPS fractions from A. fumigatu5 extract 
attenuated the increase in neutrophil numbers (Pirie et a/2003). 
Clinical manifestations of endotoxemia in human patients include: muscle 
tremors, lowered blood pressure, tachycardia, and tachypnoea. Multiple 
organ failure and death may occur in severe untreated cases (Pleiner et a/ 
2002). Additional signs of endotoxemia in horses include vascular 
dysfunction, systemic inflammation, and pulmonary hypertension. 
Horses are sensitive to the effects of LPS exposure; like human patients, 
endotoxemia in horses is viewed as a significant cause of mortality (Morris 
1991, Moore 2001). Equine mortality rates from gastro-intestinal 
dysfunction or systemic inflammation are increased by the effects of 
endotoxemia (Neuder et a/2009). 
The relative contribution of either organic dust or LPS fractions to the 
induction of airway inflammation in RAO is undefined. However, LPS is a 
highly potent agonist for the human and equine immune system (Moore 
2001). LPS contributes significantly to development of acute and chronic 
airway inflammation in many human and equine diseases. It can therefore 
be regarded as an important factor in respiratory disease. 
Airway remodeling in RAO and asthma 
Episodes of inflammatory exacerbation in asthma and RAO can cause 
significant tissue damage. The presence of a continued pulmonary insult 
instigates airway hyper-responsiveness (Berend et a/ 2008) in a self-
perpetuating cycle of respiratory injury (Fig.9). 
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Figure 9: Cycle of airway damage and Injury In RAO and asthma 
(Adapted from 8eachey 1998) 
Over time, repeated inflammatory episodes from exposure to 
environmental pathogens will cause alterations to the surrounding 
respiratory tissue. Such alterations may inhibit or affect the healthy 
functioning of the lung and are classed as airway remodelling (Marinkovic 
et a12007, Berend et a/2008). 
Dysfunctional changes to epithelial cells from repeated 
inflammation 
The pulmonary mucosa is an integral part of innate and adaptive immunity. 
It represents the first pOint of contact for host defence against airborne 
pathogens and actively modulates airway function (Knight & Holgate 2003, 
Kato & Schleimer 2007). 
The effect of unresolved pulmonary inflammation is noted as a factor in the 
pathogenesis of human chronic lung conditions (Polito & Proud 1998). 
Allergen-induced inflammation can create crosstalk between mucosal Des 
and epithelial cells. This crosstalk has been correlated with the initiation of 
asthma (Ham mad & Lambrecht 2008). 
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Persistent or prolonged inflammation causes loss of epithelial integrity and 
the physical defence it provides (Matera et al 2002, Kato & Schleimer. 
2007). Injury to the protective mucosal layer in equine gastro-intestinal 
conditions enhances the damaging effect of endotoxin (Moore et aI2001). 
Damaged respiratory epithelial cells become increasingly permeable to 
airborne pathogens or environmental pollutants (Polito et a/1998, Greene 
& McElvaney 2005, Knight & Holgate 2003, Mayer et a12008, and Holgate 
2008). 
Signs of uneven epithelial repair and structural damage are seen in RAO-
affected horses (Berend et al 2008). Airway remodelling may develop 
following prolonged respiratory damage and is evident through tracheal 
changes. This includes: epithelial thickening, goblet cell hyperplasia, 
basement membrane thickening, increased cellular matrix and hypertrophy 
or hyperplasia of ASM (Robinson 2001). Tracheal changes contribute to 
significant airway wall narrowing with diminished airflow in RAO and 
asthma. AHR significantly increases bronchoconstriction and irreversible 
lung damage in both conditions (An et al 2007). The ability of the 
pulmonary mucosa to repair may subsequently deteriorate (Yang et al 
2006). 
The airway epithelium regulates airway function, has significant roles in 
immunity, and directly affects the development of airway remodelling. This 
suggests that the epithelial layer is pivotal in the modulation of airway 
disease. Minimising pulmonary inflammation and epithelial damage would 
therefore seem to be fundamental in the treatment or inhibition of RAO. 
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Increase in smooth muscle layer in RAO and asthma 
An increase in the thickness of the smooth muscle layer surrounding the 
airways is a feature of both RAO and asthma (Hirst et a12004, Herszberg 
et al 2006). ASM thickening can significantly restrict airflow during 
episodes of bronchoconstriction (Bai and Knight 2005). The severity of 
both conditions is thought to be reflected by the advancement of ASM 
increase (Robinson 2001, James et a12012). 
Targeting the pathogenesis of ASM increase is a focus of asthma studies 
and RAO investigations. ASM increase in humans is attributed to muscle 
cell hyperplasia, hypertrophy and a reduction or failure in cell apoptosis 
(Hirst et a/2004). ASM hyperplasia found in small and large airways of 
asthmatics is particularly noted as a major factor in fatal asthma (James et 
a12012). A similar scenario is evident in horses with RAO where ASM 
proliferation is attributed to both increased myocyte proliferation and 
apoptosis. It is suggested that the abnormal apoptosis serves as a way to 
limit the increase in ASM growth (Herszberg et a/2006). 
The relative contribution of either hyperplasia or hypertrophy towards 
airway remodelling in asthma remains under debate, and is largely un-
investigated in RAO. Typical mitogens and inflammatory factors cited as 
capable of ASM increase in asthma include epidermal growth factor, 
platelet-derived growth factor isoforms, fibroblast growth factor 2, tryptase, 
endothelin-1, thromboxane A2 leukotriene D, IL-1 J3, IL-6, and TNF-a 
(Hirst et a/2004). The source of these factors originates from crosstalk 
between the damaged epithelium and ASM or the innate immune 
response of ASM cells (James 2005). Epithelial loss and smooth muscle 
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hyperplasia have been recorded in children with asthma, suggesting the 
strong relationship between alterations in the epithelium and abnormal 
ASM thickening (Zhou et aI2011). Continued expression of inflammatory 
mediators from damaged epithelium may promote ASM hyperplasia 
(James 2005). 
Vascular smooth muscle cells are noted as having the capacity to change 
their phenotype in response to the localized environment (Alexander and 
Owens 2012). A similar ability may exist in equine and human smooth 
muscle cells. Smooth muscle phenotype in asthma is proposed as one 
potential mechanism for the transformation of healthy cells into asthma-like 
cells, which may have differing capacities to generate markers and 
inflammatory mediators. Conventional asthma treatment fails to fully 
control the extent of smooth muscle alteration (An et aI2007). 
Evaluation of airway inflammation and remodeling 
In order to investigate the mechanisms of inflammation and remodeling in 
RAO and asthma, numerous methods have been developed in vitro in 
various spices. 
Equine and human models of the airway epithelium in 
vitro 
In vitro cell culture models are a vital tool in the study of airway diseases 
mechanisms in horses and people. They have made significant 
contributions to understanding inflammatory disturbances, bronchial tissue 
alterations and the efficacy of new drugs for clinical research. 
In vitro pulmonary models provide several advantages over studying 
respiratory disease in vivo or ex vivo. In vitro methods afford the ability to 
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carefully control the culture environment, exclude variability in data from 
other respiratory cell types, and study primary cell characteristics such as 
differentiation, repair potential and specific responses to pathogens. 
Equine and human models of the airway epithelium in 
vitro 
In vitro systems include 2-dimensional monolayer cell systems with 
continuous or primary cells, and 3-dimensional studies composed of air-
liquid interface and organotypic cultures. 
Two-dimensional cell culture studies 
Human continuous respiratory cell lines 
Continuous respiratory cell lines are derived from human lung carcinomas, 
or those created by mutagenesis. Continuous cell lines can provide 
valuable information when investigating human respiratory models of 
disease. Advantages include increased availability over primary cell 
cultures, and consistency between cell batches whereas primary cells may 
vary. Assessment of the physiological aspects and disease mechanisms of 
epithelial cells are often studied using an immortalized cell line BEAS-2B, 
a continuous cell line derived from lung tissue and demonstrating epithelial 
cell morphology. 
Primary bronchial cell culture 
Primary bronchial epithelial cells have been successfully isolated and 
cultured from human, bovine, canine and murine species (Spurzem ef 8/ 
2005, Kato ef 812006, Newby ef a/2007, Eries & Browlie 2010). Initial 
methods to culture primary equine bronchial cells have been described by 
incubation of equine tracheal segments for 24hrs in media containing 0.1 % 
pronase (Sime et 81 1997). Similar works have isolated respiratory 
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epithelial cells by digesting equine nasal tubinates in a Type I 
collagenase/type XIV protease mix (Lin et a/2001), and by 0.1 % protease 
digestion of isolated equine bronchi (Ainsworth et a/2009). These studies 
required serum supplementation of cell media and use of collagen coated 
culture flasks to aid initial growth and cell adherence. 
High yields of viable ETE cells have been obtained by digesting tracheal 
mucosal epithelium in media containing 0.25% trypsin. In contrast to 
primary cells isolated with pronase/protease, the use of collagen-coated 
culture flasks was unnecessary after initial dissociation of cells from 
mucosal tissue (Shibeshi et a/2008). Additionally, cellular characterisation 
is described in this study after primary cells were maintained for extensive 
periods in culture. Monolayer cells developed beyond cobblestone 
morphology and were described by the authors as 'pseudostratified 
columnar epithelium-like'. 
Culture of primary airway smooth muscle cells 
Primary airway smooth muscle cell culture has also been established in 
humans, rabbit, cow, and dog, although relatively unstudied in the horse 
(Hirst et a/1995, Bonnaci et a/2003, Halayako et a/2005, Alkhouri et a/ 
2011). Initial work by Fleischmann et a/ (1993) describes the enzymatic 
dissociation of primary myocytes from ferret trachealis muscle using 
Collagenase D and elastase. This method was further developed for 
collection of equine myocytes by digestion of minced trachealis muscle for 
20 mins in collagenase (Fleischmann et a/1996). Additional work with this 
method determined electrical activity but did not detail culture or 
identification of isolated cells. 
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Equine culture of primary smooth muscle cells has primarily focused on 
vascular smooth muscle. Smooth muscle cells have been successfully 
cultured from tunica media explants derived from equine palmar digital 
arteries (Rodgerson et a/ 2001). Vascular smooth muscle cells derived 
from explants of ascending aorta, pulmonary artery and digital artery are 
also reported (Janicke et a/2003). Cells were also maintained in serum-
enhanced media and identified by ICC staining with anti-a-actin 
monoclonal antibody (clone 1 A4). Neither study details the length of time 
taken for primary cells to become confluent, or attempts to passage 
cultured cells. 
Three-dimensional studies of asthma and RAO 
Two dimensional lung models are often criticised as not being 
physiologically realistic. Accordingly, increasingly sophisticated 
representations of the lung are being developed to enable exploration of 
morphological and immunological mechanisms of disease (Pampaloni et a/ 
2007). Relevant model systems for equine three dimensional respiratory 
cell studies include air-liquid interface systems (ALI), respiratory explants 
and organ tissue culture (Pampaloni et a/2007). 
ALI cell culture 
Bronchial cells grown at the air-liquid interface are regarded as a 
significant contribution to investigations of respiratory biology (Keismer et 
a/ 2009). Immortalized human bronchial epithelial cells exhibited the 
capacity to differentiate when cultured in a three-dimensional system 
(Delgado et a/2011). BEAS-2B cells maintained at the air-liquid interface 
(ALI) developed into basal, mucin-producing, and columnar ciliated 
epithelial cells (Vaughan et a/2006), Similarly, primary equine bronchial 
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epithelial cells differentiated when cultured at the ALI and demonstrated 
the capacity for mucus production (Schwab et 81201 0), cilliogenesis and 
tight junction formation (Quintana et 8/2011). 
Organ ALI culture 
Cultures of equine mucosal explants in vitro have been described by 
Vandekerckhove et 81 (2009). Mucosal tissue explants from vestibular, 
intranasal septum, the nasopharynx and the trachea were maintained in 
serum free media at the ALI for up to 96hrs without loss of morphology or 
epithelial integrity. Explants of equine mucosal tissue maintained on fine 
mesh gauze for up to 96 hrs demonstrated EHV-1/EHV-4 disease 
mechanisms highly similar to in vivo reactions (Vanderhocke et 8/2011). 
Whole organ explant cultures are also described in the horse (Lin et 81 
2001), where tracheal rings were dissected into sections with cartilage and 
basement membrane intact. Tracheal sections were maintained epithelial 
side up on a gyrorotary platform in a CO2 free atmosphere. Explants 
maintained in these conditions were viable for 48hrs before morphological 
degeneration of the epithelium became evident. 
1.13 Summary 
RAO and asthma are complex respiratory diseases where repeated 
inflammation instigates airway hyperesponsiveness and subsequent 
alteration of bronchial tissue. Lack of LXA4 and receptor ALX in severe 
asthma suffers is a potential mechanism of the development of chronic 
inflammation. Use of an in vitro equine respiratory model with selected 
mediators (Table 5) to examine LPS induced inflammation and potential 
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inflammatory resolution by LXA4 may aid understanding of the 
pathogenesis of RAO and asthma. 
Mediatorl molecule Classification Principal action 
Initiation of anti-
ALX receptor 
inflammatory pathways 
Initiation of inflammatory 
TLR4 receptor 
pathways 
TNF-a cytokine Inflammation 
IL-113 cytokine Inflammation 
iNOS enzyme Inflammation 
Inflammation/inflammatory 
COX-2 enzyme 
resolution 
Table 5: Important mediators In RAO and asthma 
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1.14 Thesis hypothesis 
Equine inflammation and its resolution can be modelled in vitro using 
respiratory epithelial and smooth muscle models. 
1.15 Aims of the thesis 
• Asses and select in vitro equine models of respiratory epithelium 
and airway smooth muscle 
• Characterise the response of selected models to LPS, a known 
instigator of inflammation on chosen mediators of inflammation and 
inflammatory resolution. 
• Compare the response of selected models to LXA4, considered to 
initiate inflammatory resolution, on chosen mediators of 
inflammation and inflammatory resolution. 
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Chapter 2: Materials and Methods 
Details are given here of standard methods used in the chapters 
describing inflammation and inflammatory resolution (Chapters 4, 5 and 6) 
in the in vitro respiratory model. Specific details for any methods used are 
described in each individual chapter. 
2.1 Materials 
Cell culture grade PBS, F-12 (Hams) Nutrient mixture, 10,OOOU/ml 
penicillin/10,OOOlJg/ml streptomycin (Pen/Strep), 250IJg/mi Fungizone 
(Amphotericin B in water), SYBR Green master mix, Alex-Fluor 488, all 
NuPage reagents/gels and MagicMarkTM XP, were purchased from 
Invitrogen, Paisley, UK. 
PVDF membranes were obtained from Amersham, Buckinghamshire. 
BEGM was obtained from Lonza; Slough, UK with porcine trypsin/2.65mM 
EDT A, heat inactivated FBS, Leibovitz's 15 and DMEM from Fisher 
Scientific, Loughborough, UK. Polysciences Polybead Microsphere® 
beads and 13mm tissue culture cover-slips-were acquired from Sarstedt, 
Leicester, UK. 
Pan-cytokeratin PCK-26 was sourced from AbCam, Cambridge, UK and 
antibody smooth muscle actin (clone 1A4) was acquired from Dako, 
Cambridgeshire, UK as was Expose Polyvalent HRP/DAB Detection kit. 
Antibodies for ALX and COX -2 for Western Blot were obtained from Novus 
Biologicals, Cambridge UK, and New England Biolabs, Ipswich, UK 
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respectively. Antibody for ~ - a c t i n n was a kind gift from Dr S.Dunham 
(Nottingham School of Veterinary Medicine and SCience, Nottingham). 
The Bradford assay reagent was purchased from Bio-Rad, Hemel 
Hempstead, UK and RIPA buffer obtained from Sigma-Aldrich, Poole, UK. 
LipoxinA4 and the nitrite/nitrate fluorometric assay kit were supplied by 
Cayman Chemicals, Cambridge Biosciences UK. 
The full address of each supplier is detailed in appendices 
2.2 Preparation of cultured equine primary cells 
and treatment protocols 
Preparation of equine primary cells prior to incubation with vehicle 
Culture media for primary equine cells was removed and replaced with 
fresh culture media 12 hrs prior to treatment. All cell populations were 
washed with warmed sterile cell-culture grade PBS (Invitrogen, Paisley, 
UK) which was removed and discarded before incubation with the relevant 
vehicle. 
Incubation of primary cells with lipolysaccharide, carprofen or 
lipoxin A4 
Cells were incubated with fresh medium (control) or medium containing 
LPS from Escherichia coli (serotype 0127:88), (Sigma-Aldrich), carprofen 
and LXA4, (Cayman Chemicals, Cambridge, UK). Concentrations of each 
treatment are indicated (Table 6) with specific amounts and incubation 
times detailed in the relevant chapters. 
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Treatment Concentration per ml 
Lipolysaccharide O . 1 - 1 0 0 ~ g g
Carprofen 4 ~ g g
LXA4 1 0 0 ~ M M
Table 6: Primary cell treatment types and concentrations 
Preparation of treatment vehicle solutions 
A stock solution of 1 mg/ml LPS solution was prepared under sterile 
conditions by dissolving E.Colipowder (Sigma-Aldrich, Poole, UK) ground 
with 25mls of sterile cell culture media, aliquoted and kept at _20DC. 
Carprofen solutions were made from 2mg of Rimadyl® tablets (Sigma-
Aldrich, Poole, UK) ground in a sterile mortar and pestle, added to SOmis 
of cell-culture media and sterile filtered using a 0.211M syringe filter 
(Whatman, Maidstone, UK). Carprofen solutions were used immediately. 
A 50111 aliquot of LXA4 (25119 of product in 250 III of solution) was 
evaporated under a nitrogen stream for 20 minutes. A 5119/ml stock 
solution was prepared by adding 1 ml of sterile cell culture grade PBS. 
2.3 Isolation of ribonucleic acid (RNA) 
Total RNA from cell samples was extracted using commercial RNA 
purification kits (RNeasy Mini kit, Qiagen and Pure Link, Invitrogen, 
Paisley, UK). All plastic-ware and materials were certified RNAse free by 
the manufacturers, with additional treatment for 45 minutes in a ultra-violet 
flow hood. Cell samples (approximately 20l1g of tissue or 4.8 x 105 cells) 
were lysed with a 600 III volume of guanidine-isothiocyanate lysis buffer 
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with 10 IJI of ~ - m e r c a p t o e t h a n o l l added. The cell lysate was then passed 
through a disposable sterile 21-gauge needle and sterile plastic 1 ml 
syringe 4-5 times. Total homogenisation was achieved by micro-
centrifugation of the cell lysate in spin columns supplied in the kit. 
RNA extraction and elution was performed using silica-gel membrane 
purification according to the kits instructions. Additionally, an on-column 
digestion of DNA (RNase-Free DNase, Qiagen) in each sample was 
performed. Each sample was incubated with 80 III DNase mix for 15 
minutes at room temperature to eliminate contaminating genomic DNA. 
The RNA quality and concentration of each sample was assessed through 
spectophotometric absorption according to Beer-Lambert law. RNA 
sample concentrations ranged from 0.10-1 I1g of total RNA. Samples with 
an absorption ratio of> 1.7 were considered to be sufficiently pure for use 
in first strand complementary deoxyribonucleic acid (cDNA) synthesis. 
Quantified RNA samples were aliquoted into 10111 samples for -80°C 
storage or used immediately in cDNA synthesis. 
2.4 Reverse transcription of total RNA for 
synthesis of first strand eDNA 
Samples of cDNA were obtained from isolated RNA by use of the 
SuperScript III First Strand Synthesis System (Invitrogen, Paisley, UK). All 
reagents for total cDNA synthesis were supplied by the manufacturer. All 
samples were standardized to ensure that equal concentrations of RNA 
per sample were used in cDNA synthesis. 
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Total RNA samples were reverse-transcribed into cDNA by the use of 
either oligo-dT or random hexamers in three main stages. The initial step 
and synthesis mix (Table 7) enabled the linearization of RNA secondary 
structures. 
Component Volume 
0.10-1 \.1g total RNA NjJI 
50 ng/\.11 random hexamers 1 \.11 
10 mM dNTP mix 1 1-11 
OEPC-treated water NjJI 
Total volume 1Olli. 
Table 7: Components of Initial stage of cDNA synthesis mix 
Samples were incubated for 65°C for 5 min and placed on ice for 1 min. 
The second step enabled annealing of the random hexamers to the RNA 
and subsequent formation of cDNA. Each sample had 10 1-11 of second 
stage cDNA synthesis mix added (Table 8). 
Component Volume per sample reaction 
10X RT buffer 21-11 
25 mM MgCb 41-11 
0.1 M OTT 21-11 
RNaseOUT (40 UlI-II) 1 1-11 
SuperScript III RT (200 U/I-II) 1 1-11 
Total volume 201-11 
Table 8: Components of the second stage of cDNA synthesis mix. 
Each sample reaction was then incubated for 10 minutes at 25°C followed 
by 50 minutes at 50°C. Reactions were then terminated by heating 
samples at 85°C for 5 min. All samples were immediately chilled on ice. 
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To complete the cDNA synthesis each sample had 1 IJI of RNase H added 
before a final incubation step for 20 min at 3]oC. All samples were used 
directly in polymerase chain reactions (PCR) or stored directly at -Boac. 
2.5 End-point and real time polymerase chain 
reaction (peR) 
End-point peR 
End-point and real time PCR (q-PCR) methods were both used to amplify 
specific genes of interest. This was achieved by either separation of PCR 
products through agarose gel electrophoresis (end-point) or detection of 
PCR product by emission of a fluorescent signal (real-time). 
peR primers and primer design 
The primers sequences and conditions used in end-point and q-PCR were 
obtained from either published papers (Berndt et a/ 2007, Zhang et a/ 
2009), from Dr Richard Hammond (personal communication), Dr Steve 
Dunham (personal communication) or designed using NCBI-BLAST primer 
design. 
To minimise non-specific annealing (primer-dimers), primer pairs used in 
experiments (Table 9) were designed to be 1B-22 bases long, with a GC 
content of no more than 50%. Annealing temperatures for each sense and 
anti-sense strand were 60aC or with no more than 1°C difference between 
the primer pairs. Primer pairs and their predicted amplicon length for each 
gene of interest were verified via NCBI-BLAST and EMBL-EBI multiple 
sequence alignment programme ClustalW2. 
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Gene Amplicon 5'-3'strand 3'-5'strand 
size (sense) (antisense) 
ALX 213 AAACCACCGCACTGTAGGTC CGGATGATCCCTCTGACTGT 
TLR-4 91 TCTGGAGACGACTCAGGAAA 
GCAAGAAGCACCTCAGGAGTTT 
GC 
TNF-a 74 CGACTTTGCGGAGTCCGGGC GTGGGCGAGGACGGACGTAC 
I L - 1 ~ ~ 69 CTGCAGCGGCAATGAGAAT TGGAAGCTGCCCTTTCATCTG 
iNOS 372 TAGAGGAACATCTGGCCAGG TGGCAGGGTCCCCTCTGATG 
COX-2 320 GAGTACCGCAAACGCTT TTATTGCAGATGAGAGACTG 
j3-actin 107 CACCACACCTTCTACAAC ATCTGGGTCATCTTCTCG 
GAPDH 365 GAGATGATGACCCTTTTGGC GTGAAGGTCGGAGTCAACG 
18-S 204 ATGCGGCGGCGTT A TTCC GCTATCAATCTGTCAATCCTGTCC 
Table 9: PCR primer pairs used In experimental studies 
End-point peR 
A standard 25 III peR reaction mix (Table 10) was prepared in a 0.21-11 
sterile disposable RNA/DNA-free eppendorf. 
Component Volume 
GoTaq Hotstart Colourless mix 1 2 . 5 ~ 1 1
Sense primer 1 . 5 ~ 1 1
Anti-sense primer 1 . 5 ~ 1 1
DEPC -treated water 8 . 5 ~ 1 1
Sample of eDNA 1 ~ 1 1
Total volume 25 ~ I I
Table 10: End-point PCR synthesis mix. 
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All reactions were kept chilled on ice. Reference genes GAPDH, 18S or 
Beta-actin were used to measure constitutive cellular RNA expression and 
no template controls (NTC) omitted cDNA to act as negative controls. 
Samples were placed in an automated thermal cycler with a heated lid and 
run using a standard PCR protocol. An initial 2min denaturing step of a 
single cycle at 95°C was followed by 35-45 consecutive cycles of three 
distinct stages (Table 11). A final extension step was performed at 72°C 
for 10 minutes to allow total synthesis of full length products. 
PCR cycle Cycle temperature Cycle time 
Denaturing 95°C 60 seconds 
Primer annealing 50-65°C 60 seconds 
Extension/elongation 72°C 60 seconds 
Table 11: End-point PCR protocol for cycle temperature and time 
Annealing temperatures (Tm) for each primer pair were used where stated 
in the original papers. If required, Tm was optimized thereafter, by 
calculated by the percentage of G and C bases in the primer. 
Agarose gel electrophoresis 
The predicted size of the PCR products determined the % (w/v) of agarose 
used in the gel. DNA products of <500bp were separated on gels of 2%, 
1.5% gels for products of 500bp -1200bp and 0.8% for products of 
>1200bp. Agarose gels were run for approximately 90 minutes at 100V. 
Agarose powder and 1 x Tris-EDTA acid buffer (TAE, 40 mM Tris, 20 mM 
glacial acetic acid, 1 mM EDTA, pH 7.6) were heated until the agarose had 
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fully melted. The solution was cooled under cold running water to 
approximately 37°C. 
Ethidium bromide (3.Sj,JI) was mixed in with the agarose solution and the 
gel poured into a casting tray. The gel was placed into a PCR tank, 
covered with 1 x TAE buffer and samples loaded. DNA loading buffer was 
used to prepare the samples at a ratio of 3j,J1 buffer to 1 OJ,J1 cDNA sample 
(1 :3 ratio), with 12j.J1 of buffered sample loaded into each well. A standard 
1 Kb DNA ladder (10 Ill) was separated with the samples and used to 
estimate the size of PCR products. 
Sequencing of peR products 
Products from endpoint PCR were used to determine that the chosen 
primer pairs were successfully amplifying the relevant gene of interest. 
PCR samples were sent for commercial Sanger DNA sequencing to 
SourceBioscienes, Nottingham. A typical6j,J1 PCR sample for sequencing 
contained a cDNA concentration of 1 ng/j,J1 per 100bp. The generated 
amplicon sequences were verified with NCBI-BLAST, and are detailed in 
the appendices. 
Real time peR 
The relative concentration of RNA in samples was quantified by emission 
of a fluorescent signal by use of qPCR. SYBR Green (Invitrogen, Paisley, 
UK), a fluorogenic dye that binds to double stranded DNA, was used to 
detect the amount of reverse-transcribed cDNA in samples. The strength 
of signal emission is proportional to the copy number of the gene of 
interest. 
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Real time PCR synthesis mix and cycling programmes 
Each cDNA sample was diluted 1/25 in DE PC-treated water before the 
addition of a SYBR Green (Invitrogen, Paisley, UK) master mix (Table 12). 
Component Volume per reaction 
SYBR Green 10111 
DE PC-treated water 2.2111 
Primer 2.8 III (1.4 of each primer) 
cDNA or DEPC-treated water for NT control 
5 III 
Total volume 20 ~ . I I I
Table 12: Components of real time PCR SYBR Green master mix. 
Each individual reaction was repeated in triplicate, with all samples loaded 
into a 96-well plate. Negative controls were represented by the omission of 
cDNA in samples to act as a no template (NT) reaction. 
Samples were run on a Lightcycler 480 (Roche, West Sussex UK) with 
thermal cycler conditions as follows: incubation at 95°C for 5 minutes, 
followed by 45 cycles of 95°C for 10s, 60°C for 15 and 72°C for 30s. A 
final extension step of 10 minutes at 72°C was performed. 
Standard curves and relative quantification of product for q-PCR 
Standard curves were used to measure the concentration of product and 
the efficiency of all primer pairs. Standard curves were constructed from a 
serial dilution of pooled equine tracheal epithelial cells, airway smooth 
muscle cells (Chapter 3), and equine mononuclear cells. Dilution factors 
were 5-fold, with each reaction in duplicate and as follows: 1 :5, 1:10, 
1 :250, 1: 1250, 1 :6250 and 1 :31250. 
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The efficiency of each primer pair used was then calculated from the anti-
log concentration generated from Ct values and each serial dilution. A 
correlation coefficient of 1.000 indicates a perfect fit for the standard curve. 
Quantification of mRNA samples in real-time peR 
Values for the absolute concentration of each mRNA sample were derived 
from the mean average of each triplicate reaction. A melt curve analysis on 
the final product indicated whether a specific product was amplified and 
the presence of primer-dimers. Relative quantification of the mRNA 
samples was then calculated by dividing target gene values with reference 
gene values. 
Isolation of peripheral blood mononuclear cells from 
whole blood for real time peR standards 
Peripheral blood mononuclear cells from whole blood were used to provide 
a positive control for ALX real time PCR standards. Whole blood samples 
(10mls) were obtained from Welsh Mountain ponies by jugular 
venipuncture into vacutainers and kindly provided by Dr Julia Kydd (School 
of Veterinary Medicine and Science, Nottingham). 
All samples were collected with 150 units/ml of heparin to prevent 
coagulation of blood. Peripheral blood mononuclear cells (PBMCs) were 
isolated using a standard Ficoll-Paque gradient method within 2 hours of 
collection. The plasma layer (10mls) was removed from each tube and 
carefully layered over 4.5mls of Ficoll-Paque (GE Healthcare, Chalfont St 
Giles, UK) in a 15ml sterile disposable polypropylene tube. Samples were 
centrifuged at 400 x g for 10 minutes at 20°C. The upper layer of 
supernatant was aspirated, and the layer containing PBMCs transferred 
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into a fresh 15ml sterile tube. Cells were washed twice in 5mls sterile PBS 
followed by centrifugation at 400 x g for 10 min at 20°C to remove 
platelets. The cell pellet was re-suspended in D-MEM (high glucose) with 
10 % FBS (Invitrogen, Paisley, UK). 
Statistical Analysis of q-PCR values 
Values for mRNA expression were derived as mean numbers from 
triplicate samples following normalization to the reference gene from each 
individual experiment. Statistical significance was determined through 
STDEV, standard SEM and ANOVA analysis of the raw data. A p-value of 
<0.05 in ANOVA analysis was regarded as statistically significant. 
2.6 VVestern blot 
Preparation and quantification of protein samples 
Cultured primary equine cells were grown to 70-80% confluency as 
described. An ice-cold RIPA lysis/extraction buffer containing phosphatase 
and protease inhibitors (Complete EDT A-free Protease Inhibitor Cocktail), 
(Roche, West Sussex UK) was used to harvest cells. Cell samples were 
kept on ice and incubated for 30 mins in 1 O O ~ I I per sample of prepared 
RIPA buffer. Cell Iysates were then centrifuged at 800g, 4°C for 10 
minutes. The resulting cell supernatants were stored at -80°C before use 
in protein studies. 
Quantification of protein samples using the Bradford protein assay 
The concentration of protein in each sample was ascertained by the use of 
the Bradford protein assay (BioRad). This assay employs colorimetric 
absorbance of Coomassie Blue dye with protein concentration dependant 
on the amino acids present in the sample. Sample readings are taken at 
595 nm where the absorption spectrum of the dye is held. 
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Protein standards and quantification of samples 
A set of 5 protein standards (0.05mg/ml to 0.5 mg/ml) to quantify unknown 
samples were prepared by diluting 1.45mg/ml BSA in double distilled 
water. A 1:4 dilution of Bradford reagent (BioRad) was prepared with 
sterile water and filtered through filter paper. A 10 III sample of each 
protein standard or unknown was mixed thoroughly with 200l1l of the 
diluted Bradford reagent. All standards and samples were repeated in 
triplicate in a 96 well plate. Samples were incubated at room temperature 
for 10 minutes, then protein concentrations quantified with the Fluorostar 
microplate reader set at 595 nm 
Denaturing of protein samples for separation on polyacrylamide gels 
Protein samples were denatured prior to separation through 
electrophoresis on polyacrylamide gels. Up to 7.5111 of protein sample 
containing 25119/ml of protein was combined with 2.5111 of NuPage LDS. 
Sample buffer (4x) and 1 III of NuPage Reducing Agent (Invitrogen, 
Paisley, UK), to make a total volume of 10 Ill. Samples were then heated 
in a thermal block at 70°C for 10 minutes. Denatured samples were used 
directly in electrophoresis or stored at -80°C. 
Separation of proteins from cell Iysates on polyacrylamide gels. 
Prepared denatured proteins were separated on a precast 8-12% NuPage 
Bis-Tris gel used in a NuPage X Cell Sure lock module (Invitrogen, 
Paisley, UK). NuPage SDS Running Buffer (MES, 20 xs) was prepared by 
adding SOmis of stock solution to 950mls of chilled deionised water and 
used to fill the module. The inner module chambers then had 500111 of 
NuPage antioxidant added to ensure optimal separation of proteins. The 
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denatured samples and protein ladder were loaded at 10111 per sample per 
well. Gels were then run at approximately 200V for 1 hour. 
Protein transfer onto PVDF membrarie 
Separated proteins were transferred from polyacrylamide gels after 
electrophoresis onto PVDF membranes (Hybond-P), (Amersham, 
Buckinghamshire, UK). Transfer buffer was prepared by combining 50mls 
of NuPage Transfer buffer, 1ml of NuPage antioxidant, and 100ml of 
methanol per gel made to a final 1 l volume with deionised water. The 
PVDF membrane was soaked in 100% methanol for 30s prior to use. 
Proteins were transferred in an XCell II Blot module filled with prepared 
buffer for 1 hr at 30V. 
Detection of transferred proteins and visualisation using Eel 
Three main steps were performed before ECl detection: blocking the 
membrane to prevent background staining, overnight incubation with the 
primary antibody, and then subsequent incubation with the secondary 
antibody 
Blocking of PVDF membranes 
The PVDF membranes were blocked for 1 hr at room temperature in 
200mls of 5% BSA solution made with 0.2% TBS-Tween. The membrane 
was then washed 3-4 times with TBS-Tween before incubation with the 
primary antibody. 
Incubation with primary antibody 
Membranes were then incubated for 12-14 hrs at 4°C in 1 Om Is of primary 
antibody added to a 5% BSA solution (diluted in 0.2% PBS-Tween). Table 
13 gives the details, concentrations and predicted molecular weight of the 
antigens recognised by the primary antibodies. The concentration of 
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primary antibodies was obtained according to manufacturer's 
recommendations. 
Species 
Molecular 
Primary Antibody Concentration 
primary 
weight 
antibody was (kDa) 
raised in 
ALX 
Target antigen is Mouse 
1/500 30 
FPR 1/2 (A LX monoclonal 
receptor) in human 
COX-2 
Target antigen is Rabbit 
1/1000 60-80 
COX-2 in human, polyclonal 
mouse and rat 
Mouse 
l3-actin 1/1000 40 
monoclonal 
Table 13: Details of primary antibodies used In Western Blotting 
Following incubation with the primary antibody, membranes were washed 
twice in 0.1 % PBS-Tween. Blots were incubated at room temperature for 1 
h r with the relevant secondary antibody diluted 1/1000 in 5% BSA solution. 
The transferred proteins were immediately detected using ECL. Each blot 
was incubated for 5 minutes in ECl Western blotting reagent (Amersham, 
Buckinghamshire, UK) prepared according to the manufactures' 
instructions. 
Blots were then visualised on the Trio+ Variable Mode Imager (GE 
Healthcare, Chalfont St Giles, UK) or by exposure on high quality X-ray 
chemiluminescence film (Cl-XPosure), (Thermo-Scientific). A rainbow 
molecular weight marker (MagicMark ™ XP), (Invitrogen, Paisley, UK) 
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identified the position and molecular weight of the proteins of interest with 
~ - a c t i n n serving as the reference gene. 
2.7 Nitrate Assay 
A commercial nitrite/nitrate fluorometric assay kit (Cayman Chemicals, 
Cambridge, UK) was used to measure the NO concentration in media from 
cultured primary equine cells. All reagents to measure NO expression 
were supplied in the kit. Media was collected from treated cells and stored 
at -80°C until use. 
Construction of the nitrate standard curve 
A nitrate standard curve was constructed from a 200 ~ M M stock nitrate 
standard to measure unknown NO concentrations in samples. Serial 
dilutions of this stock solution were prepared with Assay buffer with NO 
standard concentrations ranging from 500, 250, 125,62.5,31.3, 15.6, and 
7.8 pmol. 
Preparation of standards and samples for NO assay 
A 3 0 ~ 1 1 aliquot of each prepared standards was combined with 5 0 ~ 1 1 of 
Assay buffer. A 2 0 ~ 1 1 volume of each unknown sample was mixed with 6 0 ~ 1 1
of Assay buffer, 1 O ~ I I of Enzyme CoFactor Mixture and 1 O ~ I I of Nitrate 
Reductase Mixture. Each 8 0 ~ 1 1 standard or unknown sample was added to 
a 96-well plate in duplicate and incubated for 1 hr at room temperature. 
Each sample and standard was further incubated at room temperature with 
1 O ~ I I of DAN reagent. An additional 2 0 ~ 1 1 of NaOH was added and the plate 
read on a fluorometer. The excitation wavelength was set to 365nm with 
an emission wavelength of 430nm. 
81 
The nitrate standard curve was constructed by plotting fluorescence vs. 
picomoles of nitrate. Total NO expression in samples was calculated 
according to the following equation. 
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Chapter 3: Development of in vitro equine 
respiratory models 
3.1 Introduction 
In order to fully investigate RAO, recent work has focused on advancing in 
vitro techniques. To allow the investigation of the mechanism of acute 
inflammation and its resolution in vitro, methods are used to isolate 
respiratory cells types such as bronchial epithelial cells and airway smooth 
muscle cells. 
The methods available to investigate equine respiratory disease in vitro 
are varied and offer their own relative advantages and disadvantages. The 
most suitable approach to asses RAO inflammation in vitro therefore 
requires careful assessment of the available methods. 
3.2 Aims 
• Develop equine in vitro models of bronchial epithelium and airway 
smooth muscle 
• Characterise and assess selected models for viability and suitability 
for in vitro respiratory investigations of inflammation and 
inflammatory resolution 
To achieve these aims, respiratory tissue from sections of equine trachea 
were used to establish either primary ETE or ASM cells. Primary cells 
were obtained from enzyme digestion of tracheal tissue or from tissue 
explants. Culture of both whole organ sections and specific tissue types 
isolated from the trachea were also examined as potential in vitro 
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respiratory models. Suitable models were characterised and assessed for 
viability by: 
i. The trypan blue test for primary cells 
ii. Evidence of ciliary movement in tissue models by use of 
Polysphere beads, or by visual inspection of appearance in whole 
organ models. 
iii. Cell type and morphology in isolated primary cells were identified 
by ICC, IF and IHC methods. 
3.3 Primary cell and explant cultures 
Source of material 
Fresh equine tissue was obtained from a) a local abattoir (Red Lion, 
Nantwich), b) the Defence Animal Centre (DAC) in Melton Mowbray, or c) 
clinical cases euthanased at the School of Veterinary Medicine and 
Science at the University of Nottingham. Tissue was acquired from horses 
of both sexes with ages ranging from 3 to 29 years old. Age of the horses 
was determined by either passport details (DAC and Vet School) or 
approximate dental ageing (abattoir). Horses euthanased at the DAC and 
the Veterinary School were determined to be free from systemic disease 
(based on clinical history) with no known inflammatory conditions or recent 
administration of medication. 
To ensure that healthy tissue was used in experiments, the carcass from 
all sources was inspected for any signs of systemic disease, including 
mucopurulent nasal discharge suggestive of bacterial respiratory infection. 
The trachea was dissected free immediately after slaughter and examined 
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for signs of gross pathology such as respiratory disease. This included 
mucosal surface inflammation, evidence of mucopus, excessive mucus 
production and primary tracheal lesions (considered uncommon in the 
horse). 
Tissue collection 
Isolated equine trachea was washed extensively in sterile cell culture 
grade ice-cold PBS (Invitrogen, Paisley, UK). Tissue collected from the 
abattoir was transported on ice back to the laboratory in PBS containing 
1% (v/v) of Pen/Strep (10,000U/mI//10,000IJg/ml respectively) (Invitrogen, 
Paisley, UK) and 1 % (v/v) 250 !-Ig/ml Fungizone (Amphotericin B in water), 
(Invitrogen, Paisley, UK). Maximum transport time of abattoir tissue was 
approximately 2 hours. 
Tissue preparation 
All tissue preparation and dissection was performed under a laminar flow 
hood under aseptic conditions. The adventitia and any adherent tissue 
attached to the exterior of the trachea were removed. Approximately 15-
20cms of trachea was opened longitudinally, by sharp dissection, for 
further dissection or tissue isolation. All steps requiring rinsing of isolated 
tissue were performed using sterile cell-culture grade PBS containing 1 % 
(v/v) of 1 0,000U/m1/1 O,OOOlJg/ml Pen/Strep and 1 % (v/v) 250IJg/mi 
Fungizone (AmphoteriCin B in water) unless otherwise described. 
3.4 Isolation of primary equine tracheal epithelial 
cells using trypsin 
Primary tracheal epithelial cells were isolated from the trachea after the 
method described by Shibeshi et a/ (2008) with minor modifications. 
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Tissue preparation was as described. The epithelial layer was removed 
from the mucosa using serrated edge forceps. Isolated tissue was 
macerated manually using scissors into 1-2mm3pieces and approximately 
500l1g of tissue placed in a disposable sterile SOml Falcon tube containing 
20m Is of sterile PBS (Invitrogen, Paisley, UK). The tissue was washed 3-4 
times in fresh sterile PBS by centrifugation for 1 minute at 1200 rpm 
(300g), 15°C to eliminate contaminating red blood cells. 
Minced washed tissue was then placed into 20m Is of warmed (37°C) F-12 
Nutrient Mixture (Hams), (Invitrogen, Paisley, UK) containing 0.2S% 
porcine trypsin/2.6SmM EDTA (Sigma-Aldrich, Poole, UK), 1 % (v/v) of 
1 0,000U/ml/1 O,OOOl1g/ml Pen/Strep and 1 % (v/v) 2S011g/ml Fungizone 
(Amphotericin B in water) (Invitrogen, Paisley, UK). Tissue samples were 
incubated in a water bath tissue for between 30m ins and 1 hour (3rC) 
and agitated regularly to enhance enzymatic digestion. 
Following enzymatic digestion, supernatants were aspirated from each 
sample and enzyme action halted by the addition of 20% (v/v) heat-
inactivated FBS, (Fisher SCientific, Loughborough, UK) to each sample. 
Samples were pelleted by centrifugation at 300g for 10 minutes at 15°C. 
Cell pellets were re-suspended in 20mls of warmed (3rC) sterile PBS and 
filtered through disposable sterile 40111 cell strainers. Cell suspensions 
were again centrifuged at 300g for 10 minutes at 15°C. The cell pellet from 
each sample was re-suspended in 1 ml of warmed (3rC) serum-free 
BEGM, (Lonza, Slough, UK). 
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Following a cell and viability count, cells were seeded at 6-8 x105/ml in 
uncoated 25cm3 tissue culture flasks or 6-well uncoated tissue culture 
plates. Cell cultures were maintained in a tissue incubator in humidified 5% 
CO2 at 37°C to allow for attachment and growth. Cells were inspected after 
24 hours for signs of contamination. Non-adherent cells or contaminated 
cells were discarded. Spent media was removed from viable healthy cells 
and fresh media added. Primary cells isolated by trypsin digestion of 
epithelial tissue approached 70-80% confluency within 2-5 days of being 
cultured. 
3.5 Isolation of primary equine tracheal epithelial 
cells using pronase 
Tissue was collected and prepared as described above. Tracheal epithelial 
cells were isolated according to the method of Quintana et a/ (2011). 
Segments of whole trachea were dissected into 1 cm x 6cm sections. 
Approximately 2-3 sections of dissected trachea were placed into a 50ml 
Falcon containing 30mls of sterile PBS supplanted with 1 % (v/v) of 
Pen/Strep and Fungizone (Invitrogen, Paisley, UK). Tracheal sections 
were washed for 45 minutes at 4°C on a roller. The PBS was discarded 
and this step repeated. 
Tissue was digested in 0.2% pronase (Streptomyces Griseus, Sigma-
Aldrich) in 10mls of F-12 Nutrient Mixture (Hams) containing 1% (v/v) of 
1 0,000U/ml/1 O,OOOJlg/ml Pen/Strep and 1 % (v/v) 250Jlg/ml Fungizone 
(Amphotericin B in water) (Invitrogen, Paisley, UK), at 4°C overnight on a 
roller. Enzyme action was halted; the supernatant and cell samples were 
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processed and collected as before by centrifugation to obtain a cell pellet. 
A viability and cell count was performed. 
Cells were again cultured at 6-8 x105/ml in serum-free BEGM in 25cm3 
collagen-coated tissue culture flasks or 6-well collagen-coated polystyrene 
tissue culture plates. Isolated cells were cultured at 3]oC, 5% CO2 with 
media changed 24 hrs after collection with fresh media every 2-3 days 
thereafter. Cells successfully isolated with pronase typically approached 
70-80% confluency between 5 -14 days. 
3.6 Primary tracheal epithelial cells from explants 
of tracheal epithelial tissue 
Sections of equine tracheal epithelial tissue were removed from the 
prepared trachea using rat tooth forceps. These strips were placed apical 
side up onto a 144 x 21mm disposable tissue culture plate and rinsed 
again with sterile, culture grade PBS. Isolated epithelial tissue sections 
were dissected further into approximately 1 cm x 0.25cm sections and 
allowed to adhere onto uncoated 6-well tissue culture plates. Two mL of 
serum-free BEGM media was added to each well using disposable 
RNAse/DNAse-free 1 O O O ~ L L tips (Fig.10). 
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Figure 10: Primary equine epithelial cells cultured from equine mucosal explants 
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The tracheal mucosal explants were cultured at 3rC, 5% CO2 in a CO2 
incubator with media changed after 24 hours. Media was changed every 
48 hours thereafter. Explants were left for up to 2 weeks to allow for 
growth of respiratory epithelial cells. 
3.7 ALI tracheal cultures 
ALI cultures from explants of isolated equine epithelial 
mucosal tissue 
Tissue preparation and collection was as previously described. Tissue 
explants of whole tracheal mucosa were dissected from the tracheal 
cartilage using sterile disposable scalpels . Isolated sections were 
dissected further into 2cm x 2cm pieces and washed 2-3 times with sterile 
PBS. Prepared explants were placed into 6-well tissue culture plates, 
allowed to adhere and 1 ml of fresh BEGM media (Lonza, Slough, UK) was 
added using RNA/DNA-free 1 O O O ~ L L tips (Fig.11). This ensured that the 
media was in contact with the tissue but did not cover it. 
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Figure 11: Air-liquid Interface explants from whole sections of equine respiratory mucosa 
Explants were cultured at 3rC in a C02 incubator, and at 35°C in an 0 2 
incubator. The surface of the explants was moistened each day using the 
surrounding media. 
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ALI cultures from explants of whole tracheal sections 
Whole tracheal explants were prepared by dissecting sections of trachea 
into 2cm x 1 cm pieces. The ALI cultures were prepared according to the 
method by Hamilton et al (2006). 
Platforms of 1 % agarose gel were constructed by dissolving agarose 
powder in cell-culture grade PBS (Invitrogen, Paisley, UK). The agarose 
solution was heated in a microwave until evenly dissolved and 1 ml of 
prepared solution placed in each well of a 12-well tissue culture plates until 
set. The solidified agarose plugs were removed using a sterile disposable 
scalpel and placed into 6-well tissue culture plates surrounded by 2ml of L-
15 medium (Fisher Scientific, Loughborough, UK). 
A 1 cm x 2cm strip of autoclaved filter paper soaked in L-15 medium was 
placed on top of each agarose platform. Strips of sterile filter paper 
(Whatman pic, Maidstone, UK) under the explants were allowed to touch 
the surrounding media to keep the explants moist. The prepared sections 
of trachea were placed on the agarose/filter paper platforms (Fig.12). The 
ALI explants were cultured at 35°C in an O2 incubator for 24-72 hours. 
L-151lledia 
surrounding 
tracheal 
explallts 
Figure 12: ALI of whole tracheal explants. 
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6-well tissue 
culture plate 
Tracheal epithelial 
mucosal explants 
3.8 Primary airway smooth muscle cell culture 
from equine trachealis muscle explants 
A 25cm2 section of equine trachea was collected and prepared under the 
conditions as described previously. The trachea was opened longitudinally, 
and the mucosa covering the trachealis muscle removed using sterile 
forceps. The trachealis muscle was dissected from the trachea by using 
serrated edge forceps and any remaining adherent mucosa or connective 
tissue removed. The excised muscle trachealis muscle was washed on a 
144 x 21 mm tissue culture plate. 
The trachealis muscle was furthered dissected into 1 mm x 1 mm explants 
using sterile disposable scalpels. Either 1 or 2 ASM explants were placed 
into each well of an uncoated Nunc 6-well tissue culture plate and allowed 
to adhere for up to 5 minutes. Explants were covered with 2mls D-MEM 
(high glucose), (Fisher Scientific, Loughborough, UK) containing 10% FBS 
and supplemented with 1 % (v/v) of 1 O,OOOU/ml/1 O,OOOjJg/ml Pen/Strep 
and 1 % (v/v) 250IJg/ml Fungizone (Amphotericin B in water) (Invitrogen, 
Paisley, UK). 
The ASM explants were cultured at 3rC, 5% CO2 in a CO2 incubator. 
Media was changed after 5 days. Cell growth was apparent after 
approximately 7 days, with cells approaching near-confluency (70-80%) 
after approximately 3 weeks. Cells were identified as ASM cells through 
morphological appearance under the light microscope and ICC staining. 
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3.9 Cell count, assessment of cell viability and 
evaluation of cell type 
Cell count and viability 
Freshly isolated ETE cells and ASM cells were isolated and cultured as 
described. Cell count and viability of ETE and ASM cells count was 
determined with the Trypan blue exclusion test. Adherent cells from 2 wells 
of a six-well plate were dislodged with trypsin, centrifuged to obtain a cell 
pellet and re-suspended in 1 ml of cell culture media, before being 
manually counted as described. 
A 1:2 dilution was prepared with 101-11 of 0.4% Trypan Blue and 101-11 of 
original cell suspension. Viable cells were recognised by appearing 
colourless, cells that had taken up the Trypan blue stain were considered 
non-viable. An average cell count from the 1: 2 dilution of cell suspension 
and Trypan blue was used to calculate the cell count/viability per ml. 
Viability of epithelial explants 
Viability was assessed through visible cilia movement of the explants as 
viewed under a light microscope. 
Viability of ALI tracheal explant sections 
The viability of the ALI culture system was assessed through activity of the 
respiratory mucocillary escalator. A 1 Dill sample of Polybead 
Microsphere® beads (Polysciences, Northampton, UK) was placed onto 
the middle of an explant section. Movement of the beads to the edge of the 
tissue within 1 hr after incubation at 35°C indicated that the tissue was 
viable. Healthy active tissue was also indicated by the change of media 
colour after 24 hours of incubation. 
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Characterization of primary ETE and ASM equine cells 
Primary ETE and ASM cells were identified by a combination of 
morphology and ICC staining. Positive and negative controls included IHC 
staining of paraffin embedded tissue sections (Table 14). Negative 
controls were incubated with the matching isotype control for each primary 
antibody used. AIIICC/IHC samples were washed three times for 5 min in 
0.1 % Tris Buffered Saline-Tween (TBS-Tween, 137 mM Sodium Chloride, 
20 mM Tris, 0.1 % Tween-20, pH 7.6) after each step. All media and 
reagents were removed before continuing to the next stage of the protocol. 
Preparation of primary cells for staining 
Primary ETE and ASM cells were collected and isolated as before. Both 
ETE and ASM cells were cultured to 70-80% confluency either in the 6-
well tissue culture plate or on sterile 13mm disposable plastic cover slips 
(Sarstedt, Leicester, UK). 
Cells were fixed prior to staining by incubation in an ice-cold 1:1 solution of 
acetone-methanol for 10 minutes. Use of acetone-methanol enables 
fixation of antigens while retaining cellular and subcellular structure. 
Acetone-methanol fixation also enables permeabilisation of cells to allow 
full access to the target protein by the labelling antibodies. Use of 
formaldehyde fixation may induce cross-linkage of proteins and prevent 
detection of the antigen, thus requiring a subsequent antigen retrieval step. 
Preparation of tissue sections for staining 
Paraffin embedded tissue sections of either rat kidney and mouse colon 
were initially immersed for 5 minutes (x2) in fresh xylene baths. The tissue 
sections were a kind gift from Dr Katie Asplin (Liphook Equine Hospital, 
Hampshire). The tissue sections were then taken through a series of 
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alcohol baths (1 00-50%) with an incubation time of 2 min per bath. The de-
waxed sections were then used immediately in the blocking steps. 
Inhibition of peroxidase activity and blocking step 
Samples were incubated in 3% H20 2 solution (30% H20 2 diluted in PBS) 
for 20 minutes at room temperature to inhibit endogenous peroxidase 
activity. Non-specific binding was blocked by incubating all samples in 
10% BSA solution diluted in 0.1 % PBS-Tween for 1 hour at room 
temperature. 
Incubation of samples with antibody and development of IHCIICC 
stain 
Following aspiration of the BSA solution, samples were incubated 
overnight (12-14hrs) at 4°C with the relevant primary antibody or matching 
isotype control (Table 14). 
Species 
Positive 
Primary 
Ab Isotype 
primary Ab 
Protein Ab reacts with tissue 
antibody (Ab) was raised 
control 
In 
Cytokeratin 5,6 and 8 in 
Rat kidney: 
Mouse simple squamous 
Pan- 19G1 , able to (anti- epithelia and 
cytokeratin 26 monoclonal express 
human) pseudostratified 
cytokeratin 8 
epithelia 
Mouse colon: 
Alpha smooth Mouse Cytoplasmic a-actin 
IgG2a, able to 
muscle actin (anti- isoforms present in 
Monoclonal express a-
(Clone 1A4) human) smooth muscle cells 
actin 
Table 14: Primary ICCnHC antibodies and Isotypes used In primary equine cell 
characterization 
Two to three drops of the secondary polymer Horse Radish Peroxidase 
(HRP) antibody (Dako, Ely, UK, supplied in kit) were then applied to each 
sample and the sample incubated for 30 minutes at room temperature. 
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This step incorporates a modified labelled avidin-biotin step method which 
enables a biotinylated secondary antibody to form a complex with 
peroxidase-conjugated streptavidin molecules (Fig.13) 
• 
• Avidin-Biotin complex 
~ ~... ' 
.'oti,yl",d mond." .,"body ., 
Primary antibody 
Ti".",'"," A A 
Figure 13: Representative image of complex formed between avidin and biotin during 
IHCIICC staining. 
(Figure adapted from www.dako.com) 
Samples were washed with PBS-Tween (5 minutes x 3) after both primary 
and secondary antibody incubation steps. Each sample had 2-3 drops of 
chromogen developing solution (1 drop of chromagen to 1 ml of substrate 
buffer) applied (Dako, Ely, UK, supplied in kit) and left until brown staining 
was visible to the eye. The reaction was halted by rinsing the developed 
sample under tap water. Samples that did not obviously stain within 5 
minutes were left for up to 30 minutes to account for slow development of 
stain. 
Samples were then incubated in haematoxylin for 10 seconds (primary 
cells), or 1 minute (tissue sections) to counter-stain the nucleus, rinsed 
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clear in tap water, with a final wash in ammoniated water for 1-2 seconds. 
Tissue sections were taken through a series of alcohol baths (50-100%, 20 
seconds per bath) to dehydrate and fix the developed stain. 
Cover-slips were then mounted onto samples, by either a glycerol solution 
(cells, 1:1 water to glycerol) or DPX mountant (tissue sections). Cover-
slips were allowed to dry before visualising on the inverted microscope at x 
5, 10, 40, and 63 objectives. 
Immunofluorescent staining of ASM cells 
To demonstrate the "hill and valley" morphology of the ASM cells more 
clearly, ASM cells were used in immunofluorescent (IF) staining. ASM cells 
were cultured directly on sterile disposable 13mm tissue culture cover slips 
(Sarstedt, Leicester, UK). 
When cells were approximately 80% confluent, the culture media was 
aspirated and samples washed twice for 5 minutes in warm cell-culture 
grade PBS. The cell samples were fixed in 4% formaldehyde for 10 
minutes at room temperature, and then the PBS wash step repeated. To 
reduce background staining, the fixed cells were incubated for 30 minutes 
in a 1 % BSNPBS solution for 30 minutes at room temperature. A PBS 
wash step was repeated twice. 
Each sample was then incubated for 20 minutes at room temperature in 
1/100 Alexa-Fluor 488 solution (Invitrogen, Paisley, UK). Alexa-Fluor 488 
phalloidin is a probe conjugated to green-fluorescent Alexa-Fluor 488 dye 
which stains filamentous actin in samples (specifically F-actin, a 
microfilament present in smooth muscle). Samples were then incubated for 
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3 minutes at room temperature in a DAPI solution (Fisher Scientific, 
Loughborough, UK). Samples were fixed onto glass slides and sealed 
using a 1:1 ratio of glycerol and double distilled water. 
3.10 Results 
Cell count and viability of primary cells 
Cell isolation with pronase 
Isolation of primary ETE cells with pronase was unsuccessful. Low cell 
yield, with weak adherent capabilities and slow growth indicated that this 
method was not sufficiently reliable for use in future work (based on 4 
individual experiments). 
Cell Isolation with trypsin 
Trypsin-dissociated primary ETE cells averaged a mean cell count of 173 x 
104 (SEM ± 36) cells per ml from 5mg of minced tissue. Cell viability was 
estimated to be 78.6% (SEM ±3.0, calculations from 7 separate 
experiments, performed in triplicate). Isolated cells were maintained as 
submerged monolayers on collagen-free tissue culture plates. Near 
confluence of primary cell cultures was frequently apparent after 3-5 days 
(Fig.14) and cells exhibited typical "cobblestone" epithelial cell 
morphology. 
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Figure 14: Bright field Image of primary ETE cell cultures obtained from trypsin digestion 
of epithelial tissue. 
Representative images show ETE cells maintained on collagen-free 6-well tissue culture plates 
after 3 days culture (A, x1 0 magnification) and after 10 days culture (8, x40 magnification). Images 
are representative of 2 independent experiments and selected from triplicate samples. 
Viability of primary ETE cells from epithelial tissue explants 
Sections of tracheal epithelial tissue explants successfully adhered to the 
tissue culture plate (Fig.1S). Ciliary movement signifying tissue viability 
was observed under the light microscope within 1 hr of establishing 
cultures and continued for up to 7 days thereafter. 
Figure 15: Explant of equine tracheal epithelial tissue after 6 days in culture. 
Explants were cultured in BEGM media on collagen free tissue culture plates for up to 7 days to 
allow for outgrowth of primary ETE cells. 
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Cultures with no apparent ciliary movement after 24hrs were discarded 
(based on three separate experiments). Primary cells surrounding the 
explants were observed 24hrs after the initial culture set up. No further 
growth of these cells was evident after 7 days and this model was not used 
for further experiments. 
Viability of ALI sections of equine respiratory mucosa 
Adherence of ALI explants of mucosa to tissue culture plates was poor. 
Explants frequently detached during initial isolation and culture 
maintenance. Explant tissue appeared dry, and red in colour (indicating 
inflammation) despite daily bathing of sections in culture media. As such 
this model was deemed unsuitable for further study. 
Viability of ALI cultures from explants of whole tracheal sections 
Ciliary action indicating explant viability was determined through 
movement of Polybead Microsphere® beads (Polysciences) placed on 
tracheal sections. No bead movement was observed during initial set up or 
when repeated at 24hrs. Some metabolic activity was apparent from some 
loss of colour from the media after 24hrs indicating minor activity. Despite 
this, cultured explants were not considered to be sufficiently active or 
viable. This method was also deemed to be unsuitable for future work 
(based on four separate experiments). 
Characterization of primary ETE cells 
Primary ETE cells isolated with trypsin demonstrated the highly typical 
'cobblestone' epithelial cells morphology described in the literature. 
Primary ETE cells were further characterised with ICC and IHC methods 
(Fig.16) 
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Figure 16: Bright field Images of ICC and IHC stain of primary ETE cells and rat kidney 
tissue sections. 
Representative images show pan-cytokeratin (PCK-26) stain of primary ETE cells (A) and IgG1 
isotype control (8) . Paraffin embedded sections of rat kidney acted as positive control for pan-
cytokeratin (C) with isotype control also shown (0). Primary ETE cells were isolated from 2hr 
trypsin digestion of epithelial tissue. Images are representative of 3 independent experiments and 
selected from triplicate samples (A & 8: x40 magnification). 
Cultured cells and the paraffin-embedded tissue sections of rat kidney 
stained positive for pan-cytokeratin antibody PCK-26. Immunostaining of 
cells and tissue sections with the corresponding IgG isotype (negative 
control) did not show evidence of staining. It was concluded that these 
were viable cells of epithelial origin and highly suitable for the proposed 
work investigating equine respiratory inflammation and resolution. 
Characterization of primary ASM cells 
Cells isolated from explants of trachealis muscle became near-confluent 
after approximately 3 weeks. Initial detection of ASM cell morphology used 
a basic Hand E stain which revealed the characteristic 'hill and valley' 
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appearance of smooth muscle cells in culture. Further investigation of 
ASM cells was achieved with IF staining with Alexa-Fluor 488 (Fig.17). 
Figure 17: Bright field Images of IF and Hand E stain of primary equine ASM cells 
Representative images show primary equine ASM cells obtained from trachealis muscle explants 
approximately 3 weeks after initial set up. Images with (A) shows ASM cell outgrowth from explant 
(E). ASM morphology is shown in greater detail in image B. The 'hill and valley' morphology 
considered typical of smooth muscle cells is demonstrated in images C and D by a standard Hand 
E stain. For the Hand E stain , ASM cells were maintained in untreated 6-well tissue culture plates 
for 16 days. Images are from 3 individual experiments and selected from triplicate samples. 
Alexa-Fluor 488 labels F-actin microfilaments present in smooth muscle 
and enabled a more clearly defined image of AS cell morphology. To 
further identify isolated cells as smooth muscle cells, ICC and IHC 
methods were used. Cultured ASM cells and the paraffin-embedded tissue 
sections of mouse colon (included as a positive control) stained positive for 
smooth muscle actin, a protein marker for smooth muscle tissue. 
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Treatment of cells and tissue sections with the corresponding isotype 
(negative control) did not show evidence of staining (Fig.18). 
Figure 18: Bright field Images of ICC and IHC stain of primary ASM cells and mouse colon 
tissue sections. 
Representative Images show a-smooth muscle actin (clone 1A4) stain of primary ASM cells (A) and 
IgG2a isotype control (8) . Paraffin embedded sections of mouse colon acted as positive control for 
a-smooth muscle actin (C) with isotype control also shown (0). Images show primary equine ASM 
cells obtained from trachealis muscle explants cultured on untreated 6·well tissue culture plates 
approximately 3 weeks after initial set up. Tissue samples of Images are from 3 independent 
experiments and selected from triplicate samples. 
It was concluded that the cultured cells obtained from trachealis muscle 
explants were of smooth muscle origin and suitable for use in future work 
investigating ASM cell inflammation and inflammatory resolution. 
Discussion 
Respiratory models to investigate asthma in humans frequently use in vivo 
techniques. In contrast, equines are considered poor in vivo subjects, in 
102 
terms of cost and ease of maintenance. Ex vivo or in vitro methods 
eliminate the cost and difficulties associated with the use of experimental 
horses and enable the examination of disease mechanisms. Research 
using ex vivo techniques enables investigative opportunities that would be 
otherwise impossible or unethical to perform in the living animal. 
Investigations of equine airway inflammation use a variety of ex vivo 
techniques. Using samples of BAL or tracheal aspirate (T A) is a reliable 
and repeatable method and offers valuable data for detecting early 
respiratory inflammation (Hoffman 2008). However, a study using 28 
horses indicated that bronchial and tracheal brushings contain bacteria 
and fungi (10.7 and 53.6% of samples respectively). BAL, brushing 
samples and T A samples frequently includes a mixed cell population which 
hinders study of specific cell types. Sample collection also involves a 
degree of invasiveness when performed (Leguillete & Lavoie 2006). Lung 
tissue samples are considered representative of the whole lung and are 
also used extensively in diagnosing equine respiratory disorders (Lugo et 
a/2006). Whilst useful, ex vivo methods were not possible for investigation 
into equine respiratory inflammation due to the lack of available horses for 
study. 
During the development of an in vitro equine respiratory model of the 
respiratory tract, several approaches were used 
i. primary epithelial cells isolated from digested respiratory tissue 
ii. primary airway smooth muscle cells from explants of trachealis 
muscle 
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iii. primary epithelial cells from tracheal explants under submerged 
conditions 
iv. mucosal explants kept at the air-liquid interface 
v. whole organ explants cultured at the air-liquid interface 
An in vitro equine epithelial model was successfully established by trypsin 
digestion of airway epithelial tissue to obtain primary equine ETE cells, and 
explants of trachealis muscle to culture primary ASM cells. Primary ETE 
and ASM cells were identified by IHe and ICC staining with pan-
cytokeratin antibody PCK-26, and a-smooth muscle actin (clone 1A4) 
respectively. These antibodies identifies cytokeratin proteins 5, 6 and 8 
found in simple squamous epithelia and pseudostratified epithelia (PCK-
26), and cytoplasmic a-actin isoforms present in smooth muscle cells (0-
smooth muscle actin). 
Primary ETE cells were obtained by use of the method by Shibeshi et a/ 
(2008) with modifications, which routinely isolated viable and rapidly 
proliferating tracheal epithelial cells. Viability of isolated ETE cells was 
estimated to be 78.6% (SEM ±3.0) and cultures were maintained in serum-
free BEGM media until near-confluent at 3-5 days. The original 
methodology describes an average of 5 x 104 cytokeratin-positive epithelial 
cells obtained per mg of tissue. In contrast, average numbers of cells 
isolated with the original method during ETE cell model development were 
3.4 x 10 4 per mg of tissue. Viability (as determined by the trypan blue 
exclusion method) was also reduced in comparison to the original method, 
with an average of 78.6% SEM ±3.0 compared to 9%. This may have been 
due to less replicates performed compared to the original paper. However, 
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unlike the original study, it was not found necessary to remove 
contaminating fibroblasts by a phase of pre-plating prior to the culturing 
period. 
Other in vitro models attempted during the course of this study proved 
unsuitable. Studies using pronase digestion of respiratory tissue have 
proved successful in different species (You et a/2002, Rowe et a/2004, 
Fischer et al 2007). Primary equine epithelial cells dissociated from 
pronase digestion have been reported before (Sime et a/1997, Ainsworth 
et a/2009, and Lin et a/2001). 
In contrast to these studies, the unsatisfactory cell yield and viability 
obtained from pronase digestion of respiratory epithelial tissue were 
unexpected. Increasing the pronase concentration and incubation times 
(up to 18hrs, data not shown) did not improve cell yield nor did the addition 
of supplemental digestion media such as collagenase. Inspection of tissue 
at approximately 18hrs under the light microscope showed very few 
dissociated cells, and it was decided not to continue. Attempting 
alternative methods such as shorter digestion times (1-2hrs) of epithelial 
tissue using pronase but with an increased temperature (37°C) were also 
unsuccessful. One approach not tried was the inclusion of 0.1 % 
deoxyribonuclease to 1.4% pronase as successfully described by 
Quintana et al (2010). 
Attempts to enhance cell viability by increasing the adherent capabilities of 
pronase-dissociated cells were not improved by pre-coating tissue culture 
flasks with collagen, or by using commercially pre-coated tissue culture 
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flasks. Cell growth may have been improved by leaving cells for longer 
periods in culture, as reported by Sime et al (1997). However, comparable 
more recent works (Lin et a12001, Ainsworth et a12009, Quintana et a/ 
2011) report robust cell growth after approximately 5 days and this was 
taken as an indicator of superior cell viability. 
One potential factor in tissue viability and subsequent cell yield may have 
been the length of time to transport and process collected tissue samples. 
Primary ETE cells have been obtained following digestion of bronchial 
tissue in 1 % Protease XIV with 0.01 % DNase (Schwab et a/ 2010). 
Workers on this study were able to process collected tissue samples within 
1 hr of death which was not an option for our particular investigation. Our 
total time for tissue collection and preparation averaged >2hrs and this 
could have affected primary cell viability and yield. 
Attempts to improve poor cell growth after pronase isolation were 
addressed by considering culture conditions. Attempts to enhance cell 
proliferation and growth by alterations to the culture media were 
considered but not thought to be required. Cell cultures were maintained in 
BEGM serum-free media which has been formulated for respiratory cell 
culture. This media is recommended for proliferation and maintenance of 
the continuous bronchial cell line BEAS-2B, and in other works requiring 
serum-free media for bronchial cells. Enhancing cell media with serum 
supplementation (1 %) is reported to improve initial outgrowth of primary 
cells from lung tissue explants at 10-14 days in culture (Kitamura et a/ 
1990}.ln contrast, serum-enriched media (10%) increased COX-2 protein 
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and mRNA in the alveolar cell line NCI-H292 (Sung et al 2011), which 
would have affected investigations into respiratory inflammation. 
One alternative not attempted in our work was the use of a serum 
substitute such as Ultroser G (Smit et a/1995). This has been described in 
a similar equine study which isolated ETE cells with trypsin digestion 
(Abraham et aI2011). Supplementation with Ultroser G was required for 
cellular differentiation when primary cells were cultured at the ALI (air 
liquid interface). Both serum and Ultroser G have been shown to alter the 
fatty acid composition of the plasma membrane in HeLa cells in 
suspension culture (Blixt et al 1990). They were therefore considered 
unsuitable to use in LXA4 studies as LXA4 is derived from substrates 
contained within the cell membrane, and receptor ALX is expressed on the 
plasma membrane (Chiang 2002, Maderna et al201 0). 
Efforts to obtain primary bronchial epithelial cells from tissue explants were 
also unsuccessful. The use of respiratory tissue explants to obtain primary 
cells has been routinely used in previous cell culture studies (Inayama et al 
1995, Forrest et a12005, Yaghi et al201 O).The frequent detachment of the 
explant from the tissue culture plate was a hindrance that this study was 
not able to eliminate. One alternative would have been the use of collagen-
coated flasks (Margarit et al 2005), an option not explored by this 
investigation. 
Adherent epithelial explants in our study showed an initial outgrowth of 
primary cells from tissue sections. Explants were monitored daily for 
continued evidence of cilia movement which was taken as an indicator of 
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viability (Jackson et a/1996). One concern was the integrity of explants 
maintained in culture over extended periods under submerged conditions. 
Explants were removed at 7 days or when cilia movement stopped 
indicating that the explant appeared no longer viable. This was to allow for 
cell growth without potential contamination from tissue disintegration. 
Primary cells obtained from explants were further maintained for 
approximately 14-21 days (data not shown). Despite this, cultured cells did 
not continue to proliferate or change morphology suggestive of epithelial 
cells as viewed under the light microscope (Baeza-Squiban et a/1991). 
Improving the assessment of viability of mucosal explants and tracheal 
sections kept at the air-liquid-interface may have improved the quality of 
experimental work. The use of Polysphere beads is a reliable and cost-
effective method of establishing activity of the muco-ciliary escalator in 
respiratory tissue (Niesalla et a/2009). However, it does not calculate the 
percentage of live/dead cell ratio. One alternative to assess cell health 
would have been the assessment of cell apoptosis, with TdT-mediated 
dUTP-X nick end labelling (TUNEL). This qualitative method determines 
single and double-stranded DNA breaks by the use of fluorescence 
microscopy (Glorieux et a/2011). Such methods could have indicated the 
suitability of collected tissue for further work. This approach would have 
also been beneficial for attempts at ETE organ culture 
ALI methods for respiratory organ culture have been advantageous in 
virology studies (Lin et a/2001) but did not translate well for this study. 
Efforts to keep the surface of explants sufficiently moistened by either use 
of an orbital shaker or by daily bathing of tissue with culture media were 
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unsuccessful. Organ cultures from sections of whole trachea proved 
largely uncomplicated to establish during set up. Despite this, external 
tracheal adventitia could not be removed entirely and was considered to 
be a potential source of media contamination. This was particularly evident 
during alternative attempted methods (data not shown) of whole organ 
culture where tracheal sections were cultured in a rotating platform to 
mimic the in vivo state. 
Further disadvantages with this method included failure to isolate high 
quality RNA. Aseptic removal of either the epithelial or mucosal layer 
proved difficult due to the reduced dimensions of organ cultures. An 
alternative method of scraping the epithelial surface with a disposable 
scalpel collected low concentrations of poor quality RNA. The interaction of 
the epithelial layer with tracheal smooth muscle is of significant interest for 
investigations of respiratory inflammation. Isolating and attributing cell 
reactions to either tissue type were not possible with the use of whole 
organ culture, and rendered it unsuitable. 
The use of trachealis tissue explants to obtain primary equine ASM cells 
was routinely successful in generating high numbers of viable cells. Cells 
were observed from approximately 7 days after initial seeding of the 
explant, with steady growth of primary cells until confluence at 21-28 days 
thereafter. Unlike the challenges posed by lack of adherence seen in 
epithelial mucosal explants and ALI models, the smooth muscle explants 
remained firmly attached to the tissue culture flasks following set-up. 
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Primary human ASM cells have been isolated by enzymatic digestion of 
minced tissue (Mckay et a/ 1998). However, obtaining primary cells 
obtained from equine muscle explants proved to be a simple and robust 
technique and so other methods were not considered. Additionally, the 
study aimed to avoid potential baseline inflammation in cultured ASM cells 
as obseNed in primary ETE cells encountered following trypsin digestion 
of tissue. 
A 'hill and valley' morphology in cultured ASM cells considered 
characteristic of smooth muscle cells (Hirst 2004) was clearly 
demonstrated with Hand E and IF methodology. The use of alpha smooth 
muscle actin as a marker of ASM cells has been routinely used in studies 
culturing ASM cells (Hirst et a/2004, Stamatiou et a/2012). IHe of cultured 
primary cells revealed positive staining for alpha smooth muscle actin and 
on positive control tissue (mouse colon). No apparent staining was 
obseNed in matching isotype negative control cell or tissue section 
samples. 
However, identification of primary ASM cells in vitro has been of increased 
scrutiny in more recent studies (Wenzel et 8/ 2006). The reliability of 
protein actin as an identifying marker for smooth muscle is under review. It 
is noted that fibroblasts and myofibroblasts in culture also have the 
capacity to stain positive for this protein, thus rendering them 
indistinguishable from ASM cells (Wenzel et 8/2006). Myofibroblasts can 
develop from fibroblasts and are typically associated with the promotion of 
wound healing (Shimoda et 812010). Thus use of explants may constitute 
a form of wound healing e.g. the reaction of excised dissected tissue. Use 
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of serum and passaging of cells is thought to change fibroblasts to 
myofibroblasts (Wenzel & Balzar 2006). 
There were a few but important differences in the ASM cultures that 
identified them as ASM cells. The 'hill and valley appearance' is not a 
feature of fibroblasts (Hirst 2004) and was readily observed in our Hand E 
stains of ASM cultures. The proliferation rate of ASM cells in comparison 
to fibroblast cells was examined. Fibroblasts in vitro demonstrate 
considerably rapid growth (Hirst 2004). Although our cultures showed cells 
surrounding the explants within approximately 7 days, these cells did not 
differentiate and approach full growth until at least 21 days. Finally, the 
capacity for myofibroblasts to stain positive for smooth muscle actin is 
thought to be transient. IHC methods have shown that staining intenSity of 
alpha-smooth muscle actin in myofibroblasts diminishes after 15 days 
(Darby et al 1990). Cultured near-confluent equine ASM cells 
demonstrated the same depth of ICC stain as that observed in IHC-treated 
mouse colon controls. As such, the data suggests strongly that primary 
cells were smooth muscle in origin. 
Conclusion 
In vitro respiratory models were developed from the culture of trypsin-
dissociated ETE cells, and ASM cells cultured from tracheal is muscle 
explants. Primary cells characterised by IHCIICC methods were 
considered to be of epithelial and smooth muscle origin and therefore 
suitable for investigation into respiratory inflammation. 
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Chapter 4: Responses of an in vitro tracheal 
epithelial model to LPS and LXA4 
4.1 Introduction 
An exaggerated immune response from the respiratory epithelium is a 
major cause of excessive acute airway inflammation in horses and people 
(Zhang & McDowell 1992). Failure of inflammatory resolution initiates the 
pathogenesis of chronic airway disease such as asthma and RAO (Berndt 
et a/2007, Buc et a/2009). 
Previous studies have established in vitro inflammation in primary equine 
bronchial epithelial cells. Expression of molecules associated with 
inflammation such as IL-a, macrophage inflammatory protein and IL-1 ~ ~
gene expression have been detected in bronchial epithelial cells after 6 
and 24hrs incubation of LPS (Ainsworth et a/2009, Ainsworth & Reyner 
2012). 
Inflammatory resolution induced by LXA4 has been investigated in human 
bronchial epithelial models. Human bronchial epithelial cells in vitro have 
increased LXA4 expression in response to acute acid injury (Bonnans et a/ 
2006). Exogenous LXA4 has also been shown to inhibit the expression of 
TNF-a-induced IL-8 in human bronchial epithelial cells (Bonnans et a/ 
2007). However, the effect of lipoxins in equine respiratory disease has not 
been fully investigated and the mechanisms remain unclear. 
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4.2 Aims and objectives 
• Characterise the response of in vitro primary ETE cultures to 
incubation with LPS, a known mediator of inflammation 
• Compare the response of LPS-treated in vitro primary ETE cultures 
with ETE cells incubated with LXA4, a molecule thought to promote 
inflammatory resolution 
The in vitro epithelial model of ETE cells established from Chapter 3 was 
used to determine inflammation and inflammatory resolution. The effect of 
different concentrations of LPS at varying time points on ETE cells was 
assessed by expression of COX-2 mRNA. From these investigations, a 
time point and LPS concentration signifying inflammation was selected. 
The selected time point and LPS concentration was then compared to the 
response of ETE cells to stimulation with exogenous LXA4 to determine 
inflammatory resolution. 
4.3 Methods 
Primary ETE cells were obtained from trypsin dissociation of tracheal 
epithelial tissue and maintained in culture until 70-75% confluent before 
use in experiments. Primary ETE cells were not passaged prior to 
experimental investigations. Cultured cells were treated with LPS 
concentrations of 0.1, 10 and 1 O O ~ g / m l l to establish a suitable level of LPS 
to induce acute inflammation. 
Inhibition of inflammation indicated by COX-2 mRNA levels was examined 
by incubation with carprofen, an anti-inflammatory drug. Expression of 
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COX-2 mRNA used to signify inflammation was determined by end point 
and q-PCR at the chosen time points of 0, 4 and 24hrs. 
The response of ETE cells to LPS stimulus was compared with the effect 
of LXA4 treatment. ETE cells were incubated with LPS, LXA4 or pre-
treated with LXA4 for 15m ins before incubation with LPS. Control samples 
for ETE cells in all stated experiments did not receive LPS, carprofen or 
LXA4 treatment. 
Inflammation and inflammatory resolution in ETE cells were further 
assessed by: 
i. Quantification of ALX, TLR-4, TNF-a, IL-1 p, iNOS and COX mRNA 
by q-PCR 
ii. Western blot detection of ALX and COX-2 protein 
iii. Fluorometric analysis of NO levels 
Full details of the methods used to detect inflammation and inflammatory 
resolution in ETE cells are described in Chapter 2 
4.4 Results 
End-point PCR detection of COX-2 mRNA in primary ETE cells after 
24hr incubation with 10IJg/ml LPS concentration 
Basal and acute inflammatory states were examined in ETE cells obtained 
from 2hr trypsin digestion of epithelial tissue. End-point PCR was used to 
detect expression of COX-2 mRNA compared to reference gene GAPDH 
after incubation with 10jlg/ml LPS for 24hrs. The chosen time point and 
concentration was based on similar human and horse studies of the effect 
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of LPS on epithelial cells (Yang et a/2007, Ainsworth et a/2009). Results 
were visualized with agarose gel electrophoresis which revealed PCR 
bands representing COX-2 mRNA to be expressed in both control and 
LPS treated samples (Fig.19) 
400b . . .,.a... 
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Figure 19: End·point peR Image of primary ETE cells following 24hr incubation with 
101Jg/ml LPS concentration. 
Representative image of agarose gel shows COX-2 and GAPDH mRNA expression in primary ETE 
celis after 24 hrs treatment with LPS. NTC represents no template control where cDNA was omitted 
from PCR samples. Primary ETE celis were obtained from 2hr digestion of epithelial tissue with 
trypsin. 
Expression of COX-2 mRNA was taken to indicate inflammation from an 
unknown source in both control and LPS-treated ETE cell samples. No 
bands were evident in the NTC control which was performed to indicate 
any potential contamination of PCR reaction. Contamination of PCR 
product would have explained the observed positive expression in the 
control groups. Although no such contamination of PCR products was 
indicated, all areas of the experimental protocols were examined for 
potential areas of contamination and fresh reagents and consumables 
were used. 
The experiment was then repeated with a fresh set of primary ETE cells 
obtained from a different tissue donor to the previous experiment, but 
using the same methods and LPS concentration. In addition, a time zero 
sampling was included to establish if primary ETE cells were expressing 
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COX-2 mRNA prior to treatment. Evidence of COX-2 mRNA before LPS 
incubation would indicate prior inflammation in primary ETE cells which 
would have affected results for the control group samples. 
Repeat of end-point PCR detection of COX-2 mRNA expression in 
primary ETE cells after 24hr incubation with 10J,lg/ml LPS 
concentration 
Repeat of the experiment demonstrated that control cells still showed 
noticeable expression of COX-2 mRNA at 0 and 24hrs despite the 
absence of LPS stimulation (Fig.20). 
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Figure 20; End-point PCR Image of repeat of 24hr Incubation of primary ETE cells with 
1 O ~ g l m l l LPS concentration. 
Representative image of agarose gel shows COX-2 and GAPDH mRNA expression in primary ETE 
cells after 24hrs treatment with 1 0 ~ g l m l l LPS. Time zero was included to determine the 
inflammatory state of cells prior to treatment with or without LPS. Primary ETE cells were obtained 
from 2hr trypsin digestion of bronchial epithelial tissue from separate subject to previous 
experiments. 
It was concluded that expression of COX-2 mANA in untreated and treated 
samples at all stated time points was indicative of inflammation in ETE 
cells before use in experiments. 
However, accurate quantification of mANA product by end-point PCR 
analysis is limited. Use of agarose gel or ethidium bromide limits the level 
of quantative detection (Ginzinger 2002). A more sensitive method of 
detection was required as no allowance is made for fold-change values, 
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which may be as different as between 10 or 50 copies. It was possible that 
although COX-2 mRNA was present, levels in untreated samples were 
reduced compared with LPS-treated samples. It was decided to use real 
time PCR to ensure COX-2 mRNA in ETE cells was more accurately 
quantified. 
Real time quantification of COX-2 mRNA in primary ETE cells after 0, 
4 and 24hr incubation with 10J,lg/ml LPS concentration 
Primary ETE cells were again dissociated from 2hr digestion of equine 
epithelial tissue). Time pOints of 0,4 and 24hrs were included in real time 
PCR detection of COX-2 mRNA to indicate inflammation prior to or early 
on during LPS incubation (Fig.21). 
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Figure 21: q-PCR graph of COX-2 mRNA In primary ETE cells after Incubation with 1 O ~ g / m l l
LPS concentration. 
COX-2 mANA expression (relative to reference gene GAPDH) was quantified at 0, 4 and 24hrs. 
Primary ETE were isolated after 2hr trypsin digestion of tracheal epithelial tissue from separate 
subject to previous experiments. Error bars represent SEM obtained from 3 replicates from a single 
experiment. A two-way ANOVA was performed to indicate any statistical significance. Expression of 
COX-2 mANA was significantly reduced (pvalue < 0.001) in controVLPS samples (*r*) at time Ohr 
compared with all other controVLPS samples. COX-2 mANA was significantly reduced in control 
samples at 4hrs (***) compared with control samples after 24hrs (p value < 0.001) 
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Control COX-2 mRNA expression showed no obseNable difference 
compared with LPS-treated samples at Ohr. A two-way ANOVA indicated 
that control (*) and LPS-treated samples (**) at Ohr were significantly 
reduced compared with control and LPS treatment groups at 4hrs and 
24hrs (p value <0.0001). Control samples at 4hrs (***) were significantly 
reduced compared with control values at 24hrs (p value <0.0001). 
Treatment of ETE cells with LPS did not have a significant difference on 
COX-2 mRNA expression. 
Results suggest that LPS stimulation was not wholly responsible for any 
apparent increase in COX-2 mRNA expression. It was concluded that 
there was a steady increase of COX-2 mRNA over 24hrs in both control 
and LPS treated samples. The obseNed increases in COX-2 mRNA were 
attributed to inflammation caused by cell isolation or in vitro culture 
methods, rather than LPS stimulation. 
To confirm the presence of underlying inflammation in isolated ETE cells, it 
was decided to investigate the effect of incubation of ETE cells with anti-
inflammatory carprofen, a COX-2 inhibitor (Berreta et 812005), with the 
aim of reducing basal COX-2 in ETE cells. 
Effect of anti-inflammatory carprofen incubation on COX-2 mRNA 
expression in primary ETE cells 
Fresh respiratory epithelial tissue was collected from a different horse to 
previous experiments and digested with trypsin for 2hrs to isolate primary 
ETE cells. Cell samples were incubated with either 4/lglml carprofen, 
10J.lglml LPS, or both carprofen and LPS, with samples collected at 0, 4 
118 
and 24hrs (Fig.22). At this point, the house-keeping gene was changed 
from GAPDH to 188 because it proved less variable. 
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Figure 22: q-PCA graph of COX-2 mANA expression In primary ETE cells after incubation 
with 4",glml carprofen and 10",g/ml LPS concentration 
COX-2 mANA expression (relative to reference gene 18S) was quantified at 0,4 and 24hrs. Control 
samples did not receive LPS or carprofen treatment. Primary ETE cells isolated after 2hr trypsin 
digestion of tracheal epithelial tissue from separate subject to previous experiments. Error bars 
represent SEM obtained from 3 replicates from a single experiment. A two-way ANOVA was 
performed to indicate any statistical significance. Expression of COX-2 mANA was significantly 
reduced in all treatment groups at Ohr (*) compared with all other time points (p value < 0.0001) and 
increased in control samples (**) compared with other treatment groups after 24hrs (*. p value 
0.0010) 
COX-2 mRNA in all treatment groups at Ohr (*) was significantly reduced 
(p value < 0.0001) compared with samples at all other time points. LP8 
and carprofen incubation at 4 and 24hrs did not significantly increase or 
reduce COX-2 mRNA expression. At 24hrs, mRNA levels in control 
samples (**) were significantly increased (p value 0.0010) compared with 
other treatments at 24hrs. 
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It was concluded that carprofen treatment of ETE cells appeared to inhibit 
COX-2 mRNA after 4 and 24hrs incubation. Additionally, the observed 
increase in COX-2 mRNA in control samples after 24hrs indicated that pre-
existing inflammation in ETE cells was present. Based on these results, 
the culture conditions and cell isolation method were examined for 
potential causes of inflammation. 
Airway remodelling in asthma and RAO induces rapid renewal of 
respiratory epithelial cells. Human bronchial epithelial cells in vitro have 
demonstrated 2-fold or more differences in gene expression including 
those associated with immunity during proliferation or regenerative periods 
(Ross et al 2007). The potential for an initial rapid growth of cultured 
primary ETE cells isolated by trypsin treatment to develop inflammation as 
measured by COX-2 expression was explored. 
Comparison of culture time period on inflammatory capabilities of 
primary ETE cells 
Reports in human studies of epithelial repair indicate a return to a 'resting 
epithelial profile' at approximately 21-28 days after injury (Heguy et al 
2006). Accordingly, expression of COX-2 mRNA expression was examined 
in primary ETE cells after either 5 days or 4 weeks in culture. 
Quantification of COX-2 mRNA was obtained relative to reference gene ~ ~
actin. This change was required as cDNA synthesis at that time used oligo 
dT primers, which make 18S unsuitable for a reference gene due to the 
lack of a poly A tail. Subsequent work then used random hexamers due to 
low RNA concentrations extracted from cell samples. It was decided to 
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continue with ~ - a c t i n n as a reference gene for continuity in results and 
reliability in performance that equalled that of 188. ETE cells were 
obtained from 2hr trypsin digestion of epithelial tissue collected from a 
different horse to previous experiments, and COX-2 expression examined 
in untreated cells after 5 days or 4 weeks in culture (Fig.23). 
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Figure 23: q-PCR graph of COX-2 mRNA expression In ETEC after culture period of 5 days or 
4 weeks 
The effect of time spent in culture on COX-2 mRNA expression (relative to reference gene j3-actin) 
in untreated ETE cells. Cell samples were taken from each group 24hrs after a fresh media 
replacement. Primary ETE cells isolated after 2hr trypsin digestion of tracheal epithelial tissue from 
separate subject to previous experiments. Error bars represent SEM obtained from 3 replicates 
from a single experiment. A two-way AN OVA was performed to indicate any statistical significance. 
Expression of COX·2 mANA was significantly increased (p value < 0.0001) in 5 day cultures (*) 
after 24hrs compared to time zero and reduced in 4 week cultures (**) compared to 5 days old 
cultures (p value < 0.001) after 24hrs. 
Expression of COX-2 mRNA was significantly increased (p < 0.0001) in 5 
day cultures (*) after 24hrs in culture compared with time zero. Levels of 
COX-2 mRNA in 4 week old ETE (**) were significantly reduced (p<. 
0.0001) compared with 5 day old cultures after 24hrs. Reduction in COX-2 
mRNA levels at 24hrs in 4 week old ETE cells was considered to be 
partially caused by reduced growth and activity in fully confluent cells. The 
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increase in COX-2 mRNA after 24hrs in 5 day old ETE cells was attributed 
to rapid growth of cells after enzymatic isolation. 
Results for both 5 day old and 4 week old ETE cells again indicated that 
both culture period and the initial enzymatic dissociation of cells from 
tissue with trypsin were sources of inflammation. Previous attempts to 
obtain ETE cells with alternative digestion media had been unsuccessful. It 
was then decided to investigate isolation of ETE cells with reduction of 
trypsin digestion time. The aim was to collect sufficient numbers of ETE 
cells but with minimal exposure to digestion media to reduce inflammation. 
Effect of tissue digestion period and trypsin concentration 
The trypsin concentration and time period of tissue dissociation required to 
obtain primary epithelial cells was then examined. Trypsin proteolysis of 
epithelial tissue was inspected every 20 mins under the light microscope 
for dissociated primary cells. Trypsin action was halted once 1 04/ml of cells 
was present. Incubation time with trypsin during the initial cell isolation was 
accordingly reduced from 2hrs to approximately 30-45 mins. This was 
found to be sufficient to routinely obtain adequate cell numbers, and was 
the method used in all subsequent experiments where ETE cells were 
required. 
Effect of LPS concentrations on inflammatory expression in primary 
equine ETE cells 
Following the optimisation of trypsin incubation time to obtain ETE cells, it 
was decided to examine the concentration of LPS required to initiate an 
inflammatory response. It was thought that the use of 10 Ilg/ml LPS to 
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induce inflammation could be excessive, particularly as horses are 
considered sensitive to the effects of LPS (Moore 2001). Additionally, 
bronchial epithelial cells act as part of innate respiratory immunity and as 
such would be highly responsive to LPS treatment. 
The effect of three different LPS concentrations on ETE cells isolated with 
the reduced trypsin incubation time was investigated. Concentrations of 
0.1, 10 or 100 Ilg/ml LPS were used to stimulate primary ETE cells 
obtained using the reduced trypsin incubation technique. The most 
noticeable increase in COX-2 mRNA had previously been observed on 
both control and treated groups at 24hrs, and it was decided to use this 
time point in future experiments. Expression of mRNA after LPS incubation 
(relative to J3-actin) now included TLR-4, TNF-a, IL-1 J3 and iNOS in 
addition to COX-2 (Fig.24). 
Results showed that 0.1Ilg/ml LPS after 24hrs was significantly (*) 
increased for ALX (p value 0.004), TLR-4 (p value < 0.0001), TNF-a (p 
value 0.0003), and IL-1J3 (pvalue 0.0012) compared with both untreated 
samples, and 10 and 1001lg/ml LPS concentrations. Apparent increases 
for iNOS and COX-2 mRNA after 0.1Ilg/ml LPS incubation were not 
statistically different. Despite this, levels of mRNA for these genes 
appeared increased compared with other LPS concentrations. 
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Figure 24: q-PCR graph of mRNA expression In ETE cells after 24hrs incubation with 0.1, 10 
and 100 lJg/ml LPS concentrations 
Expression of ALX, TLR-4, TNF-a, IL-113, iNOS and COX-2mRNA mRNAwas relative to reference 
gene l3-actin. Primary ETE cells were obtained from 30-45mins digestion of bronchial epithelial 
tissue from 3 separate subjects to previous experiments. Error bars represent the SEM obtained 
from 3 sample means from three separate experiments. A one-way ANOVA was performed to 
indicate any statistical significance. Expression of mRNA statistically significant (0) after 24hr 
incubation with 0.11Jg/ml LPS for ALX, TLR-4, TNF-a , and IL-113 (p value 0.04, <0.0001 , 0.003 and 
0.0012 respectively) compared with controls and 10 and 1001Jg/ml LPS treatment. 
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It was concluded that a concentration of 01 .Ilg/ml LPS concentration was 
suitable to induce acute inflammation in ETE cells obtained by the reduced 
trypsin incubation time. The next aim was to compare the effect of 
incubating inflamed ETE cell with exogenous LXA4. 
Expression of ALX, TLR-4, and TNF-a, IL-1 13, iNOS and COX-2 mRNA 
in ETEC after 24hrs incubation with 0.1 IJg/ml LPS, and/or 
100IJM LXA4 
Primary ETE cells were obtained with the reduced trypsin digestion 
method. Cultured ETE cells were treated with either 0.1 Ilg/ml LPS, 100llM 
LXA4 only, or were incubated with 1 OOIlM LXA4 for 15 minutes prior to the 
addition of 0.1 Ilg/ml LPS. Relative quantification of ALX, TLR-4, and TNF-
a, IL-113, iNOS and COX-2 mRNA was calculated using q-PCR with 13-actin 
actin acting as the reference gene. Western Blotting was performed to 
determine protein expression of ALX and COX-2. A nitrate assay was used 
to measure NO release into the culture media from treated primary ETE 
cells 
Control values for mRNA values from samples were reduced compared 
with other treatment groups suggesting no inflammation in ETE cells 
obtained with reduced trypsin digestion. However, treatment with LXA4 or 
LPS did not appear to have any effect on mRNA expression for any of the 
selected genes (Fig.25). 
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Figure 25: q-PCR graph of mRNA expression in ETEC after 24hrs Incubation with 0.1 ~ g / m l l
LPS, 1 O O ~ M M LXA4 and/or LXA4 
Expression of ALX, TLR-4 TNF, I L - 1 1 , , iNOS and COX-2 mRNA was relative to reference gene 13-
actin.ETE cells obtained from 3 separate subjects to previous experiments. Error bars represent 
SEM obtained from 3 sample means from three separate experiments. A one-way ANOVA was 
performed to indicate any statistical significance. 
Incubation of ETE cells with 100llM LXA4 did not increase ALX mANA 
expression which contradicts findings in other lipoxin studies (Bonnans et 
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a/2006). Binding of LXA4 to receptor ALX should increase expression of 
ALX but this was not apparent in this experiment. 
Treatment with O.1llg/ml LPS incubation for 24hrs did not apparently 
induce inflammation in ETE cells. This again contradicts the results 
obtained from ETE cells after incubation with LPS concentrations of 0.1, 
10 and 100llgilmi. The most obvious change in mRNA compared with 
control groups appeared to be after LXA4/LPS treatment. However a high 
level of variation in SEM error bars was apparent and so no definitive 
result could be drawn from obtained q-PCR data. No statistical significance 
was obtained from analysed data. 
It was concluded that incubation of equine primary ETE cells with LPS or 
100llM LXA4 for 24hrs did not noticeably increase or decrease mRNA 
indicative of inflammation or inflammatory resolution in primary ETE cells 
Protein expression of ALX and COX·2 in primary ETE cells 
To determine if the mRNA expression was translated into protein, Western 
blotting was performed for COX-2 and ALX with ~ - a c t i n n serving as the 
reference protein. ETE cells were obtained from reduced trypsin digestion 
of tissue from a separate horse to previous experiments. Primary ETE 
cells were incubated with either 0.1 Ilg/mL of LPS, 100 11M LXA4, or pre-
treated with 100llM of LXA4 prior to LPS incubation. Protein bands for 
ALX, COX-2 and ~ - a c t i n n were observed at approximately 30 kOa, 60-80 
kOa and 40 kOa respectively which was the predicted molecular weight 
(Chapter 2) for these antibodies (Fig.26). 
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Figure 26: Western blot Image of protein expression of /l-actln, COX-2 and ALX In primary 
ETE cells after 24hr Incubation with O . 1 ~ g / m l l LPS and/or 1 0 0 ~ M M LXA4 
ETE cells were treated with 0, 1 ~ g ! m l l LPS, 1 O O ~ M M LXA4, or pre-treated for 15 minutes with 1 O O ~ M M
LXA4 before LPS incubation. Primary ETE cells were obtained from 30-45mins trypsin digestion of 
bronchial epithelial tissue from a separate tissue subject to previous experiments. 
Western blotting revealed that protein expression of ALX in all treatment 
groups at 0 and 24hrs was very strongly evident. This suggested that 
although mRNA for ALX had not been significantly expressed, protein 
levels were detectable. In contrast, COX-2 bands at the same time point 
were weakly expressed, and absent in controls and after LPS/LXA4 
incubation 
Results for COX-2 potentially suggested although protein in control and 
LXA4/LPS samples was undetected, this may have been caused by 
primary antibody inefficiency, rather than an absence of COX-2. The 
possibility of antibody inefficiency from poor technique was discounted as 
the strong and robust bands observed in the house-keeping antibody ~ ~
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actin demonstrated that method optimisation was not required. It was 
concluded that despite the absence of ALX mRNA in results obtained from 
q-PCR, protein levels of ALX were very apparent. 
Nitric oxide expression in ETE cells 
To measure NO release in ETE cells, primary ETE cell cultures were 
treated with1 OOJlM LXA4, 0.1 Jlg/ml LPS or received a 15min incubation 
with 100JlM LXA4 before 24hr incubation with 0.1 Jlg/ml LPS. ETE cells 
were obtained from reduced trypsin digestion of tissue from a separate 
horse to previous experiments (Fig.27). 
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Figure 27: Quantatlve graph representing NO expression In primary ETE cells after 
Incubation with 0.1 ~ g 1 m l l LPS, 100IJM LXA4 and/or LXA4ILPS concentrations. NO expression 
measured by fluorescent Intensity (relative units to nitrite/nitrate standard curve) 
Media supernatant was assayed by fluorometric analysis for NO release from ETE cells 24hrs after 
treatment. Primary ETE cells were obtained from 30-45mins trypsin digestion of bronchial epithelial 
tissue from a separate tissue subject to previous experiments. Error bars represent SEM obtained 
from 3 replicates from a single experiment. A one-way AN OVA was performed to indicate any 
statistical significance. 
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Supernatant from the treated cells was assayed for NO expression by 
fluorometric analysis. Nitrate analysis did not show any discernible 
difference between ETE samples after treatment with 100jlM LXA4, 
0.1jlg/ml LPS or the combined LPS/LXA4 incubation. Analysis of results 
with a one-way ANOV A did not reveal any statistical significance in data. It 
was concluded that LPS and LXA4 treatment of ETE cells did not have any 
effect on NO expression 
4.5 Discussion 
After an in vitro model of ETE cells had been successfully established and 
characterised (Chapter 3), the next stage was to establish a suitable time 
point and LPS concentration to induce inflammation in cultured cells from 
this model. Adjustments to the method to obtain trypsin-dissociated cells 
were required as both end-point and q-PCA analysis detected COX-2 
mANA expression in untreated cell samples. Potential areas of 
contamination which might have been responsible for this were examined. 
Consideration was given to tissue collection (aseptic technique, tissue 
transport), preparation of tissue, culture conditions, ANA extraction and 
cDNA synthesis. 
One potential difference to the original methodology was the transport of 
tissue in cell culture grade PBS rather than Hanks Buffered Salt Solution 
(HBSS). The use of HBSS may have offered a very minor improvement in 
cell osmolarity due to the enhanced salt ion formulation. However, 
optimisation of all aspects of the methodology did not eliminate the 
underlying acute inflammation as measured by COX-2 mANA and 
detected in untreated cells by end-point PCA. 
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Quantifying the response of ETE cells to LPS with end-point PCR was 
initially unsuccessful. To increase the level of mRNA detection, samples 
were subsequently quantified by real time PCR. ETE cells were incubated 
with 1 Ollg/ml LPS concentration for 0, 4 and 24hrs. Significant reduction of 
COX-2 mRNA was observed in both control and LPS treated samples (p 
value 0.0001) at time zero, and in control samples at 4hrs (p value 
<0.0001). It was concluded that any apparent subsequent increase in 
COX-2 mRNA representative of inflammation was unrelated to LPS 
treatment. 
Incubation with carprofen did not significantly decrease COX-2 mRNA. 
Carprofen is a COX-2 inhibitor which is frequently used for chronic 
inflammation associated with osteoarthritis (Goodrich & Nixon 2006). 
Carprofen is also reported to inhibit LPS-induced iNOS expression in ovine 
macrophages (Bryant et 8/2003). Conversely, carprofen did not inhibit 
LPS-induced COX-2 activity in vitro with samples of whole blood from 
horses (Brideau et 8/2001). It may be that carprofen is unsuitable or only 
partly effective at controlling inflammation in equine ETE cells in vitro. It 
was concluded that neither anti-inflammatory nor inflammatory stimulation 
of ETE cells obtained after 2hrs trypsin-dissociation significantly altered 
COX-2 mRNA expression at 4 and 24hrs. 
The effect of culture conditions on ETE cells obtained from 2hr trypsin 
digestion was examined. It was established that COX-2 mRNA expression 
was significantly increased (p< 0.0001) in 5 day ETE cells obtained after 
2hr trypsin dissOCiation after 24hrs in culture. The inflammation observed 
in ETE cells which was attributed to the effects of trypsin digestion of 
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tissue. Such inflammation could have been eliminated by passaging cells, 
an approach not attempted during ETE cell culture. Passaging ETE cells 
obtained by trypsin dissociation was described in the original method 
(Shibeshi et aI2008). This technique required the use of dispase II and 
collagen coated tissue culture flasks for cell adherence. The reliance of 
dispase II-passaged ETE cells on collagen coated culture plates for 
adherence indicated that essential cell viability and function was potentially 
compromised. Additionally no inflammatory profile was described in ETE 
cells passaged with dispase II. It was concluded that further manipulation 
of ETE cells would not necessarily eliminate any inflammation in primary 
cells resulting from the initial trypsin digestion of tissue. 
Finally, the effect of trypsin on dissociated primary cells was considered. 
Trypsin has been linked to TNF-a and IL-1 ~ ~ mRNA release in rat 
peritoneal macrophages as early as 30 mins after exposure and reaching 
peak levels at 16hrs (Lundberg 2000). Reduction of the incubation times 
with trypsin but not enzyme concentration successfully produced adequate 
cell numbers of good viability. 
After optimisation of the trypsin digestion time, the effect of LPS 
concentrations on ETE cells was examined. In contrast to findings in the 
initial work on primary ETE cells, LPS-induced inflammation in other 
studies of epithelial and respiratory cells with a LPS concentration of 
1 Ollg/ml has been successful (Wu et a12002, Hostanka et a12011, Xu et al 
2011, Miao et al 2012). It was considered that the LPS concentration of 
1 Ollg/ml was excessive for equine ETE cells, and effectively induced cell 
apoptosis. ETE cells were therefore incubated with 0.1, 10 and 100llg/ml 
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LPS concentrations. ALX, TLR-4, TNF-a, and IL-1 J3 mRNA expression 
were significantly increased (p values < 0.0005) after 0.1 ~ g / m l l LPS after 
24hrs. Although not statistically significant, levels of mRNA for iNOS and 
COX-2 also appeared most increased after 0.1 ~ g / m l l LPS. An excessive 
concentration of LPS affecting ETE cell viability would be in agreement 
with an investigation of LPS effects on in vitro rat cell cultures. Primary rat 
tracheal epithelial cells were cultured with 1 O ~ g / m l l of LPS for 18 hours. 
Morphological changes in cultured cells, altered rates of proliferation, and 
decreased cell density were detected. Cellular alterations were attributed 
to the adverse reaction of cells to LPS (Freitag et a/1996). 
The selected LPS concentration of 0.1 ~ g / m l l LPS was used in subsequent 
treatment of ETE cells with LXA4 and LPS to determine the potential for 
inflammatory resolution. Overall, treatment with LPS and LXA4 did not 
apparently increase or inhibit mRNA expression in any of the selected 
genes. It initially appeared that LXA4 incubation marginally reduced TNF-a 
and IL-1 J3 mRNA. Unusually, primary ETE cells cultured with exogenous 
LXA4 did not show an increase in ALX mRNA expression as would be 
expected. This is in contrast to a previous report that showed that ALX 
receptor activity is increased following binding to its ligand LXA4 (Serhan 
2005). Lack of ALX expression in our studies may be caused by several 
reasons. A simple explanation is that the receptor binding is relatively brief 
or occurs prior to our chosen time point of 24hrs. Peak expression of ALX 
has been observed in human bronchial epithelial cells 2 hours after acid 
injury to cells. Expression of ALX mRNA steadily decreased thereafter, 
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with levels reduced to almost half at 24 and 72 hours (Bonnans et al 
2006). 
Inconclusive results after LXA4 studies were potentially caused by the 
previous use of COX-2 to signify inflammation at the chosen time point of 
24hrs. COX-2 expression unrelated to inflammatory episodes is indicated 
in other studies, with levels deemed to be cell-specific and unpredictable 
(Ermert et al 2000). COX-2 mRNA has been detected in baseline 
conditions in rat bronchial epithelial cells (Ermert et al 2011). COX-2 
mRNA and protein is also commonly expressed in human bronchial 
epithelial cells and BEAS-2B cells in culture without inflammatory 
stimulation (Watkins et al 1999, Pierzchalska et al 2007). Ermert et al 
2011). Minimal COX-2 mRNA expression has been found in bronchial 
biopsy specimens from non-asthmatics (0.6%) compared with asthmatics 
(4.6%) (Redington et al 2001). This indicates a potential for irregular 
expression of COX-2 that is subject-specific and differs according to minor 
changes in tissue source or the health of each individual. It also suggests 
that COX-2 is not as reliable a marker of inflammation as previously 
thought. 
A time point of 24hrs to detect inflammation had been considered suitable 
based on previous experiments with COX-2 mRNA. Comparison of 
findings at 24hrs in ETE cells after LPS and LXA4 investigations indicate 
that earlier time points are necessary to accurately quantify peak levels of 
mRNA expression. Early COX-2 expression has been demonstrated in 
other equine cells associated with acute inflammation. Equine leukocytes 
expressed COX-2 mRNA at 30 minutes and at 4hrs after 1 0 ~ g / m l l LPS 
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(Eckert et a/2007). Additional increases of both mRNA and protein were 
observed within 1 hr after 10l-lg/ml LPS treatment (Ermert et a/ 2011). 
Expression of molecules such as TNF-a and IL-1 J3 may also occur also 
earlier than at 24hrs. Detection of TNF-a and COX-2 was observed in 
equine monocytes within 1 hr of treatment with 100pg/ml LPS but 
expression had declined to baseline at 20hrs (Sun et a/201 0). Use of a 
single time pOint at 24hrs was therefore an important limiting factor in 
assessing inflammation and inflammatory resolution. Our study performed 
some pilot trials on COX-2 mRNA expression at 1 and 4 hours (data not 
shown), but there was very little difference in mRNA expression levels. 
Ideally, samples should have been taken at much earlier time points; for 
example 15 mins, 30 mins 1 hr, 4hrs and 24hrs. These particular pOints 
were beyond the time and resources of this study. 
Detection of protein with Western blotting after LXA4 studies showed that 
signal for ALX protein was highly abundant and Signal for COX-2 protein 
very weak. This may have been due to insufficient protein in the sample, or 
the antibody concentration being too low. However, protein samples were 
quantified as sufficient before use (Chapter 2) and the strong signal 
detected in ALX and loading control J3-actin discounted this possibility. 
It was concluded that absence of bands in COX-2 was more likely to result 
from a poorly performing antibody, rather than low protein levels. The 
primary antibodies were selected for their reported performance in several 
species and applications. No cross-reactivity for use in equine tissue in 
either primary antibody was described on the data sheet. However, BLAST 
analysis of the amino acid sequence for each primary antibody suggested 
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they would be suitable to detect protein levels in equine cells. Steps to 
optimise the COX-2 primary antibody should have attempted, such as 
performing a series of experimental dilutions to determine an optimal 
antibody concentration. Additionally, efforts should have been made to test 
the primary antibody on the suggested positive control, the mouse 
macrophage cell line Raw264.7. Finally, it should be considered that that 
particular chosen COX-2 primary antibody was suspect or simply 
unsuitable for use in equine tissue or Western blotting. The validity of data 
for protein expression could also have been improved if experimental 
repeats had been performed. 
Similarly, nitrate analysis by fluorometric detection of ETE cells would 
produce more reliable data if further repeats were carried out. Lack of 
observable differences in NO expression in ETE cells may be caused by 
sampling at the wrong time. Expression of iNOS mRNA is seen as early as 
6hrs (Hao et al 2011), with levels of NO observed in human bronchial 
epithelial cells after 12 and 24hrs stimulation with TNF-a (Robbins et al 
1994), and in murine epithelial cells at 24hrs (Robbins et al 1994). 
Expression of NO can be affected by culture conditions and growth factors 
in media (Asano et aI1994). Accurate quantification can therefore be 
challenging. 
Results from experiments examining COX-2 mRNA expression and 
determining time points were based on samples obtained from a different 
horse for each experiment. Similarly, LXA4 data resulted from tissue 
obtained from three different horses. Both factors provide considerable 
scope for variation in cell expression due to potential differences in each 
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subject's health and history. Repeated testing from a small number of the 
same horses would enable to the development of an individual immune 
profile for each horse. This could then determine if similar cellular 
responses between each horse could be observed during induced 
inflammation or inflammatory resolution in vitro. Unusual or dissimilar data 
obtained from experiments could then be attributed to either a particular 
individual or a single experiment. This should eliminate much of the 
variation observed in collected data, particularly the LXA4 experiments. 
It was concluded that use of a different horse for each experiment was the 
strongest factor in producing comparable and reliable data. 
4.6 Conclusion 
An in vitro respiratory epithelial cell model is suitable for use in 
investigations of airway inflammation and potential inflammatory 
resolution. Treatment of ETE cells with LPS induces some evidence of 
inflammation but LXA4 incubation does not cause observable inflammatory 
resolution. Alterations to the chosen time pOints are required, as is 
assessment of COX-2 as a marker of inflammation, and the concentration 
of LXA4 used to upregulate ALX. Such adjustments may then improve 
investigations of LXA4 into airway inflammation in horses. 
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Chapter 5: Effect of LXA4 incubation on 
acute inflammation in primary equine airway 
smooth muscle cells 
5.1 Introduction 
Remodelling of ASM after chronic inflammatory exacerbations initiates an 
increase in the layer of trachealis muscle in both human and horse 
(Robinson et aI1996). Factors contributing to ASM increase include cell 
hyperplasia or hypertrophy (Wright et al 2012), failure of cell apoptosis 
(Ding et a12008) and cell migration (Halwani et aI2011). 
An increase ASM in human and horses significantly contributes to airway 
hyper-responsiveness and is relative to disease advancement (James et al 
2009). ASM increase is also highly apparent in people affected by severe 
or refractory asthma (Macedo et al 2009, Tillie-LeBlond et al 2008). 
Prevention of ASM increase or reversal of such remodelling changes is a 
focus of asthma and RAO treatment. 
5.2 Aims and objectives 
• Establish the response of in vitro ASM cells to incubation with LPS, 
the same inflammatory mediator used to incubate primary ETE cells 
• Compare the LPS-induced response of ASM cells to treatment with 
LXA4 treatment, to investigate potential inflammatory resolution. 
To achieve these aims, the in vitro model of primary ASM cells established 
in Chapter 3 was incubated with different concentrations of LPS at varying 
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time points. This was to determine a suitable time point and LPS 
concentration to induce inflammation. 
Inflammatory resolution was examined by comparing the selected time 
point and LPS dose with LXA4 or a combination of both LPS and LXA4. 
The response of ASM cells to treatment was analysed by quantification of 
mRNA and detection of protein expression. 
5.3 Methods 
Primary equine ASM cells were cultured from explants of trachealis muscle 
and maintained in serum-supplemented DMEM media until 70-75% 
confluent. ASM cells obtained from explants were not passaged before 
experimental use. 
Primary ASM cultures were treated with LPS concentrations of 0.1, 10 and 
1 O O ~ g 1 m l l to determine a suitable level of LPS to induce acute 
inflammation. Expression of COX-2 mRNA was used to signify 
inflammation at the chosen time points of 12, 24 and 72hrs based on 
similar papers (Belvisi et a11997, Pang & Knox 1997, Chen& Khalil 2006) 
The response of ASM cells to inflammatory stimulus was compared with 
the effect of LXA4 treatment. ASM cells were incubated with LPS, LXA4 or 
pre-treated with LXA4 for 15m ins before incubation with LPS. Control 
samples for ASM cells did not receive either LXA4 or LPS treatment. The 
same methods used in Chapter 4 were used here with details explained in 
Chapter 2. 
5.4 Results 
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ASM expression of COX-2 mRNA at 12, 24 and 72hrs after incubation 
with 0.1, 10 and 1 O O ~ g / m l l LPS concentrations 
A time and concentration study was performed to determine the response 
of ASM cells to LPS incubation. Concentrations of 0.1 and 101lg/ml LPS 
induced the most noticeable levels of COX-2 expression at 72 hours in 
ASM cells compared with all other samples (Fig.28) 
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Figure 28: q-PCR graph of COX-2 mRNA expression in primary ASM cells after time and 
concentration course of LPS 
COX-2 mRNA (relative to reference gene l3-actin) was quantified at 12. 24 and 72hrs after 
treatment with 0.1. 10 and 1 OOIlg/ml LPS concentrations. ASM cells were obtained from a separate 
tissue subject to previous experiments. Error bars represent SEM obtained from 3 replicates for 
each sample from a single experiment. A two-way ANOVA was performed to indicate any statistical 
significance. Expression of COX-2 mRNA was significantly increased after 72hrs (*) of 0.1Ilg/ml 
LPS (**) compared with controls (p value 0.0115) and all other time points (p value 0.0015). 
Data analysis with a two-way ANOVA revealed 0.1Ilg/ml LPS (**) 
significantly increased COX-2 mRNA levels compared to control samples 
(p value 0.0115) but not to 10 or 1 OOllg/ml LPS concentrations. Expression 
of COX-2 after 72hrs (*) of 0.1Ilg/ml LPS was also significantly increased 
compared to 12 and 24hrs (pvalue 0.0015), suggesting this was a suitable 
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time point to examine inflammation in ASM cells. In contrast to ETE cells, 
no noticeable expression of COX-2 mRNA in control samples was 
observed at the chosen time points of 12, 24 and 72hrs. This indicated that 
ASM cells cultured from airway smooth muscle explants were free from 
detectable inflammation prior to use in experiments. 
Although not statistically Significant, COX-2 mRNA mean values for 
101lg/ml LPS were closely similar to those from 0.1Ilg/ml LPS 
concentrations. The experiment was repeated with a fresh set of primary 
ASM cells from tracheal is explants cultured from a different horse to 
previous experiments. These cells were stimulated with 0.1 and 10 Ilg/m L 
LPS concentrations for 72hrs to determine the most suitable LPS 
concentration. In addition to COX-2 mRNA, the number of genes 
examined was increased to include mRNA for ALX, TLR-4, TNF-a, IL-113, 
and iNOS. This was to provide a more detailed indication of the response 
of ASM cells to incubation with LPS. 
Expression of ALX, TLR-4, TNF-o, IL-113, iNOS and COX-2 mRNA In 
primary ASM cells after 0.1 and 10 J,lg/mL LPS 
concentrations. 
Results showed that mRNA levels after incubation with 0.1 and 10 Ilg/mL 
LPS concentrations were still very similar (Fig.29). 
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Figure 29: q-PCR graph of mRNA expression In primary ASM cells after incubation with 0.1 , 
and 1 O ~ g / m l l LPS concentrations 
Expression of ALX, TLR-4, TNF-a, I L - 1 ~ , , iNOS and COX-2 mRNA (relative to reference gene ~ ~
actin) was quantified after 72hrs treatment. ASM cells were obtained from trachealis muscle 
explants from separate tissue subject to previous experiments. Error bars represents SEM obtained 
from 3 replicates for each sample from a single experiment. A one-way ANOVA was performed to 
indicate any statistical significance. 
Error bars variation was particularly noticeable for ALX mANA expression. 
LPS incubation appeared to decrease ALX mANA compared with control 
values. One way ANOVA analysis of mANA data did not reveal any 
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statistical significance to aid interpretation of results. Variation in the data 
and lack of statistical significance may be attributed to the small sample 
sizes. 
Despite this, it was appeared that 0.1 ~ g / m l l LPS induced a slightly more 
obvious change in mRNA expression in TLR-4, TNF-a, IL-1 p, iNOS and 
COX-2 mRNA. Therefore, this LPS concentration was then used when 
comparing the response of ASM cells to both LPS and LXA4 incubation. 
Response of primary ASM cells incubation with 0.1 ~ g / m l l LPS, 1 O O ~ M M
LXA4 and/or LXAlLPS concentrations. 
A time point of 72hrs incubation with 0.1 ~ g 1 m l l LPS concentration was 
selected as suitable to induce inflammation in ASM cells. As the effects of 
LXA4 incubation on smooth muscle have not been extensively studied in 
vitro, the same concentration of 1 O O ~ M M and 15min pre-incubation time as 
with ETE cells was used. Results for mRNA expression for ALX, TLR-4, 
TNF-a, IL-1 p, iNOS and COX-2 mRNA after investigation of the effects of 
exogenous LXA4 were variable and inconsistent at both 24 and 72hrs 
(Fig.30, 31). 
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Figure 30: q·PCR graph of mRNA expression In primary ASM cells after 24hrs Incubation 
with 0 . 1 ~ g / m l l LPS, 1 0 0 ~ M M LXA4 and/or LXAlLPS concentrations. 
Expression of ALX, TLR-4, TNF-a, I L - 1 1 , , iNOS and COX-2 mRNA (relative to reference gene ~ ~
actin) was quantified in primary ASM cells after 24hrs treatment. Primary equine ASM cells were 
obtained from trachealis muscle explants from 3 separate tissue subjects to previous experiments. 
Error bars represents SEM obtained from 3 sample means from three separate experiments. A one-
way ANOVA was performed to indicate any statistical significance 
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Figure 31: q-PCR graph of mRNA expression In primary ASM cells after 72hrs Incubation 
with O.11.1g/mllPS, 100l.lM lXA4 and/or lXAllPS concentrations. 
Expression of ALX, TLR·4, TNF-a, IL-1P, iNOS and COX-2 mRNA (relative to reference gene 13-
actin) was quantified in primary ASM cells after 72hrs treatment. Primary equine ASM cells were 
obtained from the same tissue subjects as that at 24hrs. Error bars represents SEM obtained from 
3 sample means from three separate experiments. A one-way ANOV A was performed to indicate 
any statistical significance. 
Values for treatment samples were frequently similar to control groups for 
all genes, suggesting that incubation with LXA4 or LPS had little or no 
effect on ASM cells. Although a negative result was shown for COX-2 
mANA expression after 24hr incubation of ASM cells this time point was 
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included for the ASM cell LXA4 experiments. Primary ETE cells had 
previously shown the greatest response at 24 hours. This time point would 
therefore be important during the subsequent co-culture experiments 
examining the epitheliallASM relationship potential during inflammation. 
Despite an initial difference in LXA4/LPS samples for ALX, TLA-4, IL-1J3, 
and iNOS mANA at 24hrs, SEM error bars were again extremely variable, 
and could not be considered reliable. The level of inconsistency in mANA 
expression was observed at both 24 and 72hrs for all the chosen genes. 
Use of one-way ANOVA for data analysis to compare differences between 
control and treated samples did not reveal any significant results. It was 
concluded that LXA4 treatment of primary equine ASM cells could not be 
shown to clearly resolve inflammation, as quantified by mANA expression. 
To determine if mRNA values were translated into protein, further analysis 
of media supernatant and cell lysate samples was performed by 
fluorometric detection and Western blotting respectively. 
Protein levels of COX-2 and ALX in ASM cells after 24 and 72hrs 
treatment with LPS and/or LXA4 
Western Blotting was performed on ASM cells after 24 and 72hrs 
incubation with either 0.1, 10 100 Ilg/mL of LPS, 100 11M LXA4, or 
LPS/LXA4 incubation. The three different LPS concentrations were 
included as previous mRNA expression with 0.1 and 10 llg/mL of LPS had 
been closely similar. The proteins of interest were ALX and COX-2, with J3-
actin serving as the reference gene. Protein bands for ALX, COX-2 and ~ ~
actin were observed at approximately 30 kDa, 60-80 kDa and 40 kDa 
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respectively (Chapter 2) which was the predicted molecular weight for 
these antibodies (Fig.32). 
40 kDa 
ALX 30kDa 
MW Con LPS LPS LPS LXM LXM LXM! LXM! 
marker O.11lg/ml 101lg/m11001lglm11001lM 100IJM LPS LPS 
72hr 72hr 72hr 72hr 24hr 72hr 24hr 72hr 
COX-2 
MW Con LPS LPS LPS LXM LXM LXM! LXM! 
marker 0.11Jg/ml 101lg/mI1001lg/ml 100llM 100llM LPS LPS 
72hr 72hr 72hr 72hr 24hr 72hr 24hr 72hr 
50kDa 
p-actin 
40kDa 
MW Con LPS LPS LPS LXM LXA4 LXA41 LXMI 
marker O.11Jg/ml 10IJg/mi 1 OOIJg/mI1 OOIJM 100IJM LPS LPS 
72hr 72hr 72hr 72hr 24hr 72hr 24hr 72hr 
Figure 32: Western blot image of protein expression of p-actin, COX-2 and ALX in 
primary ASM cells after Incubation with 0.1, 10 and 100J,lg/ml LPS and/or 100J,lM 
LXA4 for 24 and 72hrs. 
ASM cells were treated with 0.1 ~ ~ , , 10 and 1 0 0 ~ g / m l l LPS, 1 O O ~ M M LXA4, or pre-treated for 15 
minutes with 1 O O ~ M M LXA4 before LPS incubation. Primary equine ASM cells were obtained from 
trachealis muscle explants from separate tissue subject to previous experiments. 
As previously seen in ETE cells, the antibody for ALX protein produced a 
very strong band in all treatment groups. Results for protein expression of 
COX-2 showed bands that were again weaker than that of ALX. However, 
detected bands were stronger than those observed in ETE cell samples. A 
protein band was present for COX-2 control sample for ASM cells at 72hrs, 
suggesting a level of inflammation not caused by LPS incubation. In 
contrast, bands corresponding to COX-2 protein expression after LXA4 
and LXA4/LPS treatment were very faint. This indicates that although 
LXA4 incubation had no discernible effect on mRNA expression, it could 
have modestly reduced COX-2 protein levels at 72hrs. 
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Nitric oxide release from ASM cells after 24 and 72hrs treatment with 
LPS and/or LXA4 
In addition to Western blot detection of protein, cultured ASM cells were 
assayed for NO release in cell supernatant samples 24 and 72hrs after 
treatment with LPS and LXA4. Primary ASM cell cultures were treated with 
1 O O ~ M M LXA4, 0.1 ~ g / m l l LPS or received 15min incubation with 1 O O ~ M M
LXA4 before incubation with 0.1 ~ g / m l l LPS (Fig.33). 
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Figure 33: Quantatlve graph of fluorometrlc detection of NO expression In primary ASM 
cell supernatant after Incubation with O.1/ml LPS and/or 1 0 0 ~ M M LXA4 concentration over 
24hrs. NO expression measured by fluorescent Intensity (relative units to nitrite/nitrate 
standard curve) 
Primary ASM cells were treated with O.11lg/ml LPS, 100llM LXA4, or pre-treated for 15 minutes with 
100llM LXA4 before LPS incubation. Primary equine ASM cells were obtained from trachealis 
muscle explants from separate tissue subject to previous experiments. Each error bar represent a 
group mean (SEM) obtained from 3 replicates means from a single experiment. A one-way ANOVA 
was performed to indicate any statistical significance 
LXA4 treatment of ASM cells after 24hrs appeared to very marginally 
reduce NO expression compared with control and other treatments. 
However, no statistical difference was apparent in NO levels in ASM 
cells after 24hr incubation. Nor was there any statistical difference in 
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NO expression in ASM cells after LPS/LXA4 treatment over 72hrs 
(Fig.34). 
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Figure 34: Quantatlve graph of fluorometric detection of NO expression In primary ASM cell 
supernatant after Incubation with O.1/ml LPS and/or 1 0 0 ~ M M LXA4 concentration over 72hrs. 
NO expression measured by fluorescent Intensity (relative units to nitrite/nitrate standard 
curve) 
Primary ASM cells were treated with 0.1 J..lg/ml LPS, 100J..lM LXA4, or pre-treated for 15 minutes with 
100J..lM LXA4 before LPS incubation. Primary equine ASM cells were obtained from trachealis 
muscle explants from the same tissue subject as from NO assay at 24hrs. Each error bar 
represents a group mean (SEM) obtained from 3 replicates means from a single experiment. A one-
way ANOVA was performed to indicate any statistical significance 
It was concluded that treatment of ASM cells with LPS or LXA4 had no 
effect on the expression of NO after 24 or 72hrs. 
5.5 Discussion 
The in vitro model of ASM cells successfully developed and characterised 
by the use of equine trachealis muscle explants was used for these 
experiments. The response of in vitro ASM cells to treatment with either 
LPS or LXA4 or both was examined to determine inflammation and 
inflammatory resolution. 
One consideration to determining inflammation in respiratory smooth 
muscle was the potential response of in vitro ASM cells. The 
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characteristics of ASM cells, either in vivo or in vitro can demonstrate 
diverse biological reactions according to their environment. As such, in 
vitro ASM cells from trachealis muscle may exhibit synthetic, contractile 
and inflammatory phenotypes (Wright et a12012). Smooth muscle cells in 
vitro are capable of converting between a contractile sessile state to a 
synthetic phenotype in response to stimuli such as mechanical strain and 
inflammation (Beamish et al201 0). ASM cells demonstrating a synthetic 
phenotype are able to respond to inflammation by proliferating, whereas 
the contractile type participates in bronchoconstriction (Wright et a/2012). 
A potential disadvantage to culturing ASM cells with explants is that cells 
must undergo several doubling cycles before confluence (Hirst 2004). 
Such doubling is reported in vascular smooth muscle studies to reduce 
contractile properties in cells. Cultured equine ASM cells showed steady 
proliferation, and both baseline and inflammatory states were established. 
Accordingly, it was considered that a contractile phenotype from explant 
culture was not present and cells were suitable for investigations into 
inflammation. 
ASM cells exhibit immune cell properties and in asthma demonstrate a 
pro-inflammatory phenotype (Damera & Panettieri 2011). Molecules known 
to stimulate ASM cells include expression of toll-like receptor TLR-4. TLR-
4 mRNA and protein levels have been associated with ASM proliferation 
(Su et a/2012). TNF-a and IL-1 J3 induce inflammation in human ASM cells 
(Keslacy et a/2007, Heffler et a12007), and also act as potential mitogens 
for ASM (Hakonarson & Grunstein 2003, Tagaya & Tamaoki 2007, Nie et 
al 2011). Additionally, IL-1 J3 and TNF-a mediate COX-2 expression in 
150 
human ASM cells (Belvisi et a/1997, Pang & Knox 1997). An in vitro ASM 
model was used to assess if equine ASM cells exhibited a similar 
inflammatory response to that observed in human studies. COX-2 mRNA 
was significantly increased after 72hrs incubation with 0.1 Ilg/ml LPS 
concentration (p value 0.0115), and this was considered to be a suitable 
time point and LPS concentration. An inflammatory response at 72hrs has 
also been observed in human airway smooth muscle cells at 72hrs (Xie et 
a/2005, Chen& Khalil 2006, Roth et a/2013). COX-2 mRNA has been 
detected in cultured human ASM cells at 12hrs with protein corresponding 
to COX-2 at 24hrs (Belvisi et a/ 1997). Peak expression of PGE2, an 
inflammatory molecule associated with COX-2 expression has been 
observed in human ASM cells at 24hrs (Pang & Knox 1997). In contrast, 
equine ASM cells did show noticeable levels of COX-2 at these times. 
However, repeating incubation of ASM cells with 0.1 and 10llg/ml LPS 
again induced very similar mRNA levels of ALX, TLR-4, and TNF-a, I L - 1 ~ , ,
iNOS and COX-2 at 72hrs. Previous experiments with ETE cells had used 
a reduced LPS concentration of 0.1Ilg/ml due to difficulties experienced 
with underlying inflammation in primary cells. This may have unduly 
influenced the decision to use the same LPS concentration for ASM cells. 
It should have been considered that ETE and ASM cells may not exhibit 
similar levels of immune defence. Bronchial epithelial cells are frequently 
cited as providing vital early defence for innate immunity. Although ASM 
cells have the ability to generate an inflammatory phenotype (Barnes 
1998, Morris et a/ 2005, Damera & Panettieri 2011, Ramakrishna et a/ 
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2012), they are less likely to be as reactive as ETE cells, where respiratory 
defence is paramount in immunity. 
Results for primary equine ASM cells at 72hrs with 0.11lg/ml LPS are in 
contrast to comparative studies of equine vascular smooth muscle cells in 
vitro where COX-2 mRNA expression was detected at 12, 24 and 48hrs 
after incubation of vascular smooth muscle cells with 10Ilg/ml LPS 
(Janicke et aI2003). Data to detect in vitro inflammation in ASM cells may 
have been more definitive if a time point of 48hrs had been included. The 
use of 72hrs in ASM studies of equine respiratory disease may have 
missed important inflammatory and inflammatory resolution points. Based 
on the similar results for ASM cells after 0.1 and 10llg/ml LPS 
concentrations and data obtained from equine vascular studies, it may 
have been preferable to examine the response of ASM cells to an 
increased LPS dose of 10llg/ml at earlier time pOints such as 48hrs. 
Such alterations could have improved the data obtained for the LXA4 
study. Comparative investigations into the effect of LXA4 on smooth 
muscle in human and horse are limited. LXA4 is thought to inhibit vascular 
smooth muscle cell chemotaxis thus regulating cellular remodelling 
(Parameswaran et al 2004). Unusually, although LXA4 activity was 
attributed to inhibition of the inflammatory molecule L TE4 no evidence of 
lipoxin receptor ALX expression was detected (Parameswaran et a/2007). 
As with ETE cells, ASM cell samples showed very little difference between 
untreated cells and cells treated with LXA4 or LPS. A very marginal 
decrease of TNF-a and IL-1 ~ m R N A A at 24hrs after LXA4 incubation was 
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detected. This result was questionable, given that control and LPS 
samples produced very similar levels of expression. ALX mRNA appeared 
to be increased in the control group compared to the LPS treatment 
groups, but this was attributed to the noticeable variation in error bar 
values, as seen with ETE cells. Error bar anomalies were again thought to 
result from individual horse variation. This highlights the need for primary 
cells to be passaged and stocks of cells to be kept in reserve to ensure 
continuity in results. 
Despite the inconsistent mRNA expression in LXA4 studies, some 
inhibition of COX-2 protein was observed after Western blot analysis. 
Bands corresponding to COX-2 protein were not detected at 72hrs in LXA4 
and LPS/LXA4 treated samples. Absence of signal for previous Western 
blot results for COX-2 protein from ETE cells had been attributed to 
antibody inefficiency. Signal for COX-2 protein was more detectable in 
other ASM samples, and thus absence of COX-2 was accredited to LXA4 
inhibition. Unlike results for previous LXA4 studies (Parameswaran et al 
2007), bands corresponding to protein expression of ALX were strongly 
evident. It can be concluded that mRNA effects of LXA4 incubation may be 
extremely brief, but still able to partially inhibit formation of inflammatory 
proteins. 
Similarly, detection of NO levels in ASM cells may also be hindered by 
brief expression of such molecules. An apparent minor difference 
observed in LXA4 treatment of ASM cells at 24hrs was lost at 72hrs, 
where no noticeable difference in treatment groups could be detected. 
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5.6 Conclusion 
Use of in vitro ASM cells obtained from trachealis muscle explants were 
suitable for use in investigations of inflammation and inflammatory 
resolution. The initial detection of inflammation by significant expression of 
COX-2 mRNA in ASM cells at 72hrs after incubation with 0.1 ~ g / m l l LPS 
was not reproduced in subsequent experiments. Nor did LXA4 incubation 
apparently inhibit inflammation either at mRNA or protein levels. It was 
concluded that inflammation and inflammatory resolution is neither 
consistently induced nor noticeably resolved in primary equine ASM cells 
with the current chosen time points and incubation concentrations. 
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Chapter 6: An equine co-culture model of 
conditioned media from primary ETE 
cultures and ASM cells 
6.1 Introduction 
The properties of epithelial cells and their effect on other immune cells 
differ according to their inflammatory state (Levine 1995). Excessive 
inflammation from damaged respiratory epithelium causes bronchial 
smooth muscle alteration in airway disease (AI-Muhsen et al 2011). 
Attempts to develop more physiologically realistic in vitro respiratory 
models to investigate this effect include the co-culture of cells with 
conditioned media from other cell types. Conditioned media is considered 
able to support cell growth and activity (Xu et aI2005). 
Data detailing conditioned media in equine co-culture studies from airway 
disease in horses is limited. Currently comparable works of equine co-
culture studies are restricted to studies of inflammatory changes in equine 
cartilage in response to endogenous cell activity (MacDonald & Benton 
1996, Gregg at aI2006). In vitro co-culture methods offer the opportunity 
to study cellular interactions in the pathogenesis of inflammatory diseases 
such as RAO on a more advanced level. 
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6.2 Aims and objectives 
• To characterise the response of primary ASM cells to incubation 
with conditioned media from primary ETE cells 
• To determine the potential for conditioned media from ETE cells to 
induce inflammation or inflammatory resolution in ASM cells by 
assessment of selected molecules 
To achieve these aims, primary in vitro ETE and ASM cells were obtained 
and cultured as described (Chapter 3). ETE cell samples were treated 
with 0.1 ~ g / m l l LPS and 1 O O ~ M M LX4 concentrations for 24hrs prior to 
harvesting supernatant medium. The response of ASM cells to treatment 
with supernatant from ETE cells was analysed by quantification of mRNA 
and detection of protein expression. 
6.3 Methods 
Primary ETE cells were collected by use of the reduced trypsin incubation 
method. Equine ASM cells were again obtained from the out-growth of 
cells from trachealis muscle explants. Primary ETE and ASM cells were 
maintained in BEGM or serum-supplemented DMEM media respectively 
until 70-75% confluent before use in experiments. Primary ETE and ASM 
cells were not passaged prior to co-culture studies. Control samples for co-
culture investigations did not receive either LXA4 or LPS treatment. 
ETE cells were then incubated for 24 hours with 0.1 ~ g / m l l LPS, 1 O O ~ M M
LXA4 or pre-treated with 1 O O ~ M M LXA4 for 15mins before 24hr incubation 
with 0.1 ~ g / m l l LPS. Media from treated ETE cells was collected, sterile 
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filtered and incubated with cultured ASM cells for a further 24hrs. Control 
samples for ETE cells did not receive either LXA4 or LPS treatment. The 
response of ASM cells to co-culture with conditioned media from ETE cells 
was assessed by the same methods as Chapter 3, and 4 with full details in 
Chapter 2. 
6.4 Results 
ASM mRNA expression after co-culture with conditioned media from 
ETE cells treated with O.1lJglml LPS, 100IJM LXA4 and/or 
LPS/LXA4 concentrations 
To determine if an inflammatory response could be transferred from ETE 
cells to ASM cells, a co-culture with conditioned media was investigated. 
ETE cells were treated with the concentrations stated in methods for 
24hrs, and this media used in cultures of ASM cells for a further 24hrs. 
Use of conditioned media from treated ETE cells did not noticeably 
stimulate a response in ASM cells after 24hrs incubation. Expression of 
mRNA in control and LXA4 treated samples from co-cultured ASM cells for 
ALX, TLR-4, TNF-a, IL-1f3 and iNOS was not apparent. This lack of 
obvious mRNA levels indicative of inflammation in control and LXA4 
samples suggested ASM cells were in a non-inflammatory state. Levels of 
mRNA were more apparent in LPS and LPS/LXA4 treated samples, 
potentially indicating the inflammatory capacity of ETE cell conditioned 
media on ASM cells (Flg.3S). 
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Figur 35: q-PCA graph ot ALX, TlA-4, TNF-a, IL-113, INOS and COX-2 mANA expression in 
ASM c II It r 24hr Incubation with conditioned media from ETE cells 
erE coli (obt In d from r duced trypsin digestion method) received 24hrs treatment with O.11lg/ml 
LPS, l00IJM LXA4 and/or LPS/lXA4. Error bars represents a group mean (SEM) obtained from 3 
sampl m an from threo s parato tissue subjects to previous experiments. A one-way ANOVA 
was p rform d to Indicate any statistical significance. 
Substantial disparity in SEM error bars was observed in all mANA 
expression for LPS and LXA4/LPS samples. Statistical analysis of results 
by one-way ANOVA did not produce any significant results. It was 
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concluded that due to the considerable variation in results, it was not 
possible to definitively state whether conditioned media from ETE cells 
either prevents or induces inflammation at the mRNA level when co-
cultured with ASM cells. To assess whether mRNA results were 
accompanied by similar protein levels, co-cultured ASM cells were 
assayed by Western blotting and fluorometric analysis. 
Protein expression of COX-2 and ALX in primary ASM cells after 
incubation with conditioned media from ETE cells over 24hrs. 
Protein bands for ALX, COX-2 and ~ - a c t i n n were observed at approximately 
30 kDa, 60-80 kDa and 40 kDa respectively which was the predicted 
molecular weight (Chapter 2) for these antibodies (Fig.36). 
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Figure 36: Western blot image of protein expression of p-actin, COX-2 and ALX in primary 
ASM cells after incubation with conditioned media from ETE cells over 24hrs 
ASM cells were incubated for 24hrs with conditioned media from ETE cells obtained from reduced 
trypsin digestion method. ETE cells received 24hrs treatment with O.1llg/ml LPS, 100llM LXA4 
and/or LPS/LXA4. Media from treated ETE cells were incubated with ASM cells for a further 24hrs. 
Primary cells were obtained from a separate tissue subject to previous experiments. 
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No significant difference was apparent in protein expression in all ASM cell 
samples. It was concluded that, as with mRNA expression, conditioned 
media from ETE cells did not produce an observable change in COX-
2/ALX protein expression in ASM cells after 24hrs. 
Production of NO in primary ASM cells after incubation with 
conditioned media from ETE cells over 24hrs 
To determine if conditioned media from ETE cells increased/decreased 
NO expression in ASM cells, supernatant from ASM co-cultured cells was 
assayed for NO expression by fluorometric analysis (Fig.37). 
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Figure 37: Quantatlve graph of fluorometrlc detection of NO expression In primary ASM cells 
after 24hr Incubation with conditioned media from ETE cells. NO expression measured by 
fluorescent Intensity (relative units to nitrite/nitrate standard curve) 
ETE cells received 24hrs treatment with 0.1 J.lg/ml LPS, 100J.lM LXA4 and/or LPS/LXA4. Treated 
ETE media was then used to incubate ASM cells for a further 24hrs. ASM cells were incubated for 
24hrs with conditioned media from ETE cells obtained from reduced trypsin digestion method. 
Primary cells were obtained from a separate tissue subject to previous experiments. A one-way 
ANOVA was performed to indicate any statistical Significance. 
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In a similar manner to the results observed for mRNA and protein levels, 
there was no distinct difference in treatment groups for ASM cells 
incubated with conditioned media from ETE cells. It was concluded that 
co-culture of ASM cells by use of conditioned media from ETE cells neither 
induces nor inhibits NO expression in ASM cells. 
6.5 Discussion 
Co-culture with conditioned media offers a simple method to study in vitro 
inflammation between the epithelial and the bronchial smooth muscle 
layer. The capacity to distinguish mediators of inflammation in epithelial 
and airway smooth muscle cells contributes to increased understanding of 
RAO pathogenesis. 
Use of conditioned media has worked well for human studies of bronchial 
epithelial cells of airway inflammation and ASM remodelling (Tang et a/ 
2012, Kuo et a/2011, Takeda et a/2009). Conditioned media from resting 
BEAS-2B cells and primary murine tracheal epithelial cells has inhibited 
TNF-a expression in monocytes, macrophages and dendritic cells (Mayer 
et a/2008). Airway alterations have been modelled by a human bronchial 
epithelial cell line 16HBE140. Conditioned media obtained from 
mechanically damaged 16HBE140 cells induced significant proliferation of 
myofibroblasts (Zhang et a/ 1999). Media from transformed human 
bronchial epithelial cells (BEAS-2B) cells was capable of relaxing pre-
contracted adult pulmonary arterial muscle (Farah et a/2009). 
In the current study, investigations in to the relationship between bronchial 
epithelium and smooth muscle layer were unsuccessful. Conditioned 
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media from treated primary ETE cells used to stimulate primary ASM cells 
did not elicit a noticeably different response in treated and untreated 
samples. Nor was there any similarity shown in the response of ASM cells 
incubated with conditioned media from ETE cells to that of ASM cells 
which were treated similarly with LPS and/or LXA4 in Chapter 5. Results 
obtained with q-PCR using LXA4 treated ETE and ASM cells were very 
similar to those of ASM cells cultured in conditioned media from LXA4 
treated ETE cells. Data was again ambiguous due to the highly variation 
shown in the SEM bars. The lack of significant response from ASM cells 
may be due the absence of molecules in conditioned ETE cell media able 
to promote or resolve inflammation. 
Previously, 0.1 and 101lg/ml of LPS concentrations produced closely 
similar mRNA expression in ASM cells, with results obtained after 72hrs 
incubation. Thus it seems unlikely that a shorter incubation period of 24hrs 
with unknown levels of potentially inflammatory products would elicit a 
response. The use of ELISA assays on collected ETE cell media could 
have been used to determine the presence of inflammatory molecules 
such as TNF-a or IL-1 f3 prior to use for co-culture. 
ASM cells may produce an inflammatory reaction to either early acute 
inflammation or from repeated episodes of inflammatory insult. One 
alternative would have been to collect increased quantities of conditioned 
media from the same ETE cell samples. Collected media could then have 
been used to change media for ASM cells every 24hrs over a 72hr period. 
This would therefore replicate repeated inflammation in vitro and extend 
the incubation time to the 72hrs time point used for ASM cells. 
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One hindrance to obtaining results with conditioned media is the change in 
culture media for ASM cells. Primary ETE cells require BEGM media, 
formulated to be serum free. Equine ASM cells were dependant on the 
presence of BSA during culture to promote cell growth. Serum withdrawal 
has been implicated as a factor in reduction of ASM cell activity. Serum 
depletion is frequently used in studies of cell cycles and their metabolism 
(Pirkmajer & Chibalin 2011). However serum withdrawal from cell media is 
linked to alterations in cell signalling and gene expression (Zander & 
Bemark 2011). Therefore use of BEGM serum-free media from ETE cells 
could have affected data obtained from ASM cells in co-culture studies. 
The addition of serum to ETE cell conditioned BEGM media was thought 
likely to affect potential results. 
One alternative could have explored the effects of a reduction of serum 
levels in ASM culture media. Assessment of the suitability of cell culture 
media can be achieved by measuring cell carbohydrate activity. 
Quantifying the molar concentration of lactate in cell media indicates the 
level of glucose uptake and subsequently, the hypoxic qualities of cell 
media used (Gstraunthaler et al 1999). This could have improved 
monitoring of ASM activity and reaction to serum reduction or change to 
BEGM media. It would have also aided the selection of a suitable media 
for both ETE and ASM cells. Finding an appropriate media for both cell 
types would enhance the development of an ALI co-culture system 
between ETE and ASM cells. Initial efforts were made to culture primary 
ETE cells with tissue culture inserts at the ALI (data not shown). Primary 
ETE ells were cultured at the ALI with BEGM, DMEM and with L-1S, but 
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did not appear to proliferate when viewed under the light microscope. 
Development of an in vitro ALI co-culture model between ETE and ASM 
cells is a key aim for future work. 
Western blotting did not appear to show any significant difference in 
treatment groups for COX-2 or ALX. There appeared to be a very minor 
difference in the strength of signal for COX-2 compared with ALX. COX-2 
seemed to be more strongly expressed compared with ALX after LPS 
incubation of samples. To enable a more accurate assessment of protein 
levels, semi-quantative analysis of Western blotting should have been 
performed on results. 
Samples used in NO analysis were again unconvincing and showed no 
difference in sample levels. As described in the discussion for chapter 3, 
NO expression is often affected by several variables in cell culture with NO 
expression frequently limited. The same variables were thought to affect 
results for co-cultured ASM cells. 
6.6 Conclusion 
In conclusion, it appears that conditioned media from ETE cells appears to 
have no significant effect on NO expression in ASM cells after 24hrs. At 
present, the use of conditioned media as a model of the interactions 
between these two cell types is unsuitable for investigations in to RAO It 
may be that after adjustment, this method could be used to investigate the 
relationship between ETE and ASM cells. 
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Chapter 7: General Discussion and 
Conclusions 
An in vitro equine respiratory model was successfully developed by culture 
of primary ETE and ASM cells. Use of an equine in vitro cell culture model 
represents a feasible method of studying bronchial inflammation and 
inflammatory resolution contributing to RAO pathogenesis. 
The horse is an excellent animal model to study human airway disorders. 
No animal model is completely representative of human asthma, but 
horses with RAO show naturally occurring clinical symptoms similar to 
asthma after exposure to organic dust. Furthermore, as a large animal, the 
horse offers a greater physiological similarity to people than small animal 
models of respiratory disease (Zosky & Sly 2007). 
Development of the model required extensive assessment of multiple in 
vitro methods, which delayed investigations into inflammation and 
inflammatory resolution. Use of the continuous cell line BEAS-2B would 
have significantly increased the rate of investigation into airway 
inflammation. Despite the reliability and practicality of an immortalized cell 
line, BEAS-2B cells were not used as they were considered to lack 
phenotypic and differential characteristics of the original airway tissue. 
Developing an in vitro smooth muscle model of primary equine ASM cells 
from culture of trachealis muscle explants proved uncomplicated. Cultured 
ASM cells showed a morphology and growth pattern highly similar to other 
equine studies of primary smooth muscle (Rodgerson et a12002, Janicke 
et aI2003). Characterisation of ASM cells showed positive staining by 
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IHCIICC labelling of a-smooth muscle actin and results were comparable 
with other studies culturing smooth muscle cells. 
In contrast, establishing an in vitro epithelial model required extensive 
optimisation. Compared with similar works (Lin et al 2001, 
Vandekerckhove et aI2009), whole organ cultures proved unsatisfactory 
due to poor tissue viability or were unsuitable for investigations into 
inflammatory resolution. 
Additionally, unlike several primary bronchial epithelial cell culture studies 
(Spurzem at a12005, Kato et a12006, Newby et a12007, Eries & Browlie 
2010, Newby et al 2007), digestion of equine respiratory tissue with 
pronase to obtain cells was unproductive. Isolation of bronchial epithelial 
cells from pronase digestion of respiratory tissue has been very successful 
for other equine studies (Lin et a12002, Ainsworth et a/2009, Quintana et 
al 2011). Work in these studies is particularly relevant, as the authors 
subsequently investigated the effects of LPS on primary equine bronchial 
epithelial cells (Ainsworth et al 2009), and the development of an 
immunological profile (Quintana et a/2011). Therefore not following the 
primary culture methods described in these works more fully may have 
been an important error. It would have been preferable to have attempted 
the described protocols more extensively, particularly by use of increased 
digestion times (up to 48hrs) and the addition of supplemented digestion 
media (e.g. DNase) described in these studies. 
Despite this, use of trypsin digested tissue produced adequate quantities 
of proliferating ETE cells, although average numbers and viability of cells 
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obtained did not equal those described in the original paper (Shibeshi et a/ 
2008). ETE cells were characterised by similar IHCIICC positive staining of 
cytokeratin protein for epithelial cells with PCK-26 as also described in the 
original paper. Use of trypsin-dissociated ETE cells for the investigation of 
RAO was novel and original. Additionally the culture and characterisation 
of airway smooth muscle cells in the horse has not been detailed 
elsewhere. Nor has an in vitro model composed of ETE and ASM cells 
been previously described in the literature. 
However, further development of both ETE and ASM cells is required in 
both characterisation and production of cell banks. For future work, it 
would be preferable to improve characterisation of primary ASM cells to 
fully distinguish ASM cells from myofibroblasts. This could be achieved by 
use of additional markers to a-smooth muscle actin to include other 
smooth muscle proteins, such as smooth muscle myosin heavy chain (sm-
MHC), calponin, and desmin (Halayko et a/1996). 
Semi-immortalization of primary cells would be one potential alternative, 
particularly given the lack of equine continuous cell lines currently 
available. Semi-immortalization of primary epithelial cells has been 
achieved through transfection of primate tissue explants with Epstein Barr 
Virus DNA (Gao et a/2002). A more practical immediate option would be 
establishing a successful method to passage both ETE and ASM cells. 
Further development of trypsin dissociated cells has been described by 
Abraham et al (2011). Primary ETE cells obtained in this manner were 
successfully passaged and were able to fully differentiate into pseudo-
stratified muco-ciliary epithelium with basal cells when cultured at the AFI. 
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Passaging of ETE cells may have been particularly important as significant 
COX-2 mRNA expression (p<. 0.0001) was observed in freshly dissociated 
cells after 5 days of culture. It was not anticipated that passaging of ETE 
cells would eliminate trypsin-associated inflammation. It is still an important 
error during model development as it had been fully detailed in the original 
methodology and should have been attempted. 
Creating reserves of primary ETE and ASM cells would enhance continuity 
between experiments and the validity of data obtained from such 
investigations. Reducing the number of tissue donors to obtain primary 
cells would prevent variety in obtaining data. Noticeable variability in data 
was observed during investigations into inflammation in ETE and ASM 
cells. Initially, persistent inflammation unrelated to LPS stimulation was 
evident in ETE cells obtained after 2hrs trypsin dissociation of tracheal 
tissue. Incubation with anti-inflammatory carprofen did not eliminate this 
inflammation, in a similar manner to other studies reporting the 
effectiveness of in vitro carprofen on equine cells (Brideau et a/ 2001, 
Beretta et a/2005). An apparent decrease of COX-2 mRNA associated 
inflammation in ETE cells was subsequently established by use of reduced 
incubation with trypsin during cell dissociation. It was considered that the 
reduced trypsin digestion method established baseline levels of mRNA 
expression in ETE cells. No evidence of obvious prior inflammation was 
observed in ASM cells obtained from trachealis explants. 
The response of ETE and ASM cells was examined after stimulation with 
LPS concentrations. The use of 0.1 Ilg/ml LPS concentration to induce 
inflammation in ETE and ASM at 24 and 72hrs respectively was partially 
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successful compared with control samples and other LPS concentrations. 
Significant increases were observed in ETE mRNA for ALX, TLR-4, TNF-a 
and I L - 1 ~ , , and initial COX-2 mRNA investigations into inflammation in 
ASM cells (all p values < 0.05). No statistical significance was evident for 
ETE cells expression of mRNA for iNOS and COX-2. Extensive 
optimisation of the methods used to detect inflammation in ETE and ASM 
cells is required. 
However, definitively establishing basal expression of selected molecules 
in ETE and ASM cells may be challenging. Primary human tracheal 
epithelial cell cultures grown at the air-liquid interface have not 
demonstrated transcriptional differences to those of in vivo airway epithelia 
(Pezzulo et al201 0). In contrast, an immunological profile was established 
(Quintana et a12011), with primary equine epithelial cells cultured at the 
ALI. Despite no stimulation of fully differentiated cells with inflammatory 
molecules, expression of IL-B, TNF-a and IL-6 were detected in the model 
after 4 weeks. The presence of these molecules indicates low level or 
persistent inflammation which would affect studies of inflammation or 
inflammatory resolution. Nor has an immunological profile for in vitro 
equine ASM been determined. Studies into human ASM indicate that in 
vitro ASM has an inflammatory phenotype, which equally hinders studies 
of inflammation (Damera & Panettieri 2011). 
Statistical analysis of collected data was performed with both one and two 
way ANOVA and corroborated by Tukey's multiple comparison tests. Use 
of these tests was determined by the distribution pattern of collected data. 
Parametric tests can place rigid restrictions on results with assumptions of 
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normally distributed Gaussian numbers. However, it was considered to be 
the most appropriate test, which would then highlight any statistically 
significant data. To improve the reliability and validity of collected data, 
alterations to the number of genes used and the selected time points are 
necessary. Reduction in the number of genes examined is desirable to aid 
repeatability of experiments. Examination of genes more closely 
associated with the early initiation of inflammation such as TNF-a or I L - 1 ~ , ,
rather than COX-2 should improve detection of acute inflammatory onset. 
Additionally, as previously mentioned, the selected time points of 24 and 
72hrs may be unsuitable for quantification of mRNA expression. 
A final and important factor in reducing variability in data was the source of 
tissue used in experiments. Data for inflammation studies which examined 
COX-2 mANA expression were obtained from primary cells collected from 
a separate horse for each experiment. Similarly, LXA4 data was resulted 
from tissue obtained from three separate horses. Both factors induce 
considerable scope for variation in cell expression due to the potential 
differences in each subject's health and history. 
Consideration should also be given to the use of tracheal tissue from the 
upper respiratory tract to examine RAO. Human airway epithelial cells from 
trachea and bronchi have high levels of similarity and expression profiles 
(Pezzulo et al201 0). Additionally, equine mucosal explants collected from 
septum, the nasopharynx and the trachea and maintained at the AFI 
showed no difference in viability determined by TUNEL staining 
(Vandekerckhove et aI2011). 
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However, RAO is a disorder affecting the lower respiratory tract and 
comparable studies which have successfully instigated inflammation after 
LPS stimulation have used lung bronchi (Ainsworth et a/2009, Lin et a/ 
2001). Therefore the use of tracheal tissue to investigate inflammation of 
the lower respiratory tract may not have been suitable. 
Although an in vitro model of primary ETE and ASM cells was successfully 
established, it is clear that induction of inflammation in the model is not 
reliable. Use of peripheral blood monocytes cells (PBMCs) isolated from 
whole blood as described in Chapter 2 offers an alternative to the model 
with several advantages. Samples could be obtained from a reduced 
number of donors (complete with a known history, definitive ages and 
health score), therefore restricting the variability evident in results from 
different tissue sources. Use of whole blood samples also reduces the 
potential contamination from tissue collection and processing, and effect of 
tissue viability after transport. Increased access to regular numbers of cells 
also improves the opportunity to examine increased numbers of earlier 
time points. 
An important factor in use of peripheral blood monocytes is the potential 
improved expression of receptor ALX. This is the first time that the effect of 
exogenous LXA4 on acute inflammation in primary ETE and ASM cells has 
been investigated. Detecting irregularities in the synthesis of LXA4 and its 
receptor ALX in horses offers a valuable diagnostic tool to investigate 
RAO. 
Expression of the lipoxin receptor ALX has not previously been detected in 
primary ETE or ASM cells. It was therefore an unknown variable and 
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determining inflammatory resolution solely by expression of ALX could 
have been a limiting factor. In order to obtain q-PCA standards of sufficient 
quality for ALX, it was necessary to use a pooled selection of mANA from 
ETE, ASM and PBMCs. Although ALX is known to be expressed in human 
cells, it is also expressed in monocytes and lymphocytes (Serhan 2005). 
Such cells are present in cell populations obtained from PBMCs and may 
show increased levels of ALX mANA compared with epithelial cells. 
Establishing definitive levels inflammation and inflammatory resolution in 
PBMCs would aid similar detection in ETE and ASM cells. 
There is also potential for the ALX receptor to be poorly expressed in 
equine ETE cells, and this could be an interesting point to establish for 
future RAO investigations. The LXA4 receptor ALX is a surface G-protein 
coupled receptor whose biological functions are not fully understood. ALX 
has an affinity for LXA4 but is able to bind to other substrates which could 
potentially reduce LXA4 action (Chiang 2002). ALX is capable of binding 
bacterial peptide tripeptide formyl-Methionine-Leucine-Phenylalanine 
(fMLF) and its analogues derived from Escherichia coli (Le et aJ2001). The 
ALX receptor in BEAS-2B cells increased in response to incubation with 
LPS, TNF-a and to scratch injury (Shao et aJ2011). ALX is also reported 
to bind to acute phase protein serum amyloid A (SAA) , a protein 
associated with lung inflammation in people with COPD (Bozinovski et aJ 
2012). Variation in the capacity of ALX to bind to available substrates 
would explain in part the results observed for treatment of ETE and ASM 
cells with LXA4/LPS concentrations 
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It is very likely that the LXA4 concentration used did not sufficiently 
stimulate ETE or ASM cells to activate the ALX receptor. This was in 
contrast a similar study where treatment of human bronchial epithelial cells 
after acid injury with 100/lM of LXA4 was associated with expression of 
ALX and decreased IL-6 mRNA expression (Bonnans et a/ 2006). 
Variation in ALX expression was observed in an in vitro model of equine 
tendon explants (Dakin et a/2012). Expression of LXA4 (approximately 
100 pglml) was observed at 24hrs after I L - 1 ~ ~ stimulation with peak levels 
of ALX recorded at 72hrs. 
However, the immune responses of different cell types (tenocytes 
compared with ETE/ASM cells) may be dissimilar and as such LXA4/ALX 
binding will also differ. To determine such binding a time and concentration 
course of exogenous LXA4 on ALX expression should be performed in a 
similar manner to selection of a suitable LPS concentration. 
Conclusion 
Culture of primary ETE and ASM cells are suitable for use as an in vitro 
respiratory model. Treatment of the model with LPS induces detectable 
inflammation in cultured ETE and ASM cells. However, such inflammation 
is not sufficiently repeatable nor is there conclusive or definitive evidence 
of inflammatory inhibition mediated by exogenous LXA4. It must be 
concluded that the obtained data is not able to support the hypothesis 
which must therefore be rejected. 
As such, further optimisation of the model is required by: 
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• Continued characterisation of ETE and ASM cells or use of 
alternative cells types 
• alterations to chosen time points of detection 
• reduction in number of markers of inflammation used 
Modifications to the existing model may then enable detection of 
potential inflammatory resolution associated with RAO and support the 
original hypothesis. 
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Appendices 
Appendix 1: Untreated data 
Expression of mRNA for COX-2 in ETEC after 0, 4 and 24 hrs incubation 
with 101Jg/mL LPS in ETEC (1 sample) 
Treatment groups COX-2IGAPDH ratio mean 
ControlOhr 0.3027 
Control4hr 0.4967 
Control 24hr 2.0875 
LPS Ohr 0.3514 
LPS 4hr 1.1606 
LPS 24hr 1.7096 
Expression of mRNA for COX-2 in ETEC after 0, 4 and 24 hrs incubation 
with 10IJg/mL LPS and 41Jg/ml carprofen 
Treatment groups COX-2I18S ratio mean 
ControlOhr 0.05702 
Control4hr 0.26787 
Control 24hr 0.62965 
Carprofen Ohr 0.21653 
Carprofen 4hr 0.14274 
Carprofen 24hr 0.33566 
LPS Ohr 0.10459 
LPS 4hr 0.20525 
LPS 24hr 0.46303 
Carprofen/LPS Ohr 0.07474 
Carprofen/LPS 4hr 0.29406 
Carprofen/LPS 24hr 0.21082 
Expression of mRNA for COX-2 expression in 5 day and 4 week old 
ETEC after incubation 
Treatment groups COX-2IBeta actin ratio mean 
Control Ohr 5 day 0.0017 
Control 24hr 5 day 0.11247 
Control Ohr 4 week 0.00120 
Control 24hr 4 week 0.02293 
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Expression of mRNA in ETEC after 0.1, 10 and 100 J-Ig/ml LPS over 24 hrs 
(1 sample) 
Treatment TargetlHK ratio Time zero Normalised target 
groups mean ratio gene 
Control Control Control Control 
ALX 0.0014 0.0095 0.1551 
TLR-4 0.0558 0.0501 1.1143 
TNF-a 0.0160 0.2026 0.0792 
IL-1 J3 0.0004 0.0006 0.7748 
iNOS 0.0458 0.0488 0.9389 
COX-2 0.1091 0.1204 0.9063 
0.1 lJg/mL 0.1 lJg/mL 0.1 lJg/mL 0.1 lJg/mL 
ALX 0.0354 0.0095 3.7079 
TLR-4 0.1444 0.0501 2.8803 
TNF-a 0.0852 0.2026 0.4208 
IL-1 J3 0.0043 0.0006 7.1519 
iNOS 0.0960 0.0488 1.9670 
COX-2 0.8818 0.1204 7.3225 
10 IJQ/mL 10 IJQ/mL 10 lJg/mL 
ALX 0.0020 0.0095 0.2151 
TLR-4 0.0841 0.0501 1.6787 
TNF-a 0.0115 0.2026 0.0570 
IL-1 J3 0.0009 0.0006 1.5306 
iNOS 0.0545 0.0488 1.1180 
COX-2 0.4284 0.12043 3.5576 
100 IJQ/mL 100 IJglmL LPS 100 IJQ/mL 100 IJglmL LPS 
LPS LPS 
ALX 0.0046 0.0095 0.4908 
TLR-4 0.0516 0.0501 1.0291 
TNF-a 0.0309 0.2026 0.1525 
IL-1J3 0.0008 0.0006 1.3732 
iNOS 0.0430 0.0488 0.8815 
COX-2 0.1091 0.1204 0.9065 
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Expression of mRNA in ETEC after LXA4 and LPS incubation over 24hrs 
(3 samples) 
Treatment 
groups 
ALX Time zero Average of normalised 
ratio samples 
Control 0.0022 1.1333 
1 0 0 ~ M M LXA4 0.0022 1.7432 
0.1 ~ G / m l l LPS 0.0022 1.4416 
LPS/LXA4 0.0022 6.0002 
TLR-4 
Control 0.01025 3.9682 
1 0 0 ~ M M LXA4 0.01025 8.0945 
0.1 ~ G / m l l LPS 0.01025 5.6793 
LPS/LXA4 0.01025 5.2443 
TNF-a 
Control 0.00439 77.1092 
1 0 0 ~ M M LXA4 0.00439 36.1645 
0.1 ~ G / m l l LPS 0.00439 86.9177 
LPS/LXA4 0.00439 309.7666 
IL-1 (3 
Control 0.0001 5.5475 
1 0 0 ~ M M LXA4 0.0001 4.6752 
0.1 ~ G / m l l LPS 0.0001 9.8018 
LPS/LXA4 0.0001 20.1245 
iNOS 
Control 0.0012 24.4892 
100ilM LXA4 0.0012 91.5493 
0.1 ~ G / m l l LPS 0.0012 66.6176 
LPS/LXA4 0.0012 30.9618 
COX-2 
Control 0.0011 22.7333 
1 0 0 ~ M M LXA4 0.0011 111.9172 
0.1 ~ G / m l l LPS 0.0011 91.6903 
LPS/LXA4 0.0011 127.2503 
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Co- culture studies 
ALX Time zero ratio normalised mean samples 
control 0.0003 0.0034 
LXA4 0.0003 0.0007 
LPS 0.0003 0.0062 
LXA4/LPS 0.0003 0.0025 
TLR-4 
control 0.0009 0.01355 
LXA4 0.0009 0.02220 
LPS 0.0009 0.02517 
LXA4/LPS 0.0009 0.03077 
TNF-A 
control 0.0014 0.01574 
LXA4 0.0014 0.00617 
LPS 0.0014 0.02717 
LXA4/LPS 0.0014 0.03151 
IL-1B 
control 0.0002 0.0004 
LXA4 0.0002 0.0002 
LPS 0.0002 0.0006 
LXA4/LPS 0.0002 0.0005 
iNOS 
control 0.0031 0.0038 
LXA4 0.0031 0.0067 
LPS 0.0031 0.0091 
LXA4/LPS 0.0031 0.0053 
COX-2 
control 0.0119 0.0216 
LXA4 0.0119 0.0564 
LPS 0.0119 0.0926 
LXA4/LPS 0.0119 0.0802 
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Appendix 2: peR standard curves, melt curves and reference 
genes 
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Appendix 3: Primer sources and sequenced genes 
Primer sources 
Beta actin and 18s: ZHANG, Y. W., DAVIS, E. G. & BAI, J. (2009) 
Determination of internal control for gene expression studies in equine 
tissues and cell culture using quantitative RT-PCR. Vet Immunol 
Immunopathol, 130, 114-9. 18S, B-actin 
TLR-4: BERNDT, A., DERKSEN, F. J., VENTA, P. J., EWART, S., 
YUZBASIYAN-GURKAN, V. & ROBINSON, N. E. (2007) Elevated amount 
of TOil-like receptor 4 mRNA in bronchial epithelial cells is associated with 
airway inflammation in horses with recurrent airway obstruction. Am J 
Physiol Lung Cell Mol Physiol, 292, L936-43. 
COX-2, GAPDH and iNOS: Personal communication from Dr Richard 
Hammond 
IL-1J3: Personal communication from Dr Steve Dunham 
ALX and TNF-a: Charlotte Beynon 
Amplicons from sequenced PCR products 
ALX 
5"NGGA TICTIGCTCTAATCCTCACCTCACAAA nnCCTCTICTICACT 
ACAAAAAGTGATGGGAAAGGGAATACACTCTGTACTTICAGCTICGAA 
TCCTGGGGTAACACCACTGATGAGAAGAGGAAGATAACCGTCACCGT 
GTIGACAGTCAGAGGGATCATCCGA3" 
TLR4 
5"GCAGAGCAGCAGAAAGCAGACAACATGATGCAGAAACCTCTACCT 
GAAGGAAAAACTCCTGAGGTGCTICTIGCAGG3" 
TNF-a 
5"CCCTGGTICGAGAAGCCAACTICGGGCCTGGGGTCAGCATCGTGG 
AGCGGCAGTACGTCCGTCCTCGCCCACACCAAGTAGACCTGCCCGG 
ACTCCGCAAGTCGATGNGTCCTGGTAAAGTAGTAACCGGATICCACT 
TCGTIGCACTGACGTCCGATCATGTGGGGTCGACATGCGCACGCCC 
GGACTCCGCAAAGTCGATACCAGGTAAGAGCTGCTGATGNGGAGCG 
AGGACCGTGCCCCTCTACGCAGCTGAGTCGGGCTGTGCTGGACCGG 
GGTCTGGGCCCCTCACGGCCGCCTGCCCGGACTCCTCAAACAT3" 
222 
INOS 
5"CCAGGCTGGAAGCCGTAACAAAGGAGATAGAAACAACAGGAACCT 
ACCAGCTGACGGGAGATGAGCTCATCTTTGCCACCAAGCAGGCCTG 
GCGCAATGCCCCCCGCTGCATCGGGAGGATCCAGTGGTCCAACCTA 
CAGGTCTTTGACGCCCGGAGCTGTTCTACTGCCCAGGAAATGTTCGA 
ACACATCTGCAGACACCTGCGTTACTCCACCAACAATGGCAACATCA 
GGTCGGCCATCACCGTGTTCCCCCAGCGGAGCGATGGAAAGCATGA 
CTTCCGGATCTGGAATGCTCAGCTCATCCGGTATGCCGGGTACCAGA 
TGCCTGATGGCAC3" 
COX-2 
5"ACTT ACGGAGAGAAGGAAATGGCTGCGGAGTT AGAAGCACTCTAT 
GGTGACATTGATGCCATGGAGCTGTATCCTGCCCTTCTGGTGGAAAA 
GCCTCGCCCAGATGCCATCTTCGGGGAGACCATGGTAGAACTTGGG 
GCACCATTCTCCTTGAAAGGACTTTTGGGTAATCCTATCTGTTCTCCT 
GACTACTGGAAACCCAGCACTTTTGGTGGAGAAGTAGGTTTTAAAATC 
ATCAACACTGCCTCAA TTCAGTCTCTCANCTGCAATAAA3" 
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Appendix 4: List of suppliers and addresses 
AbCam pic 
330 Cambridge Science Park, 
Cambridge 
CB40FL 
Amersham Biosciences 
Amersham PI 
Amersham, 
Buckinghamshire 
HP79NA 
Bio-Rad Laboratories 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Herts 
HP27DX 
Cayman Chemicals 
Cambridge Biosciences 
Munro House Trafalgar Way, 
Bar Hill, 
Cambridge CB23 8SQ 
Dako UK Ltd 
Cambridge House 
8t Thomas Place, Ely 
Cambridgeshire CB7 4EX 
Fisher Scientific 
Bishop Meadow Road 
224 
Loughborough 
LE11 5RG 
GE Healthcare 
Pollards Wood 
Nightingales Lane 
Chalfont St Giles 
Buckinghamshire 
HP84SP 
Invitrogen 
Life Technologies Ltd 
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF, UK 
Lonza 
Lonza Biologics pic 
228 Bath Road 
GB-Slough, Berkshire SL 1 4DX 
Polysciences, 
Northampton, 
Park Scientific Ltd. 
24 Low Farm Place 
Moulton Park 
GB-NN3 6HY Northampton 
Roche Diagnostics Limited 
Applied Science 
Charles Avenue 
Burgess Hill 
West Sussex 
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RH159RY 
Sarstedt Ltd. 
68 Boston Road 
Beaumont Leys 
Leicester LE4 1AW 
Sigma-Aldrich 
Poole 
Dorset 
BH124QH 
Thermo Fisher Scientific 
Stafford House 
Boundary Way 
Hemel Hempstead 
HP27GEUK 
Qiagen 
Qiagen House, 
Fleming Way, 
Crawley 
West Sussex 
RH10 9NQ UK 
Whatman pic 
Springfield Mill 
James Whatman Way 
Maidstone 
Kent 
ME142LE 
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